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Functional and Genetic Analysis of Choroid Plexus Development in Zebrafish
Abstract
The choroid plexus (CP) is an epithelial based structure localized within the brain ventricles and functions
as the blood-cerebrospinal fluid barrier (BCSFB). Under normal conditions, the CP is responsible for
generating the cerebrospinal fluid (CSF) and regulating its components. Abnormal CP function has been
associated with neurodegenerative diseases, tumor formation in CP epithelia (CPe), and hydrocephalus.
Despite the significant role of the CP in these disorders, little research has been done to characterize its
functional properties and genetically dissect the pathways involved in normal CP development and
disease. For this study, we have utilized zebrafish, (Danio rerio), as a model system to better understand
the genetic components of CP development. Their transparent nature and rapid ex utero development
provide mechanisms to visualize CP formation that is not possible in other model systems. By utilizing an
enhancer trap line, Et(cp:EGFP) sj2 that expresses the enhanced green fluorescent protein (EGFP) in CPe,
we have demonstrated that the zebrafish CP possesses barrier properties such as tight junctions,
transporter activity, and regulating central nervous system (CNS) homeostasis. After validating that the
zebrafish CP is similar to higher vertebrates, we have initiated a genetic screen to answer questions such
as: 1) what genes are needed for CP development, function, and maintenance, 2) what are the signaling
pathways involved, and 3) how do these pathways interact with one another to form the BCSFB? This
study is the first to employ an unbiased approach using a forward genetic screen to genetically dissect
the CP and identify genes essential for its formation and function. As a result of this genetic analysis, we
have confirmed 10 mutant lines with CP abnormalities. The mutants generated in this study will be used
in future investigations to elucidate specific genes and signaling pathways essential for CP development,
function, and maintenance and will provide a better understanding of how genetic mutations contribute to
CP- related diseases. We have also mapped the gene for one mutant line, cp27.5, to Chromosome 21.
Using a combination of classical positional cloning and whole-exome sequencing (WES), we identified the
mutated gene as squamous cell carcinoma antigen recognized by T cells (sart1). sart1 plays a role in
assembling the spliceosome, a multi-ribonucleoprotein complex essential for processing pre-mRNA. By
characterizing cp27.5 mutants, we identified a number of proteins with altered expression levels and
patterning primarily within the brain and eye. Using RNA-Seq analysis, we also identified multiple genes
up-regulated or down-regulated due to the sart1 mutation. While sart1 itself was up-regulated, we also
identified increased expression of genes involved in apoptosis such as tp53 and mdm2. A loss of
photoreceptors and lack of retinal lamination in mutants is related to a down-regulation of vision-related
genes such as phosphodiesterase 6H, (pde6h) and opsin-1, short-wave-sensitive 1 (opn1sw1), both of
which are expressed in photoreceptors. Future studies will investigate the role of sart1 in splicing and the
mechanisms involved in producing the phenotypes observed in cp27.5 mutants.
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ABSTRACT
The choroid plexus (CP) is an epithelial-based structure localized within the brain
ventricles and functions as the blood-cerebrospinal fluid barrier (BCSFB). Under normal
conditions, the CP is responsible for generating the cerebrospinal fluid (CSF) and
regulating its components. Abnormal CP function has been associated with
neurodegenerative diseases, tumor formation in CP epithelia (CPe), and hydrocephalus.
Despite the significant role of the CP in these disorders, little research has been done to
characterize its functional properties and genetically dissect the pathways involved in
normal CP development and disease. For this study, we have utilized zebrafish, (Danio
rerio), as a model system to better understand the genetic components of CP
development. Their transparent nature and rapid ex utero development provide
mechanisms to visualize CP formation that is not possible in other model systems. By
utilizing an enhancer trap line, Et(cp:EGFP)sj2 that expresses the enhanced green
fluorescent protein (EGFP) in CPe, we have demonstrated that the zebrafish CP possesses
barrier properties such as tight junctions, transporter activity, and regulating central
nervous system (CNS) homeostasis. After validating that the zebrafish CP is similar to
higher vertebrates, we have initiated a genetic screen to answer questions such as: 1)
what genes are needed for CP development, function, and maintenance, 2) what are the
signaling pathways involved, and 3) how do these pathways interact with one another to
form the BCSFB? This study is the first to employ an unbiased approach using a forward
genetic screen to genetically dissect the CP and identify genes essential for its formation
and function. As a result of this genetic analysis, we have confirmed 10 mutant lines
with CP abnormalities. The mutants generated in this study will be used in future
investigations to elucidate specific genes and signaling pathways essential for CP
development, function, and maintenance and will provide a better understanding of how
genetic mutations contribute to CP-related diseases. We have also mapped the gene for
one mutant line, cp27.5, to Chromosome 21. Using a combination of classical positional
cloning and whole-exome sequencing (WES), we identified the mutated gene as
squamous cell carcinoma antigen recognized by T cells (sart1). sart1 plays a role in
assembling the spliceosome, a multi-ribonucleoprotein complex essential for processing
pre-mRNA. By characterizing cp27.5 mutants, we identified a number of proteins with
altered expression levels and patterning primarily within the brain and eye. Using
RNA-Seq analysis, we also identified multiple genes up-regulated or down-regulated due
to the sart1 mutation. While sart1 itself was up-regulated, we also identified increased
expression of genes involved in apoptosis such as tp53 and mdm2. A loss of
photoreceptors and lack of retinal lamination in mutants is related to a down-regulation of
vision-related genes such as phosphodiesterase 6H, (pde6h) and opsin-1,
short-wave-sensitive 1 (opn1sw1), both of which are expressed in photoreceptors. Future
studies will investigate the role of sart1 in splicing and the mechanisms involved in
producing the phenotypes observed in cp27.5 mutants.
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CHAPTER 1.

INTRODUCTION

Central Nervous System Barriers
Central nervous system (CNS) barriers serve as protective and regulatory
mechanisms that allow the brain and spinal cord to remain in a homeostatic environment
and function efficiently. While these structures prevent harmful components from
entering CNS tissues, they can also create obstacles for efficient drug delivery. Each
barrier consists primarily of tight junction and transporter proteins that function to either
restrict entry into or transport components across the barrier. These proteins are localized
to endothelial or epithelial cells depending on where the barrier is localized. While the
focus of this study is on the choroid plexus (CP) or blood-cerebrospinal fluid barrier
(BCSFB), understanding the function of other CNS barriers is essential due to their
interdependence with one another in maintaining a homeostatic environment throughout
the CNS. Brief descriptions of these barriers are presented in the following paragraphs.
Blood-Brain Barrier
To date, four CNS barriers have been described (Liddelow, 2011); three of which
are represented in Figure 1-1. The most studied is the blood brain barrier (BBB) which
is comprised mainly of endothelial cells that express tight junction and transporter
proteins to create a barrier between blood and brain tissue. Additional cell types
contributing to this barrier include astrocytes, pericytes, microglia, and neurons to
collectively form the neurovascular unit (Abbott et al., 2010). The BBB develops by
embryonic day 11 in mouse (Abbott et al., 2010) and is formed by birth (Saunders et al.,
2000). Previous studies have shown that signaling mechanisms, such as the
Wnt/β-catenin pathway, are essential for BBB development and results in increased
expression of the tight junction protein Claudin 3 (Liebner et al., 2008). Disruption of the
BBB is associated with pathologies such as Alzheimer’s disease, multiple sclerosis,
epilepsy, and brain tumors. In Alzheimer’s disease, patients have reduced cerebral blood
flow and reduced glucose uptake by the brain vasculature (Bell and Zlokovic, 2009).
Multiple sclerosis involves the recruitment of immune cells across the BBB into the brain
resulting in CNS inflammation, while epileptic patients may exhibit a temporary opening
of the BBB during an attack (Abbott et al., 2002). Utilizing the BBB as a drug delivery
route has proven to be a challenge due to a number of transporters expressed on the
endothelial cells that not only inhibit drug uptake, but also aid in drug resistance by
pumping them out of the brain and back into circulation (Bronger et al., 2005). Future
studies investigating mechanisms that restore a disrupted BBB or temporarily modulate it
for drug delivery will prove to be invaluable for treating these pathologies.
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Figure 1-1.

Central Nervous System Barriers.

The BBB is formed between brain endothelial cells and the surrounding brain tissue
consisting of cells such as astrocytes and neurons. The ependymal layer creates a
transient barrier between the CSF and the brain. The BCSFB consists of the CP epithelia
(CPe) that forms a barrier between the CSF and fenestrated blood vessels. The
meningeal barrier is localized to the outer surface of the brain (not shown).
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Meningeal Barrier
Another barrier is the meningeal cover surrounding the outer surface of the brain.
It consists of three layers, the dura mater, the leptomeninges containing the arachnoid
membrane, and the pia mater (Decimo et al., 2012). The subarachnoid space is a region
enclosing the CSF that spans between the arachnoid and pia layers. Although not as well
characterized as the BBB, it plays an important role in regulating the exchange between
the blood vessels in the pia layer and the cerebrospinal fluid (CSF) localized to the
subarachnoid space. The meninges originate from the neural crest cells (Mack et al.,
2009). Early in development, this layer is called the inner endomeninx later forming the
pia-arachnoid, and the outer ectomeninx forms the dura and cranial bones (Mack et al.,
2009). The meningeal layer also plays an important role in the development of the
cortex. It can secrete retinoic acid that regulates neuron production by influencing
neuroepithelia to become neurons (Siegenthaler et al., 2009) and bone morphogenic
protein (BMP)7 to regulate corpus callosum development in the brain (Choe et al., 2012).
Subarachnoid hemorrhaging can occur in this layer. These hemorrhages can be caused
by a traumatic injury or as a result of too much or too little CSF production, coagulation
disorders, or vascular deformities (Mack et al., 2009). Pneumococcal meningitis is
another condition commonly associated with the meninges where infections of
Streptococcus pneumoniae can infect the brain and result in inflammation of the
subarachnoid space (Barichello et al., 2013).
Neuroependymal Cell Layer
The neuroependyma or ependymal cells line the brain ventricles and form a
barrier between the brain and CSF. However, unlike the BBB which contains tight
junctions between endothelial cells, the neuroependymal cells have “strap junctions”
creating a primitive barrier during development (Saunders et al., 2000). It also aids in
brain formation by secreting the BMP inhibitor Noggin and promoting neural stem cells
within the subventricular zone to differentiate into neurons (Lim et al., 2000).
Ependymal cells arise from glial precursor cells and express glial fibrillary acidic protein
(GFAP) in early development (Del Bigio, 1995). The cells possess junctions at eight
weeks in humans, but still lack microvilli and cilia at this stage. Later, as cilia start to
form on the apical or CSF side of the cell, they begin to move and function to transport
the CSF in the direction of bulk flow (Del Bigio, 1995). These cells have also been
shown to have secretory function by expressing granulophysin, a membrane protein
found in transport vesicles, They also play a role in transporting and inactivating
neuropeptides by expressing receptors for these molecules and producing enzymes that
inhibit neuropeptide activity (Del Bigio, 1995). In addition, ependymal cells are related
to diseases such as ependymomas, a type of glial cell tumor, that can arise within the
spinal cord or along the brain ventricles (Hasselblatt, 2009).
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Blood-Cerebrospinal Fluid Barrier
The final barrier and the focus of this dissertation is the BCSFB. This barrier
consists of the CP which contains fenestrated blood vessels and epithelial cells between
blood and CSF. It is localized to the brain ventricles where CSF is stored. In mammals,
there are four brain ventricles: third, fourth, and two lateral ventricles, each containing a
CP. Multiple signaling pathways have been implicated in CP development such as Sonic
hedgehog (Shh) (Huang et al., 2009; Nielsen and Dymecki, 2010), BMP (Currle et al.,
2005), and Notch signaling (Irvin et al., 2004) which are discussed in more detail in
Signaling Pathways and the Choroid Plexus on pg. 7. Similar to the BBB, the BCSFB
is involved in a number of pathologies including Alzheimer’s disease, multiple sclerosis
(Wolburg and Paulus, 2010), and hydrocephalus (Wodarczyk et al., 2009). CP
papillomas and carcinomas can also arise primarily in infants and young children
(Wolburg and Paulus, 2010). How the CP contributes to these conditions is discussed in
Choroid Plexus and Disease on pg. 9.
Background of the Choroid Plexus
Historical Overview
The CP was first documented by Herophilus, an ancient Greek physician, who
described the CP of the lateral brain ventricles (Dohrmann, 1970). He observed that it
resembled a fetal membrane or ‘chorioid’ resulting in its final name ‘choroid plexus
(Dohrmann, 1970). In 1543, the morphology of the CP in the lateral ventricles was
described in De Fabrica by Vesalius (Dohrmann, 1970). The CP of the fourth and third
brain ventricles were later recognized in 1664 by Willis and in 1695 by Ridley,
respectively (Dohrmann, 1970). This structure was originally believed to house an
animal’s spirit, although future experiments done by Paul Ehrlich and Edwin Goldmann
in the late 19th and early 20th century discovered its barrier function in regulating CNS
homeostasis (Dziegielewska et al., 2001; Wolburg and Paulus, 2010). The role of the CP
in CSF production was first suggested by Willis in 1664, and in 1855, Luschka developed
the “vesicular theory” of the CP as a secretory organ (Mortazavi et al., 2014). These
historical insights have paved the way for our current thinking of the CP, not only as a
structure responsible for CSF production, but also as a potential therapeutic agent or
target in disease (see Protection and Repair of the Brain on pg. 5).
Choroid Plexus Function
CSF Production. Not only is the CP responsible for forming the BCSFB, but a
major role of the CP is to produce and secrete the CSF. Humans can produce as much as
580 ml of CSF per day and can take up to nine hours to replace this volume as it
circulates (Oreskovic and Klarica, 2010). A number of transporters and aquaporin
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channels expressed on both apical and basal sides of the CPe release ions and water into
the brain ventricle to generate the CSF (Brown et al., 2004). The apical and basal sides
of the cell differ in the types of ion transporters expressed, creating an osmotic gradient
that releases ions and water into the ventricular space. Examples of ion transporters
expressed on the apical surface include Na+-K+ ATPase and Na+-2Cl-K+ cotransporters,
while the basal side express Na+ coupled HCO3- transporters and K+-Cl- cotransporters
(Brown et al., 2004).
CSF is produced first by a passive influx of plasma filtrate from the bloodstream
into the interstitial space. Then, active transport mechanisms such as carbonic anhydrase,
converts water and CO2 into H+ and HCO3-, allowing for the exchange of these ions with
Na+/ Cl- transporters on the basolateral side. This influx of Na+/ Cl- into the cell then
activates transporters on the apical membrane to release Na+, Cl−, HCO3− and K+ ions in
an ATP-dependent manner. This creates an osmotic gradient which then stimulates
aquaporin channels to secrete water towards the ventricular space thereby producing CSF
(Sakka et al., 2011). In general, the CSF has lower concentrations of K+, compared to
concentrations of Na+ and Cl- (Sakka et al., 2011). In addition to ions, there are other
components such as glucose and amino acids found in the CSF although at much lower
concentrations compared to plasma. Overall protein in the CSF is also significantly
reduced compared to the high levels of protein expressed in plasma (Brown et al., 2004).
The route of CSF flow starts in the lateral ventricles, flows through the interventricular
foramina into the third ventricle, through the cerebral aqueduct to the fourth ventricle,
and then enters the subarachnoid space through the foramen of Magendie. Once in the
subarachnoid space, CSF flows down into the spinal cord or is reabsorbed into the
bloodstream (Sakka et al., 2011).
Protection and Repair of the Brain. Because the CP produces the CSF, it
allows the brain to be maintained in a buoyant environment aiding in protection from
injury. The CP can also expresses cytokines in situations of injury or disease that results
in an inflammatory response (Dragunow, 2013). While the traditional role of the CP is to
produce CSF and regulate CNS homeostasis, new insights have suggested that it may be
therapeutically relevant. The CP has been identified as the gatekeeper for allowing
immune cells such as leukocytes into the CSF which ultimately allows easier access to
the brain. Specific cytokines such as interferon-γ activate the CP (Schwartz and Baruch,
2014) and cell adhesion molecules such as vascular cell adhesion molecule-1 and the
enzyme CD73 each contribute to the extravasation of immune cells across the barrier
(Shechter et al., 2013). The CP has been shown to aid in an anti-inflammatory response
by allowing the trafficking of monocytes into the CSF and migrating to areas of injury
along the spinal cord (Shechter et al., 2013). The CP also secretes a number of growth
factors, such as insulin-like growth factor-II and transforming growth factor-β that aid in
the development and repair of the brain. Studies have shown that insulin-like growth
factor-II is secreted into the CSF follow damage to the brain and transforming growth
factor-β levels increase in response to brain ischemia (Chodobski and
Szmydynger-Chodobska, 2001). Neuron formation is also influenced by growth factors
that regulate progenitor cells and their patterning (Redzic et al., 2005). Because the CP

5

secretes a number of growth factors, it has been suggested that epithelial cells
transplanted into an injured brain could promote regrowth of surrounding tissue (Emerich
et al., 2005; Thanos et al., 2010). In fact, studies have shown that grafted CP cells into a
damaged spinal cord resulted in regeneration of nearby neurons (Ide et al., 2001). Recent
studies have also investigated ways to encapsulate these cells for transplantation (Thanos
et al., 2010).
Before we can better understand how the CP is deregulated or altered in disease,
we need to understand the mechanisms governing its normal development and function.
For example: while the recent proposal of using CPe for transplantation to aid in brain
repair is promising due to its secretion of a number of growth factors (Emerich et al.,
2005), a more comprehensive understanding of genetic and molecular pathways
regulating this phenomenon is needed in order to prevent off target effects from this type
of therapy. Conceivably, the lack of research investigating genetic components of CP
development and function is not that this barrier is considered less important than the
BBB, but that the ability to efficiently study this structure in a living system is hindered
due to its internal localization within the brain ventricle. While the systems discussed in
Choroid Plexus Model Systems on pg. 10 provide a snapshot or reconstruction of how
the CP develops and functions; the development of this structure has seldom been
visualized in a living system nor has it been genetically dissected.
Choroid Plexus Development
The CP develops starting at six weeks gestation in humans and embryonic day 11
in mice (Bill et al., 2008). In humans, the stages of CP development have been classified
by the amount of glycogen present in the cells, which may serve a nutritive role in the
developing brain (Dohrmann, 1970). Glycogen is absent during the initial and final
stages, but is abundant in CPe during intermediate periods (Dziegielewska et al., 2001).
Glycogen accumulation also seems to correspond to periods of cell division within the
epithelia (Sturrock, 1979). Historical electron microscopy studies have identified two
types of CPe termed light and dark (Sturrock, 1979). Studies have shown that both are
epithelial cells, but there may be functional discrepancies between them. Dark cells have
a denser cytoplasm, more ribosomes and rough endoplasmic reticulum, and have thinner,
longer microvilli compared to light cells (Dohrmann, 1970; Ormandzhieva, 2010).
After neural tube closure, the neuroepithelium, from which the CP is derived,
begins to migrate into the ventricles starting around seven weeks gestation (Mortazavi et
al., 2014; Strazielle and Ghersi-Egea, 2000). The neuroepithelia is initially
pseudostratified tall columnar epithelium at this stage. As it differentiates, it becomes
cuboidal and acquires microvilli by around week 17 and maintains this morphology for
12 weeks (Strazielle and Ghersi-Egea, 2000). At around week 29, the cells can be
cuboidal or squamous and have central or basal nuclei (Mortazavi et al., 2014). The CP
of the fourth ventricle develops first followed by the lateral and third ventricles
(Dziegielewska et al., 2001). Early in development, these structures are referred to as the
diencephalic CP (dCP) of the third ventricle, telencephalic CP (tCP) of the lateral
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ventricles, and myelencephalic CP (mCP) of the fourth ventricle (Bill et al., 2008;
Strazielle and Ghersi-Egea, 2000). Wnt3a is highly expressed within the developmental
regions that give rise to the dCP, tCP and mCP, including the diencephalic dorsal
midline, the cortical hem, and the rhombic lips, respectively (Louvi et al., 2007). The
cortical hem arises from neuroepithelium. Wnt signaling within this region becomes
up-regulated as the CP starts to develop. Studies have shown that decreased Wnt
expression in the cortical hem of mutant mice results in a loss of tCP development
(Grove et al., 1998). Also at the cortical hem, genes such as Hes1, 3, and 5 and
neurogenin 2 play a role in CP epithelial fate (Imayoshi et al., 2008). Studies have
demonstrated that Hes genes can repress neurogenin 2 and promote CP epithelial cell
fate, while neurogenin 2 can also block Hes expression and promote Cajal-Retzius cell
differentiation. Cajal-Retzius cells are neurons that aid in neuronal migration and are
also derived from the cortical hem (Imayoshi et al., 2008).
The tCP of the lateral ventricles has been perhaps the most widely studied in
terms of its development. This may be because models used to study the CP, such as the
opossum Monodelphis domestica, possess lateral ventricles that develop postnatally
(Liddelow et al., 2010). A previous study demonstrated by injecting bromodeoxyuridine
(BrdU) into developing M. domestica, that the tCP grows from the root outward toward
the tip of the CP and originates from the base of the ventricular wall where
neuroependymal cells are present (Liddelow et al., 2010). They observed that the number
of CPe increase dramatically in early postnatal stages around P3-P5, but that this rate
begins to decrease after these time points. Another interesting finding is that although
neuroepdendyma continue migrating outwards as new cells are added, they no longer
undergo mitosis after they have differentiated into CPe (Liddelow et al., 2010).
Studies performed in M. domestica demonstrate that even in early development,
the CP is functional (Liddelow et al., 2009). By injecting different molecular weight
dextrans either into the peritoneal cavity or CSF at early stages, size-selectivity was
observed regarding passive permeability across the BCSFB in both directions (blood to
CSF and CSF to blood). Protein concentration within the CSF is significantly higher in
early development than in adult stages with many proteins such as albumin and
transferrin that are believed to aid in brain development (Gato et al., 2004). While it
might seem reasonable to assume the barrier is not formed at this stage, therefore
allowing larger molecules such as proteins to penetrate the barrier, studies have
demonstrated that tight junctions are already present at these early stages (Liddelow et
al., 2011). By injecting bovine fetuin, the protein was observed to be transported across
the barrier by only a specific subset of cells in the CP and is transferred in a
unidirectional manner; it cannot be transported from the CSF into the bloodstream, but
only from blood into CSF (Liddelow et al., 2009).
Signaling Pathways and the Choroid Plexus
Developmental signaling pathways such as Shh (Huang et al., 2009; Nielsen and
Dymecki, 2010), BMP (Currle et al., 2005), and Notch (Irvin et al., 2004) have been
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found to contribute to CP formation. Shh is a morphogen involved in many aspects of
dorsal-ventral patterning and its signaling promotes proliferation of precursor cells in the
cerebellum (Huang et al., 2009). Recent evidence has shown that Shh also plays a role in
the outgrowth of the CP into the brain ventricle and is highly expressed with the CPe
themselves (Huang et al., 2009; Nielsen and Dymecki, 2010). These studies showed that
Shh secreted by CPe can act on nearby germinal zones termed the lower rhombic lip
which houses CP progenitor cells (Nielsen and Dymecki, 2010). Shh promotes
proliferation of these cells to form the mature CP. Studies have also demonstrated that
Shh secreted by CPe can act on nearby pericytes that help coordinate the outgrowth of the
fenestrated vasculature associated with the BCSFB (Nielsen and Dymecki, 2010).
While Shh is the major contributor to ventral development, BMPs are the primary
factors associated in dorsal patterning. BMP expression localized to the dorsal roof plate
is present within the embryonic dorsal midline, an embryonic patterning center involved
in CP development (Currle et al., 2005). BMPs can activate or repress transcription
factors Msx1 or Lhx2 respectively to specify CP development (Imayoshi et al., 2008). In
vitro studies have shown that BMP4 alone can influence neuroepithelial progenitor cells
to differentiate into CPe (Watanabe et al., 2012). Other BMPs such as BMP12, also
known as Gdf7, have been demonstrated in fate map studies to be activated within
neuroepithelial cells of the dorsal midline which later differentiate into the CP. These
studies demonstrate that removing Gdf7 before the CP is induced results in no CP
development. Ablating Gdf7 later in development once the CP has been induced to form
from neuroepithelia results in a reduced CP except for the posterior region of the tCP
(Currle et al., 2005).
CP development and maintenance is also regulated by Notch signaling. Notch
has been shown to be involved in organizing roof plate signaling where the dorsal
midline is localized and organizing interactions between the roof plate and neural cells in
the rhombic lip (Broom et al., 2012). This organizing region also signals for the roof
plate to induce the expression of a common marker of the CP, transthyretin (ttr), a
thyroid hormone binding protein (Broom et al., 2012). Additional studies have shown
that the membrane bound Notch ligand, delta-like 3 has overlapping expression patterns
with ttr in the CP up until around embryonic day 12.5 and that mutated delta-like 3
results in a smaller CP of the fourth ventricle (Sparrow et al., 2002). Notch2 expression
has been identified within CPe and Jagged1, a ligand of Notch signaling, is localized to
CP vasculature. Similarly, as described for Shh signaling, it has been suggested that
Notch2 may also interact with Jagged1 at the vasculature to coordinate CP development
(Irvin et al., 2004). Notch2 is also localized to the microvilli of CPe and its inhibition
results in microvilli malformation suggesting an addition role of Notch2 in CP
maintenance (Tanaka et al., 2007).
Growth factors also influence CP homeostasis. Members of fibroblast growth
factor receptor (FgfR) family are expressed in CP and one ligand, Fgf2, is expressed in
CPe in early development and adult stages (Greenwood et al., 2008). Evidence has
demonstrated that Fgf2 is not implicated in CPe proliferation (Greenwood et al., 2008),
but appears to be involved in regulating CSF production. Exogenous Fgf2 results in
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more epithelia possessing properties of dense, dark cells as described in Choroid Plexus
Development on pg. 6 with reduced secretory function (Gonzalez et al., 2010).
While the role of Wnt3a was discussed previously in Choroid Plexus
Development, other members of the Wnt pathway also act as a patterning cues for CP
development including Wnt5a, 7a, and 2b, expressed in the telencephalon within the
organizing cortical hem (Grove et al., 1998). In early development, Wnt-1 is involved
along with the transcription factor Otx2 in patterning the midbrain-hindbrain boundary of
the neural tube. These two genes overlap in their expression, but Wnt-1 extends in the
caudal direction and Otx2 is more rostral (Bally-Cuif et al., 1995). Recently, Otx2 has
been shown to be essential not only in early CP development, but also in maintenance. A
loss of Otx2 in mice at embryonic day 9 resulted in a loss of CP formation in all brain
ventricles. However, a loss of Otx2 later in development caused only the CP of the fourth
ventricle to have a smaller size, whereas the CP of the lateral and third ventricles was not
affected (Johansson et al., 2013). While multiple signaling pathways, such as those
presented here, have shown to be essential for CP development and function, how these
pathways interact with one another to generate the CP and downstream components
involved in these pathways warrants further investigation.
Choroid Plexus and Disease
A number of diseases and conditions are associated with the CP including CP
carcinomas and papillomas (Wolburg and Paulus, 2010), hydrocephalus (Wodarczyk et
al., 2009), epilepsy (Suzuki et al., 2008), multiple sclerosis (Vercellino et al., 2008), and
Alzheimer’s disease (Alvira-Botero and Carro, 2010). Recent studies have shed light on
the fact that the CP undergoes anatomical and physiological changes when these
conditions are present. For example, disruption of the BCSFB in multiple sclerosis
results in inflammation and leakage of T lymphocytes into the CSF (Vercellino et al.,
2008; Wolburg and Paulus, 2010), and in Alzheimer’s disease patients, the CP has
decreased function in amyloid beta plaque clearance (Alvira-Botero and Carro, 2010;
Wolburg and Paulus, 2010). For an extensive list of these pathologies and their
association with the CP please see Emerich et al. (Emerich et al., 2005). There are also
genetic variations that occur in the CP with these conditions, although not much is known
regarding the mechanism of these genetic pathways and how they become disrupted in
disease. A few examples include: myoclonin1 protein which is developmentally
expressed in the CP and is mutated in epileptic patients(Suzuki et al., 2008),
Twist-related protein-1 and constitutively active Notch 3 which promote invasion and
cell proliferation in CP tumors (Wolburg and Paulus, 2010), and Polycystin-1 deficiency
that results in hydrocephaly (Wodarczyk et al., 2009). A loss of genes in the CPe such as
p73, FoxJ1, and E2f5 can also result in hydrocephalus (Greenwood et al., 2008). The
CP’s role in regulating protein composition in the CSF is crucial in maintaining CNS
homeostasis. An increase of protein in the CSF has been correlated with conditions such
as schizophrenia, stroke, and depression (Liddelow et al., 2011).
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Choroid Plexus Model Systems
Previous studies have used a variety of model systems to gain insights into CP
formation and function. In vitro cell culture models are used typically to investigate
transport mechanisms across the barrier or to measure transepithelial resistance (TER).
Studies have shown that these cultured cells mimic what is found in vivo by possessing
microvilli on the apical surface, expressing tight junction proteins, and demonstrating
basolateral to apical transport across the membrane (Angelow et al., 2004).
Double-chamber culture models provide a more physiological environment containing
blood, epithelial, and CSF layers (Monnot and Zheng, 2013; Spuch and Carro, 2011). In
addition, whole-tissue experiments have been done by dissecting the CP from rat or
dogfish shark and maintaining the tissue in a CSF-like media (Baehr et al., 2006; Reichel
et al., 2008; Villalobos et al., 2002). By incubating the intact CP with fluorescent organic
ions, such as fluorescein(Villalobos et al., 2002) and Texas Red(Reichel et al., 2008),
these studies have been able to uncover the mechanisms involved in the transport of
organic ions; for example, whether it is active or passive and whether it is Na + or
K+- dependent (Baehr et al., 2006). While in vitro systems provide benefits for
understanding the CP’s role at the cellular level, they do not provide a suitable
developmental model to study how epithelial cells migrate over time to form the mature
CP and do not allow for a comprehensive genetic analysis. In addition, as other studies
have shown, other cell types such as pericytes or fenestrated capillaries can influence or
respond to signals, such as Shh secreted by CPe, indicating the importance of maintaining
the microenvironment in these studies (Nielsen and Dymecki, 2010).
Regarding in vivo models, there have been a variety of organisms used to analyze
the CP at various stages of life. Sheep, because of their significant CSF volume within
the brain ventricles, have been used to study CSF composition and evaluate how fluid
production and secretion change during aging (Chen et al., 2012; Chen et al., 2010). This
is relevant for understanding the CP’s role in age-related diseases such as Alzheimer’s
disease, where the CP has been shown to function in beta-amyloid clearance (Gu et al.,
2014). On the other hand, early CP development and size-selective barrier properties
have been investigated using marsupials such as the opossum (Ek et al., 2003; Liddelow
et al., 2009; Liddelow et al., 2010). When opossum pups are born, their brain is more
immature compared to other species with the CP just beginning to form, therefore
providing an advantage in studying early developmental processes (Ek et al., 2003; Li et
al., 1997; Liddelow et al., 2010). Previous studies using this model have provided
significant insight into the mechanisms regarding CP formation such as how epithelial
cells present in early development still reside in later stages suggesting that the CP is not
a structure with high rates of proliferation (Liddelow et al., 2010). Marsupials have also
been used to determine the transport of specific proteins across the barrier such as
albumin (Knott et al., 1997) and transthyretin (Li et al., 1997).
Mice have provided a genetic model for investigating genes and signaling
pathways important for CP development and maintenance. A transcriptome study done
in mice revealed that the CP expresses tight junctions, transporters, and neurotransmitter
receptors. Some of the more highly expressed genes were transthyretin, transferrin, and
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genes involved in energy metabolism (Marques et al., 2011). The study also showed that
while the CP has a unique transcriptome signature, it most closely resembles the BBB
(Marques et al., 2011). Other transcriptome studies have demonstrated that the human
and mouse CP are very similar in gene expression suggesting that they may also function
in a similar manner (Janssen et al., 2013). Recent microarray data comparing adult
human and mouse CP showed that there are no genes in human that are not expressed
mice, although a few genes in mice are not in human (Janssen et al., 2013). The major
difference between species in regard to CP function was that in mice, the CP is also
responsible for carbohydrate metabolism and has a more significant role in development
of the brain and eye (Janssen et al., 2013). Also, a transcriptome analysis of the CP in
early development compared to adults has shown that the expression in a large number of
genes do not vary between ages suggesting that even early on, the CP is a functional
organ (Liddelow et al., 2012).
Studies of the CP in teleosts are far fewer compared to the other models
mentioned previously. Teleosts have two identified CP structures, one in the third and
one in the fourth ventricle (Garcia-Lecea et al., 2008). Historically, the CP of the third
ventricle is often referred to as the dorsal sac or saccus dorsalis (Obermüller-Wilén,
1973). In the 1970s, comparative anatomical electron microscopy studies done in the
teleost Leuciscus rutilus demonstrated that the dorsal sac and the hindbrain CP in the
fourth ventricle are similar with one another, and also resemble the CP in mammals
(Obermüller-Wilén, 1973). These studies found tight junction proteins and microvilli
within the epithelia, and identified coated vesicles for transporting proteins
(Obermüller-Wilén, 1973). While the models discussed in the preceding paragraphs
provide a snapshot or reconstruction of how the CP develops and functions; the
development of this structure has seldom been visualized in a living system nor has it
been genetically dissected.
Background of the Zebrafish Model
We suggest zebrafish as a practical teleost model to study the CP because of
advantages such as small size, transparent nature, rapid ex utero development, and
genetic tractability (Goldsmith and Jobin, 2012). As discussed, in the following sections,
they also possess CNS structures similar to mammals. Comparable to the dogfish shark
(Villalobos et al., 2002), the CP in zebrafish lies over the brain ventricle providing an
“inside out” model that allows for live imagining of its development in real time. Besides
being an excellent developmental model system, zebrafish are also known for being
genetically tractable. Forward genetic screens are commonly used in zebrafish due to
easy maintenance and large numbers of offspring. In the following sections, the
historical rise of zebrafish as model system, a discussion of their CNS attributes, and their
use in developmental and genetic studies is described.
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Historical Overview
Zebrafish, (Danio rerio), is a relatively new vertebrate model system that has
recently gained momentum in the field of development and genetics (Grunwald and
Eisen, 2002; Stemple and Driever, 1996). Originating from streams and rivers in India
(Arunachalam et al., 2013), zebrafish began to be used for scientific research in the 1960s
when George Streisinger used them to study recessive mutations in genes responsible for
vertebrate nervous system development (Grunwald and Eisen, 2002). Zebrafish possess
multiple characteristics that made them an attractive model for these early developmental
and genetic studies. One advantage is that zebrafish are vertebrates having CNS
structures similar to mammals. They also grow rapidly outside of the mother and have a
heartbeat by 24 hours post fertilization (hpf). Their generation period is around 3-4
months. Zebrafish are transparent during larval stages allowing development to be
observed in real time. Because of their small size and large number of offspring, they are
also ideal for high-throughput small molecule and genetic screens (Grunwald and Eisen,
2002; Stemple and Driever, 1996). In 1976, Streisinger, along with a colleague Charline
Walker also developed methods for generating homozygous diploid embryos to discover
recessive phenotypes. This was done by activating eggs with ultra-violet light-treated
sperm, (which does not contribute genetic information), and suppressing the first mitotic
cleavage in the egg (Grunwald and Eisen, 2002). These findings were published in
Nature in 1981 (Streisinger et al., 1981). In addition to Streisinger, others also began
using zebrafish as a model, such as Charles Kimmel who first used zebrafish to study
neurons and brain structure (Grunwald and Eisen, 2002; Kimmel et al., 1991). Later in
1993, large-scale forward genetic screens for embryonic patterning and development
were initiated in Tubingen, Germany by Christiane Nüsslein-Volhard and in Boston,
Massachusetts by Marc Fishman (Grunwald and Eisen, 2002). It was reported that
around 4,000 phenotypes were identified that were embryonic lethal. In 1996, an entire
issue of Development was published covering forward genetic screens in zebrafish from
Boston and Tubingen (Nusslein-Volhard, 2012). It was stated that more than 400 new
genes were identified from these efforts (Nusslein-Volhard, 2012). In more recent years,
the zebrafish genome has been sequenced making it easier to identify genes from these
mutants.
Zebrafish Central Nervous System
Previous studies have confirmed that zebrafish possess CNS barriers, such as the
blood-brain barrier (BBB) with functional properties similar to mammals, and a dCP and
mCP that constitute the BCSFB (Bill et al., 2008; Garcia-Lecea et al., 2008; Jeong et al.,
2008; Xie et al., 2010). The CSF in zebrafish is localized within the forebrain, midbrain
and hindbrain ventricles. These structures are annotated in Figure 1-2. The development
of the zebrafish CNS is similar to other vertebrates in that it arises from the neural plate
on the dorsal region of the embryo (Wilson et al., 2002). However, the mechanism of
neural tube formation differs in teleosts. The zebrafish neural plate forms a solid
structure first called the neural keel and later hollows out to form a neurocoel as the cells
begin to break away from the center of the tube (Blader and Strahle, 2000). This is in
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Figure 1-2. The Zebrafish Forebrain, Midbrain, and Hindbrain Ventricles
Relative to the CP.
A dorsal confocal image with bright field overlay (A) and fluorescence (B) of a zebrafish
at 4 dpf with a intraventricular injection of a 2 mega-dalton (MD) rhodamine dextran
(red). The yellow overlay is due to GFP expression in the dCP and mCP and the
rhodamine dextran injection. (C) and (D) are similar images as (A) and (B) except from
a lateral view. H: Hindbrain, M: Midbrain, F: Forebrain. Arrowhead: dCP, Arrows:
mCP. Scalebars are 50µm.
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contrast to other vertebrates where neural folds form at the lateral edge of the neural plate
that later fuse to form the neural tube. Signals such as BMP have also been demonstrated
to be essential for neuroectoderm differentiation in zebrafish. BMPs induce the ectoderm
towards an epithelial fate rather than neuronal fate. Zebrafish mutants such as
snailhouse, which have a mutation in BMP7 and develop a larger neural plate due to
defective BMP signaling (Blader and Strahle, 2000). Shh signaling which is secreted by
the notochord underlying the neural tube plays a role in patterning ventral neurons. In
specific mutants for Shh in zebrafish, the motor neurons continue to develop normally,
but lateral floorplate cells are absent. Mutations in other components of the zebrafish
pathway such as Gli2, a downstream component of Shh, do not affect floorplate
development. This differs from mice with mutant Gli2, which do not develop a floorplate
at all (Blader and Strahle, 2000). The differences in these mutants across species may be
due to the genome duplication event in zebrafish where additional genes may compensate
for another gene’s loss of function. The zebrafish spinal cord is similar to other
vertebrates with motor neurons localized to ventral regions and sensory neurons arise
from the roof plate (Blader and Strahle, 2000).
Once the neural tube has formed, cells begin to divide asymmetrically with apical
cells differentiating into neurons. Basal cells in the neural tube express high levels of
Notch and replace the apical cells, while the differentiated neurons possess low Notch
activity (Schmidt et al., 2013). The zebrafish brain develops rapidly and by 28 hpf
resembles the brain of other vertebrate embryos (Schier et al., 1996). However, the
zebrafish brain appears to be inside-out, because as the telencephalon begins to develop,
it folds outward with the proliferative zones on the outer surface. In mammals, the neural
tube evaginates, so that the dividing cells are more internal (Schmidt et al., 2013). The
same holds true for the zebrafish ependymal cells which are found at the top and
dorsolateral regions of the brain ventricle in the telencephalon (Schmidt et al., 2013). As
is discussed in Zebrafish as a Model for Choroid Plexus Development on pg. 15, the
CP is also found on the outer surface of the brain.
A number of zebrafish mutants have been discovered from large-scale forward
genetic screens having defects in various aspects of brain development. These mutations
affect dorsal-ventral/ anterior-posterior patterning, midbrain-hindbrain boundary
formation, neurogenesis, brain ventricle inflation, and brain and notochord morphology
(Schier et al., 1996). Additional mutants have also been identified for genes involved in
brain ventricle formation and inflation such as Na+K+ ATPase in the snakehead mutant
revealing that circulation is required for ventricle expansion as the brain develops
(Lowery and Sive, 2005).
While some aspects of brain development and morphology in zebrafish may differ
compared to mammals, zebrafish do possess CNS barriers similar to other vertebrates. In
recent years, a number of studies have described the zebrafish BBB demonstrating that it
has barrier properties similar to those found in other vertebrates, such tight junctions and
transporters. One of the earlier studies demonstrated that the zebrafish BBB expressed
the tight junction Claudin-5 (Cldn5) and Zonula Occludens-1 (ZO-1) which are known
markers of barrier properties (Jeong et al., 2008). Another common marker of the BBB is
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the multidrug resistance transporter-1, (MDR1). Zebrafish also have Mdr1 expression
that localizes to the brain vasculature and is already present as early as 2 dpf (Umans and
Taylor, 2012). In 2010, a transgenic line was created expressing GFP in the plasma to
monitor BBB permeability in zebrafish. Using this line, they found that the vasculature
of the brain and eye are functional at around 3 dpf based on the presence of GFP retained
within the vasculature (Xie et al., 2010). Studies have also demonstrated that within the
zebrafish, neuroepithelial cells lining the brain ventricle express Cldn5 that is essential
for maintaining its barrier properties between the CSF and the brain. A loss of Cldn5
resulted in reduced ventricle expansion and increased permeability between cells (Zhang
et al., 2010).
Zebrafish as a Model for Choroid Plexus Development
In recent years, there have been two studies using zebrafish to analyze CP
development and identify signaling pathways involved in its formation (Bill et al., 2008;
Garcia-Lecea et al., 2008). These two studies generated distinct enhancer trap lines
expressing the green fluorescent protein (GFP) in the dCP and mCP. The enhancer trap
lines were generated using the Tol2 transposase system (Urasaki et al., 2006), a molecular
tool commonly used in zebrafish for generating enhancer trap or transgenic lines.
Typically, constructs are injected into single-celled embryos and contain a fluorescent
reporter to visualize integration of the construct. Once the embryos are raised to
adulthood, their offspring can be screened to look for germline transmission of the
transgene.
The zebrafish enhancer trap lines, referred to as Gateways and Et Mn16, provide a
first-hand look into how the CP develops over time in a living organism simply by
monitoring GFP expression. In Gateways, they detected GFP as early as 24 hpf and at 36
hpf observed a sheet of cells near the midline called the tela choroidea (TC). These cells
combine to form the mCP between 72-144 hpf (Garcia-Lecea et al., 2008).
Transplantation experiments in embryos demonstrated that the CPe originated from
neural crest cells of rhombomere 5 (Garcia-Lecea et al., 2008). Utilizing the transparent
nature of zebrafish larvae, they were also able to visualize the surrounding vasculature as
the CP develops simply by incubating the larvae in Cell Trace™ Bodipy® TR methyl
ester (Garcia-Lecea et al., 2008). In our studies, we have observed by intravenously
injecting fluorescent tracers into 4 dpf larvae that the overlying vasculature around the
CP does not possess barrier properties as observed by lack of the BBB marker, glucose
transporter 1 (Glut1) within the vasculature (refer to Zebrafish CP Possesses
Transporter Activity on pg. 35 and Figure 1-3). This confirms what has been found in
mammals where the vasculature in the CP does not have barrier properties, is fenestrated,
and connected by covering structures called diaphragms (Ormandzhieva, 2010). To
determine the signaling pathways essential for proper CP development, previous studies
on the zebrafish CP utilized transgenic lines with defects in Notch and Shh signaling and
crossed them with Gateways. Using time-lapse imaging, they monitored what affects
these pathways had on the developing CP. Defects in Notch signaling caused the cells to
differentiate early resulting in a region of GFP- negative cells along the ventricle and the
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Figure 1-3.

Vasculature Surrounding the CP Does Not Possess Barrier Properties.

(A) A 70 kilo-dalton (kD) albumin tracer (blue) was injected intravenously into the
Et(cp:EGFP)sj2 line at 4 dpf . GFP is expressed in the dCP (arrowhead) and mCP
(arrow). The brain vasculature is expressing mCherry (red) under the control of the BBB
maker glut1. (B) A magnified image of the mCP (green) and the surrounding fenestrated
vasculature in blue/dashed line. BBB vasculature is shown in red. Scalebars are 50 µm.
GFP-positive cells forming smaller dispersed aggregates rather than one compact
structure. Loss of Shh signaling resulted in fewer numbers of cells and activation of
apoptosis in CPe (Garcia-Lecea et al., 2008).
A similar analysis was done using the Et Mn16 line. This line forms a rounded CP
structure by 5 dpf. They also visualized vascular development utilizing a genetic
approach by crossing it with Tg(gata1:dsRed) and identified that the vasculature
surrounding the CP originates from the dorsal longitudinal vein (Bill et al., 2008). Using
a chemical approach by treating larvae with the Notch inhibitor DAPT, the CP was found
to be larger overall, thereby also demonstrating the importance of Notch signaling in CP
development. A genetic analysis looking at more specific roles of Notch signaling was
done by injecting morpholinos knocking down expression of a number of Notch receptors
and ligands (Bill et al., 2008).
Few studies have identified genes specifically expressed in the CP. A recent
study identified a secreted protein called Clusterin specifically expressed in the CP of the
developing zebrafish (Jiao et al., 2011). This localization is similar to mice in that for
early development, low levels of Clusterin are detected throughout the brain, but the
highest expression resides in the CP (Jiao et al., 2011). Clusterin, which aids in
aggregation, has be associated with an increased risk of Alzheimer’s disease a plays a
role in the clearance of amyloid (Aβ) peptide (Lambert et al., 2009; Thambisetty et al.,
2010). Using the Gateways transgenic line discussed previously and two-color
fluorescent in situ hybridization, Clusterin expression was detected in some of the
GFP-positive cells of the intact CP (Jiao et al., 2011). Another advantage of using
zebrafish in this study was that they were able to answer an outstanding question of
whether the role of Clusterin was regulated by IGF signaling. Because of their small size
and large numbers of offspring per clutch, they aliquotted 30 to 50 zebrafish embryos per
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condition onto a 24-well plate, added an IGF-IR inhibitor to the embryo media, and
determined by in situ hybridization that clusterin mRNA was not affected by IGF
signaling(Jiao et al., 2011).
Zebrafish Genetic Screening Strategies
Zebrafish mutagenesis screens can be performed using a variety of approaches.
The first step in performing a mutagenesis screen is treating the organism with a mutagen
that will introduce mutations into the genome. Ideally, this mutation would also be
introduced into the germ cells, so that it is carried throughout successive generations. A
typical mutagen used in zebrafish screens is N-ethyl-N-nitrosourea (ENU) which
introduces point mutations into the genome. It has been reported that ENU will introduce
germ line mutations for one in every 1 x 105 base pairs (de Bruijn et al., 2009). The
efficiency of ENU mutagenesis also depends on how many rounds of treatment and how
long the organism is exposed to the mutagen. Other compounds have been used such as
Ethyl methanesulphonate (EMS); however the potency is not as efficient as ENU in
zebrafish. Additionally, more non-specific methods can be used such as X-ray, ionizing
radiation, and trimethylpsoralen; however, these can induce small to large deletions or
translocations which may result in mutations in multiple genes at a specific locus (Patton
and Zon, 2001).
After mutagenizing the parental generation, the next step is to determine what
type of screen will be performed. Typically, in forward genetics, diploid screens are used
where embryos are screened for recessive mutations in the F3 generation. This involves
mating numerous siblings within F2 families until a mutation is identified in
approximately 25% of the F3 offspring. This strategy is demonstrated in Figure 1-4.
Another approach is to generate gynogenetic homozygous diploid embryos using either
heat shock or early pressure treatment. This strategy using ultraviolet-irradiated sperm to
activate the egg, does not contribute genetic information. After activation, embryos can
undergo early pressure treatment where meiosis II is inhibited as the spindles are broken
down and the egg retains both sister chromatids as it progresses through mitosis (Patton
and Zon, 2001). Heat shock can also be performed where the first mitosis resulting in
haploid embryos. The second mitosis then occurs resulting in homozygous diploids at all
loci, however, these embryos have a decreased survival rate compared to those with early
pressure treatment. Haploid screens are primarily used to look at early developmental
stages or patterning since haploid embryos typically do not live past 3 dpf (Patton and
Zon, 2001). A limiting factor to these genetic screening strategies is that they only screen
for genes that produce an identifiable phenotype.
Enhancer screens are typically performed to identify the expression patterns for
classes of genes in a cell or tissue specific manner. In zebrafish, they are initiated by
inserting transposons such as Tol2 or Sleeping Beauty into the genome (Korzh, 2007).
Transposons are DNA fragments that can change positions within the genome. In the
case of inserting a transposable element into the zebrafish DNA from another species
such as Tol2 from medaka fish, an enzyme called transposase is used to allow the insert
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Figure 1-4.

Schematic Diagram of an ENU F3 Forward Genetic Screen.
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to jump to different regions of the genome. This strategy provides easy identification of
where the transposon is inserted by using reporter genes, such as GFP, under the
regulation by a weak promoter to be detected in specific regions regulated by these
enhancers (Korzh, 2007).
For retroviral insertions or insertional mutagenesis screens, fragments of DNA are
randomly inserted into the genome and act as a mutagen. These inserted retroviral DNAs
can disrupt exons by introducing premature stop codons, or causing nonsense mediated
decay (Sivasubbu et al., 2007). Insertion into an intron can result in gene silencing or
alternative splicing. Another possibility is that the intron insertion has no effect on the
wild-type transcript resulting in hypomorphs or only a partial loss of gene function
(Sivasubbu et al., 2007). This may pose a problem for this screening method since it is
reported that around 70% of retroviral insertions are in introns (Sivasubbu et al., 2007).
Another obstacle in these studies has been identifying a retrovirus with strong expression
(Sivasubbu et al., 2007). Nonetheless, this method has been utilized as a rapid screening
strategy to identify genes involved in zebrafish embryonic development without the need
for positional cloning (Allende et al., 1996; Amsterdam et al., 1997; Gaiano et al., 1996).
Using Zebrafish for Genetic Analysis
A major hurdle in forward genetics has been the time and effort it takes to map a
gene, with some genes even being deemed “unmappable” due to their position along a
chromosome. However, the zebrafish genome [1.5 giga bases (Gb)] has now been
sequenced making gene identification much easier. Access to the zebrafish genome
assemblies such as Zv8 or more recently Zv9, is also provided through database websites
such as Ensembl (Flicek et al., 2014). In recent years, whole genome and exome
sequencing have been utilized in zebrafish providing an alternative and more rapid way
to identify the gene mutation (Kettleborough et al., 2013; Ryan et al., 2013). In the
following paragraphs, traditional and innovative strategies for discovering causative
genes are described along with the advantages and disadvantages of each approach.
Positional Cloning. Positional cloning is the method typically used to identify
mutated genes from mutants isolated in forward genetic screens. Previous methods for
detecting these genes included chromosome walking by using large genomic libraries of
DNA constructs inserted into bacterial artificial chromosomes (BACs) and sequencing
them to look for mutations (Zhou and Zon, 2011). Today, with the sequenced zebrafish
genome, this strategy is no longer necessary. The method of positional cloning or genetic
mapping is based on the process of recombination between chromosomes and identifying
polymorphic regions within the genome (Zhou and Zon, 2011). Polymorphisms are
regions of repetitive DNA sequences that are unique to that genome. The idea is that
once the original zebrafish strain is outcrossed into a polymorphic strain (having a
genetic backgrounds that differ from one another), the rate of recombination should be
high in areas distant from the gene carrying the mutation and low as the distance from the
mutation decreases (Zhou and Zon, 2011). This is because the mutation is only found in
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the original strain. Also, because mutants are selected based on a specific phenotype, all
mutants should have the same genetic sequence at that locus. Recombination events can
be analyzed by gel electrophoresis where, at the site near the mutation, the majority of
mutants should only have a single band representing recombination events near zero at
this location. The genes amplified in this region are said to have genetic linkage to the
mutated gene (Zhou and Zon, 2011). This process has become more convenient in recent
years as mapping panels have been generated containing 192 primer pairs amplifying
simple sequence length polymorphisms throughout the genome (Henke et al., 2013).
After outcrossing the original line into a polymorphic strain and identifying
heterozygous pairs in the next generation, the first step in positional cloning is to perform
bulked segregant analysis. The goal of this step is to find a map position or the
chromosome containing the mutation. This is typically done by having a pool of
wild-type and a pool of mutant DNA from multiple zebrafish larvae and amplifying the
DNA with polymorphic markers designed throughout the entire genome. Once a
chromosome has been identified, the process of high resolution genetic mapping, using
individual wild-type and mutant DNA samples and additional polymorphic markers for
that chromosome, is done to define a critical interval (Zhou and Zon, 2011). Once an
interval is defined containing a region of candidate genes, these genes can be sequenced
to see if they contain the mutation. While this strategy does provide a way to identify the
mutant gene, it is often time consuming and can be difficult to identify the gene if it is
near the telomere where multiple recombination events occur.
Whole Genome and Exome Sequencing. To overcome this obstacle, new
technologies using next-generation sequencing (NGS) are being used to rapidly identify
genetic mutations. Whole genome sequencing (WGS) is a method that amplifies the
entire genome, including non-coding regions. This approach is similar to bulked
segregant analysis in positional cloning in that pools of wild-type and mutant DNA are
used for sequencing. Alternatively, only mutant DNA can be used and compared to a
reference genome, but this may produce false positive hits (Henke et al., 2013). After
sequencing, the data is analyzed by identifying small nucleotide polymorphisms (SNPs)
and screening for homozygous regions within the mutant DNA. This process of
homozygosity-by-decent involves looking for regions within the genome with decreased
levels of heterogeneity and reduced levels of SNPs (Bowen et al., 2012). Depending on
the coverage efficiency, heterozygous regions within the genome should increase as it
moves away from the mutation (Henke et al., 2013). Since most disease causing
mutations occur within the coding regions of the gene and sequencing the entire genome
can results in large amounts of unused data, an alternative approach is whole-exome
sequencing (WES). WES, which utilizes similar strategies as WGS, provides better
coverage of sequence reads by sequencing only exons within the genome. A number of
genes in zebrafish mutants originating from forward genetic screens have been identified
using this technique (Kettleborough et al., 2013; Ryan et al., 2013).
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RNA-Seq Analysis. A final approach in genetic mapping is RNA-Seq analysis.
This technique is similar to WES sequencing in that it only sequences the coding regions
or RNA and provides better coverage than WGS (Miller et al., 2013). In addition,
RNA-Seq determines the amount of transcript in the sample. This technique is useful for
comparing gene expression levels between wild-type and mutant and determining if other
genes are affected by the mutation in the target gene (Miller et al., 2013). While
RNA-Seq provides better coverage due to the smaller size of the targets, certain aspects
remain that may be a hindrance for identifying the mutation such as identifying mutations
affecting splice sites and the inability to detect weakly expressed transcripts (Ryan et al.,
2013). Identifying the gene containing the causal mutation is similar to the previously
mentioned strategies. Homozygous regions have an allele frequency of 1, with 1 being
the highest frequency. The average allele frequency on the linked chromosome reaches
the highest frequency at the mutated locus (Miller et al., 2013). Discovering genetic
pathways critical for CP development and function and the mutations that contribute to
disease is now possible due to the expansion of innovative methods utilizing in vivo
model systems such as the zebrafish, and breakthroughs in genetic technologies such as
WES and RNA-Seq.
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CHAPTER 2.

CHARACTERIZATION OF THE ZEBRAFISH CHOROID
PLEXUS
Introduction

Previous studies using zebrafish examined the involvement of Shh and Notch
signaling in CP development (Bill et al., 2008; Garcia-Lecea et al., 2008). However,
these studies do not analyze functional CP barrier properties such as tight junctions and
transporters. Here, we generated an enhancer trap line, Et(cp:EGFP)sj2, that expresses
enhanced green fluorescent protein (EGFP) specifically in epithelial cells of the dCP and
mCP. Using this enhancer trap line, we visualized its development in vivo and
demonstrated that several components of the zebrafish CP are comparable to human and
that it is functional in regulating entry into the CSF from the bloodstream. The goal of
this study was to further establish zebrafish as a model to study CP development by
demonstrating barrier properties similar to other vertebrates and to generate tools to
characterize CP mutants identified in future studies.
Central Nervous System Barrier Properties
CNS barriers possess physical and chemical properties to regulate homeostasis
within the brain. The physical barrier consists not only of the cells themselves, whether it
be endothelium or epithelium, but also specialized proteins such as tight junctions and
adherens junctions that substantially impede macromolecules or xenobiotics from
penetrating between adjacent cells (Zlokovic, 2008). Chemical composition of the brain,
blood, and CSF is regulated by numerous transporters expressed on both sides of the cell
membranes that regulate the entry of hydrophilic molecules, proteins, and nutrients that
cannot cross the barrier by diffusion (Zlokovic, 2008).
Claudin Proteins Regulate Paracellular Transport
The major classes of tight junctions include four-membrane spanning proteins
such as claudins and occludins, and single-membrane spanning proteins such as junction
adhesion molecules (JAMS) (Gunzel and Yu, 2013). Others have suggested that while
each class of tight junction protein is important, Claudins appear to have the most
significant role in regulating barrier permeability (Gunzel and Yu, 2013). Claudins are
expressed at the most apical portion of the cell and interact with Claudins on adjacent
cells (Figure 2-1). In mammals there have been around 24 types of proteins identified
(Krause et al., 2009). A single cell can express multiple different types of Claudins while
interacting with either the same or different type of Claudin on the adjoining cell (Furuse
et al., 1999).
Krause et al. (2009) describes the Claudin protein structure found in mammals.
While Claudins are characterized by two extracellular loop domains (ECL1 and ECL2),
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Figure 2-1.

Claudin Proteins Regulate Paracellular Permeability.

Modified with permission. English, D.P., and Santin, A.D. (2013). Claudins
Overexpression in Ovarian Cancer: Potential Targets for Clostridium Perfringens
Enterotoxin (CPE) Based Diagnosis and Therapy. International journal of molecular
sciences 14, 10412-10437.
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they also contain around seven N-terminal amino acids, and 25-55 C-terminal amino
acids (Krause et al., 2009). ECL1 is primarily responsible for the barrier properties of
Claudins. This loop contains two cysteines that aid in ECL1 formation and mutations of
these amino acids lead to increased barrier permeability (Gunzel and Yu, 2013). It is
likely that these two cysteines together form disulfide bonds in the protein structure
(Gunzel and Yu, 2013). ECL1 also contains positive and negative charges causing pore
formation in certain types of Claudins which allows small molecules to traverse the
barrier (Krause et al., 2009). Claudins can be grouped into pore-forming and barrier
forming tight junctions. Pore-forming Claudins consist of Claudins 2, 7, 10, 15, and 16
while barrier-forming proteins include Claudins 1, 5, 11, and 14 (Krause et al., 2009). A
combination of these two Claudin classes expressed at CNS barriers can affect TER with
pore-forming Claudins decreasing TER and barrier-forming Claudins increasing TER
(Anderson and Van Itallie, 2009).
A study using zebrafish to investigate Claudin 5 (Cldn5) function in brain
ventricle expansion concluded that the ECL2 domain plays a role in tightening of the
barrier (Zhang et al., 2010). ECL2 is responsible for forming trans Claudin-Claudin
interactions (Gunzel and Yu, 2013). A review by Anderson et al. proposed a two
pathway model for permeability where molecules less than 4 angstroms (Å) can penetrate
depending on size and charge of the Claudins expressed within a cell. This pathway is
most likely regulated by ECL1. Another pathway for molecules larger than 4 Å is
regulated by contacts between cells and may be controlled by ECL2 (Anderson and Van
Itallie, 2009). Claudins also contain a Post synaptic density protein/Drosophila disc large
tumor suppressor/Zonula occuludens-1 protein (PDZ) domain at the C terminus. This
sequence allows it to interact with PDZ domains on scaffolding proteins within the cell
such ZO-1 (Zlokovic, 2008). ZO-1 interacts with filaments such as actin which then
holds Claudin proteins in place within the membrane (Gunzel and Yu, 2013).
In regards to Claudin expression in CNS barriers, the BBB and BCSFB differ in
the types of Claudins expressed. Claudin-5 is a tight junction largely localized to
endothelial cells of the BBB. A study performed by Nitta et al. in 2003 generated
Claudin-5 deficient mice which died within ten hours after birth. They discovered that a
loss of Claudin-5 does not affect blood vessel morphology overall, but that in the brain,
the BBB becomes more permeable to smaller molecules less than 800 daltons (Da) (Nitta
et al., 2003). Zebrafish also express Cldn5 and have two paralogues, Cldn5a and 5b.
Cldn5 expression has been identified in zebrafish brain endothelial cells starting at 2 dpf,
but is not expressed within the tail vasculature (Xie et al., 2010). cldn5a mRNA is
expressed within the midbrain, hindbrain ventricles and retina (Xie et al., 2010; Zhang et
al., 2010), while cldn5b is expressed primarily within brain vasculature (Xie et al., 2010).
Both cldn5a and b are expressed within the hyaloid vasculature of the eye (Xie et al.,
2010). Other studies in zebrafish, as described previously in Zebrafish Central Nervous
System on pg. 12, have identified Cldn5a expression within the neuroepithelial cells of
the developing brain that aid in ventricle expansion. Although tight junction expression
has not been identified specifically in the zebrafish CP, studies in other model systems
have shown that multiple Claudins are expressed within this structure such as Claudin-1,
2, 5, and 11 (Lippoldt et al., 2000; Wolburg et al., 2001). A genetic analysis in mouse
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discovered that cldn-1, 3-18 and 23 were present at some level in the CP and that cldn2
becomes up-regulated in the adult CP (Liddelow et al., 2012). Because cldn2 is classified
as a pore-forming Claudin, this may be why the CP is considered to be more of a
secretory organ and have lower TER than the BBB, which has higher expression of the
barrier-forming cldn5 (Johanson et al., 2011).
Transporter Proteins Control Transcellular Permeability
While numerous transporter families are expressed throughout the CNS, this
section will focus on two types of transporters and their expression in the CP, Organic
anion transporters (OATs) and MDRs. OATs, whose structure is shown in Figure 2-2,
are expressed throughout the body in organs such as brain, kidney, and placenta and are
responsible for the transport of small hydrophilic organic anions (Roth et al., 2012).
They typically contain twelve transmembrane domains, glycosylation sites, and
phosphorylation sites for kinases such as protein kinase C (PKC) (Burckhardt and Wolff,
2000) whose activation can inhibit transport activity (Sekine et al., 2006). In the CP,
OAT3 is expressed on the apical cell membrane and functions to remove waste from the
CSF into the bloodstream where it is ultimately excreted (Sykes et al., 2004). It is also
expressed in the kidney where it transports organic anions such as para-aminohippuric
acid (PAH), estrogens, and bile salts (Sykes et al., 2004). The transport of these organic
anions is Na+ -dependent and coupled with the transport of dicarboxylates (Sweet et al.,
2003) A known substrate of OAT3 in the CP is fluorescein, a small organic green
fluorescent tracer. Fluorescein appears to be specific to OAT3 transport in that null
OAT3 mice have no uptake of fluorescein in the CP (Keep and Smith, 2011).
MDRs play an important role in regulating CNS homeostasis and protecting the
brain from harmful xenobiotics. However, as their name implies, they are also major
contributors to drug resistance. These ATP-dependent transporters contain two to three
transmembrane domains and two nucleotide binding domains. The transmembrane
domains play a role in recognizing and aiding in transport of hydrophilic molecules
across the plasma membrane (Chang, 2003). MDRs are further classified into short and
long forms. Long forms can contain as many as17 membrane spanning domains such as
Multidrug resistance-associated protein 1 (MRP1), shown in Figure 2-3, two Walker
motifs that aid in ATP binding, and a conserved region called the “C” motif that is
involved in hydrolyzing ATP. Short forms are similar except for containing only 12
membrane spanning domains (Deeley et al., 2006). Unlike OAT3 expressed on the apical
membrane, MRP1 is expressed on the basolateral membrane of the CP and functions to
transport substrates from CSF into the bloodstream (Keep and Smith, 2011). A widely
known substrate of MRP1 is the anti-cancer drug etoposide. Studies performed in MRP1
knockout mice observed an increased accumulation of etoposide within the CSF
indicating that this transporter has a significant role in drug distribution in the CNS
(Wijnholds et al., 2000).
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Figure 2-2.

Organic Anion Transporters Control Transcellular Entry and Exit.

Modified with permission. Sweet, D.H., Bush, K.T., and Nigam, S.K. (2001). The
organic anion transporter family: from physiology to ontogeny and the clinic. American
journal of physiology Renal physiology 281, F197-205.
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Figure 2-3.

MRP1 Plays a Role in Drug Resistance at the BCSFB.

Modified with permission. Deeley, R.G., Westlake, C., and Cole, S.P. (2006).
Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette
multidrug resistance proteins. Physiological reviews 86, 849-899.
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Materials and Methods
Fish Lines and Maintenance
Zebrafish were maintained at 28.5° on a 14 h light/dark cycle. Embryos used for
imaging or screening F3 larvae were initially collected in egg water (0.03% Instant
Ocean) containing 0.02% methylene blue and treated at 24 hpf with 0.003%
1-phenyl-2-thiourea (PTU) (Sigma) to prevent pigment formation. Zebrafish were
maintained in accordance with established protocols and regulations of the St. Jude
Children’s Research Hospital and Institutional Animal Care and Use Committee.
Generation of the Et(cp:EGFP)sj2 Line
To generate the Et(cp:EGFP)sj2 line, EGFP was released from the pEGFP-N1
vector (Clontech) by BamHI and NotI digestion and inserted into the pTRE-Tight vector
(Clontech). The Tetracycline Response Element (TRE)-tight:EGFP fragment was
released by XhoI and ClaI digestion and inserted into the pT2AL200R150G vector
(Urasaki et al., 2006). Approximately 30 pg of the resulting T2 (TRE-tight:EGFP)
plasmid DNA was co-injected with 30 pg of in vitro–transcribed Tol2 transposase mRNA
into single-cell embryos of the AB strain. The embryos were raised to adults and
screened for germline transmission by examining their offspring for EGFP expression.
Fluorescent Tracer Injections
To observe transporter activity in the CP, Et(cp:EGFP)sj2 larvae at 4 dpf were
anesthetized in 0.02% tricaine and injected intravenously into the common cardinal vein
with approximately 1-2 nL of 100 µM rhodamine 123 (Sigma-Aldrich) using a
micromanipulator and a pneumatic picopump (World Precision Instruments).
Immediately after the injections, larvae were embedded in 1.2% low-melting-point
agarose (Invitrogen) made in egg water. Larvae were imaged on a Nikon C1Si confocal
microscope and analyzed using Nikon EZC1 3.91 software.
To study CP function, Casper larvae (lacking melanocytes and iridophores)
(White et al., 2008) were anesthetized in 0.02% tricaine and intravenously injected into
the common cardinal vein with approximately 0.3-2 nL of 10 mg/mL rhodamine- and
fluorescein-labeled dextrans at 2, 3, and 4 dpf. Fluorescent tracers included a 3-kDa
fluorescein dextran, a 10-kDa rhodamine dextran, and a 40-kDa anionic fluorescein
dextran (Invitrogen). Immediately after the injections, larvae were laterally embedded in
1.2% low-melting-point agarose made in egg water. To observe tracer permeability into
the brain ventricle, time-lapse images were collected every 2 min for 1 h with a Nikon
AZ100 microscope equipped with a shutter (Sutter Instruments) and analyzed with Nikon
NIS-Elements 3.2 software. Et(cp:EGFP)sj2 larvae were also injected intravenously with
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the 10-kDa rhodamine dextran at 2 and 4 dpf and imaged on a Nikon C1Si confocal
microscope with Nikon EZC1 3.91 software.
To visualize brain ventricle morphology in wild-type and mutant Et(cp:EGFP)sj2
larvae at 4 dpf, PTU-treated zebrafish were anesthetized and intraventricularly injected
with approximately 1.8 nL of 40-kDa fluorescein-labeled dextran as described previously
(Gutzman and Sive 2009). Larvae were imaged dorsally immediately after the injection,
using a Nikon SMZ1500 epifluorescence stereoscope and Nikon NIS-Elements 3.1
software. Ventricle injections of rhodamine 123 and fluorescein were performed as
described previously (Gutzman and Sive 2009) in Casper larvae at 4 dpf and imaged on a
Nikon C1Si confocal microscope with Nikon EZC1 3.91 software.
Fluorescein Treatment
Casper and Et(cp:EGFP)sj2 larvae were incubated for 4 h in the dark with 50 µM
fluorescein (Fluka). Larvae were briefly rinsed 12 times in egg water, anesthetized in
0.02% tricaine, and embedded in 1.2% low-melting-point agarose. After 30 min, larvae
were imaged using a Nikon SMZ1500 epifluorescence stereomicroscope and analyzed
with Nikon NIS-Elements 3.1 software.
Statistical Analysis of Tracer Permeability
Three regions of interest (ROIs) with areas of 0.02 mm2 were selected in both the
heart and the brain ventricle. Using the NIS-Elements 3.2 software, the mean
fluorescence intensity, which served as a read-out for tracer permeability into the brain
ventricle, was measured for each ROI over a 1 h period. Using Microsoft Excel, the
average of the mean fluorescence intensity for the 3 ROIs in the heart and the 3 ROIs in
the brain ventricle was calculated for each sample. An overall average was then
calculated for the mean fluorescence intensity in the heart and the ventricle for all trials
(n = 7). The dataset of the mean fluorescence intensity in the heart and ventricle was
normalized to give values between 0 and 1.
The ratio of the fluorescence intensity in the ventricle to that in the heart was
calculated at the 30-min time point when the leakiest tracer reached saturation. The ratio
was then normalized against the tracer having the greatest mean intensity in the ventricle
at 30 min. A one-way ANOVA test was performed in Microsoft Excel to determine
whether there was a significant difference in fluorescent intensity between the tracers and
developmental time points. A Tukey’s post-hoc test was performed to determine which
tracers were statistically significant to one another at each developmental time point. A
significance value of α = 0.05 was used, and P values were calculated using the
GraphPad software P value calculator. Error bars were based on the mean of seven
observations using standard error.

29

Immunohistochemistry (IHC)
Larvae were anesthetized in 0.02% tricaine and fixed in 4% paraformaldehyde
(PFA) (Electron Microscopy Sciences) at 4° overnight and washed the next day in 1x
phosphate buffered saline (PBS) (Calbiochem). Samples were sunk in 30% sucrose/PBS
at 4° overnight. Larval and 1-month-old brain tissues were embedded in Optimal Cutting
Temperature (O.C.T.) Compound (Tissue-Tek), frozen on dry ice, and stored at -80°.
Tissues were sectioned using a Leica CM 1950 cryostat. Sections were washed in PBS
for 5 min followed by three 5 min washes in PBST [PBS/ 0.03% Triton X-100 (Sigma)].
Sections were incubated in blocking buffer [PBST with 5% goat serum (Gibco) and 1%
BSA (Sigma)] for 3 h at room temperature. Primary antibodies were incubated at 4°
overnight followed by secondary antibody incubation for 2 h at room temperature.
Sections were washed in PBST four times for 15 min after primary and secondary
antibody incubations. Primary antibodies included rabbit anti-GFP (1:500; Invitrogen),
mouse anti-GFP (1:500, Life Technologies), rabbit anti-ZO-1 (1:25, Invitrogen), rabbit
anti-Glut1 (1:200, Novus Biologicals), and mouse anti-Zpr1 (1:100; ZIRC). Secondary
antibodies included Alexa Fluor goat anti-rabbit 488 (1:200; Invitrogen) and Alexa Fluor
goat anti-mouse 555 (1:200; Invitrogen). Antibody dilutions were prepared in blocking
buffer. Sections were counterstained with 1 µg/mL 4’, 6-diamidino-2-phenylindole
(DAPI) (Roche) for 1 min, rinsed briefly in PBS, and mounted with Fluoromount
(Electron Microscopy Sciences). Images were taken on a Nikon AZ100 microscope and
analyzed using NIS-Elements AR 3.2 software.
Whole Mount IHC
Embryos were incubated in egg water with 0.003% PTU to prevent pigment
formation. At 4 and 6 days postfertilization (dpf), larvae were anesthetized in 0.02%
tricaine and fixed in 4% PFA overnight. The next day, samples were washed in 1x PBS
followed by 1x PBST and treated with 20 µg/mL Proteinase K (New England Biolabs)
for 15 min. The reaction was stopped by adding 10% lamb serum (Gibco) followed by
additional washes in PBST. Samples were blocked with 10% lamb serum for 1-4 h and
incubated in primary antibody at 4° overnight. Samples were washed the next day in
PBST and incubated in secondary antibody at 4° overnight. Antibodies used included
rabbit anti-GFP (1:100; Invitrogen), mouse anti-GFP (1:200; Life Technologies), rabbit
anti-ZO-1 (1:50; Invitrogen), rabbit anti-Glut1 (1:100, Novus Biologicals), mouse
anti-Zpr1 (1:50; ZIRC), mouse anti-Cldn5 (1:100; Invitrogen), Alexa Fluor goat
anti-rabbit 488 (1:200; Invitrogen) and Alexa Fluor goat anti-mouse 555 (1:200;
Invitrogen). Additional washes in PBST were done the following day and stored in 1x
PBS. Samples were embedded in 0.8% low-melting point agarose (Invitrogen) made in
1x PBS and imaged on Nikon C1Si laser scanning confocal microscope. Z-stacks were
compiled to create maximum intensity projection images using Nikon NIS-Elements 3.1
imaging software.
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Live Confocal Imaging
Confocal imaging was performed on a Nikon C1Si confocal microscope and
analyzed using Nikon EZC1 3.91 software. Scans of DIC and GFP images were acquired
using a 20x objective at 4 µm intervals to create a z-stack maximum intensity projection
image. To observe CP development, larvae were collected at approximately 30 hpf and
prepared for imaging as described above. Z-stack images were acquired every 30 min
over a 65 h period. Using NIS-Elements AR 4.0 software, images were smoothed and
z-stacks were compiled to create an enhanced depth of focus (EDF) image.
Results
Generation and Characterization of the Zebrafish CP Enhancer Trap Line
Et(cp:EGFP)sj2
In the process of producing a tetracycline-inducible transgenic line, we
fortuitously generated the zebrafish CP line by an enhancer trap effect. To generate this
line, we co-injected a T2 (tetracycline response element (TRE)-EGFP) construct with
Tol2 transposase mRNA into single-cell zebrafish embryos. The TRE-EGFP construct
integrated into an enhancer region regulating the CP. The insertion was transmitted to
subsequent generations, thereby creating a stable line termed Et(cp:EGFP)sj2.
GFP expression was specifically localized to the dCP in the third ventricle and the
mCP in the fourth ventricle at 3dpf (Figure 2-4A). Unlike mammals, the zebrafish CP is
localized outside the brain allowing for easy visualization of CP development. As
mentioned in the two previous zebrafish CP studies, the mCP in teleosts exists as a layer
of GFP positive cells directly below the epithelium near the roof of the fourth ventricle
and the dCP is at the most dorsal portion of the third ventricle (Bill et al., 2008;
Garcia-Lecea et al., 2008) allowing CP development to be easily visualized in the
zebrafish due to its “inside-out” morphology.
We also detected GFP expression in the heart and swimbladder. The
swimbladder consists of epithelial cells and has been compared to the mammalian lung
(Winata et al., 2009). GFP expression along the lining of the swimbladder is shown in
Figure 2-5. Using time-lapse confocal microscopy, GFP expression was detected in a
subset of dCP cells as early as 30 hpf (see Appendix A. SupplementalMovie1). We
found that the mCP epithelial cells migrated from the outer rhombomeres into the
midbrain-hindbrain boundary as described previously (Garcia-Lecea et al., 2008) and also
anteriorly from the developing spinal cord. These cells increase in GFP intensity as they
coalesce to form a compact structure by approximately 72 hpf. There were no additional
changes in CP morphology by 96 hpf. We also observed a few GFP positive spots in
other areas of the head and eyes. However, after staining Et(cp:EGFP)sj2 larvae at 3 dpf
with a GFP antibody, we only observed labelling within the dCP, mCP, and swimbladder
(Figure 2-6).
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Figure 2-4.

The Et(cp:EGFP)sj2 Line Expresses GFP in the dCP and mCP.

(A) Confocal image of the dorsal anterior view of 3 dpf Et(cp:EGFP)sj2 larvae
expressing GFP in the dCP and mCP. (B) Whole-mount immunohistochemical staining
of Et(cp:EGFP)sj2 larvae at 6 dpf. GFP in green labels the dCP and mCP, and Zpr-1
shown in red labels the pineal gland and photoreceptors. The yellow overlay
demonstrates the interaction between the pineal gland and dCP. The solid and dashed
lines across the dCP and mCP in the inset image indicate approximate regions where
sections were taken for Figure 2-4C-D. (C) Transverse section through the dCP of 6 dpf
Et(cp:EGFP)sj2 larvae stained with GFP, DAPI, and Zpr-1. (D) Transverse section
through the mCP of 6 dpf Et(cp:EGFP)sj2 larvae stained with GFP and DAPI. (E)
Transverse section through the dCP of a 1-month-old Et(cp:EGFP)sj2 zebrafish stained
with GFP and Zpr-1. (F) Transverse section through the mCP of a 1-month-old
Et(cp:EGFP)sj2 zebrafish stained with GFP. Abbreviations: dCP, diencephalic CP; mCP,
myelencephalic CP; F, forebrain; H, hindbrain; GFP, green fluorescent protein; DAPI, 4’,
6-diamidino-2-phenylindole. For all images: filled arrowhead, dCP; open arrowhead,
pineal gland; arrow, mCP. Scale bars are 50 µm.
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Figure 2-5.

GFP Is Expressed in the Swimbladder of Et(cp:EGFP)sj2.

(A) Et(cp:EGFP)sj2 larvae at 3 dpf expresses GFP in the dCP (arrow), mCP (arrowhead),
and swimbladder. Dashed box is magnified in (B) showing GFP lining the cells of the
swimbladder. dCP, diencephalic choroid plexus; mCP, myelencephalic choroid plexus.
Scale bars are 50 µm.
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Figure 2-6.

GFP Expression Is Restricted to the dCP, mCP, and Swimbladder.

Lateral confocal fluorescent image (A) and merged image (B) of Et(cp:EGFP)sj2 larvae at
3 dpf. GFP expressed in the mCP (arrow), and swimbladder (arrowhead). Dorsal
confocal fluorescent (C) and merged image (D) of Et(cp:EGFP)sj2 larvae at 3 dpf. GFP is
expressed in the mCP (arrowhead) and dCP (arrow). dCP, diencephalic choroid plexus;
mCP, myelencephalic choroid plexus. Scale bars are 50 µm.
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To gain further insight into the location of the CP in relation to other CNS
structures, we used whole-mount IHC to stain Et(cp:EGFP)sj2 larvae with a Zpr-1
antibody labeling cone photoreceptors of the eye and the pineal gland. In other teleosts
and mammals, the pineal gland directly interacts with the CP of the third ventricle
(Omura et al., 1985; Skinner and Malpaux, 1999). Although the dCP is distinct from the
pineal gland, we found a close association between the two structures (Figure 2-4B).
Transverse sections showed the dCP positioned beneath the pineal gland (Figure 2-4C).
Additional transverse sections through the mCP showed a cluster of GFP-positive
epithelial cells directly beneath the skin surface (Figure 2-4D). GFP expression in the
dCP and mCP was retained throughout development and at later stages, as shown in an
one-month-old Et(cp:EGFP)sj2 (Figure 2-4E and 2-4F).
To further demonstrate that this is indeed the CP, we cut sections from adult
brains and identified GFP expression in a structure historically referred to as the saccus
dorsalis (Figure 2-7). This structure is analogous to the mammalian CP of the third
ventricle and the developmental dCP in zebrafish. The saccus dorsalis in rainbow trout
(Salmo gairdneri), has been described as a folded monolayer of epithelium that develops
out of the diencephalic roof plate (Jansen et al., 1976). Because the saccus dorsalis has
also been described to partially cover the pineal stalk (Tsuneki, 1986), similar to what we
show in Figure 2-4B, we conclude that this is the CP of the third ventricle in zebrafish.
Zebrafish CP Expresses the Tight-Junction Claudin 5 and Zonula Occludens-1
The mammalian CP expresses many tight-junction proteins such as claudins
(Kratzer et al., 2012; Lippoldt et al., 2000), occludens (Lagaraine et al., 2011) and
junction adhesion molecules (Lagaraine et al., 2011) to create a physical barrier between
the blood and CSF. To demonstrate that the zebrafish CP express tight junction proteins
similar to mammals, we studied Cldn5 expression due to accessibility to an antibody that
cross-reacts with zebrafish Cldn5 (Xie et al., 2010; Zhang et al., 2010). As predicted,
whole-mount IHC analysis revealed Cldn5 expression at the cell membrane of zebrafish
CPe (Figure 2-8). Cldn5 expression was also observed in the eyes, blood vessels, and
neighboring ependymal cells (Figure 2-8B and 2-8C). In addition, we analyzed ZO-1,
another tight junction protein expressed in CNS barriers. Not surprisingly, whole mount
IHC revealed ubiquitous ZO-1 expression (Figure 2-9A-C). However, transverse
sections through the mCP acquired at a higher magnification demonstrated
co-localization with the GFP positive cells of the CP indicating that along with Cldn5,
ZO-1 is also present at the BCSFB (Figure 2-9D).
Zebrafish CP Possesses Transporter Activity
In mice, multidrug resistance transporters, such as MRP1, are expressed on the
basolateral side of CPe and regulate drug accumulation in the CSF (Wijnholds et al.,
2000). In addition to drug transport, MRP1 and MDR1, efflux fluorescent dyes such as
rhodamine 123 (Saengkhae et al., 2003). To the best of our knowledge, no previous
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Figure 2-7.

The Adult Et(cp:EGFP)sj2 Expresses GFP in the Saccus Dorsalis.

Sagittal sections through adult brains were labelled with rabbit anti-GFP antibody (green)
and counterstained with DAPI (blue). (A-B) shows GFP expression in the adult CP of the
third ventricle, also known as the saccus dorsalis in teleosts. Dashed-line boxes refer to
magnified images shown in (C-D). Scale bars are 100 µm.
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Figure 2-8.

The Zebrafish CP Possesses the Tight Junction, Claudin 5.

(A) Whole-mount immunohistochemical staining of Et(cp:EGFP)sj2 larvae at 4 dpf with
GFP labeling the dCP and mCP. (B) Whole-mount immunohistochemical staining with
Claudin 5 antibody (red) showed expression in the eye (arrow), surface vessels
(arrowhead), and CP. (C and C`) Overlay of GFP and Claudin 5 staining revealed
Claudin 5 expression surrounding the perimeter of CPe and ependymal cells. Examples
of ependymal cells are shown with an asterisk (*). Images in (A) and (B) taken at 20×
magnification and (C) at 40× magnification.

37

Figure 2-9.

ZO-1 and Glut1 Expression in the CP.

(A) Dorsal confocal imaged of Et(cp:EGFP) larvae at 4 dpf with GFP expression (green)
in the dCP (arrow) and mCP (arrowhead). (B) Dorsal confocal imaged of Et(cp:EGFP)
larvae at 4 dpf with ubiquitous ZO-1 expression (red) throughout the head and eyes. (C)
Merged image of GFP and ZO-1 expression with dCP (arrow) and mCP (arrowhead).
Dotted line is representative of the section through the mCP in (D). (D) Transverse
section through the mCP shows ZO-1 expression (red) co-localizes with GFP expression
(green) in the mCP (yellow). (E) Dorsal confocal imaged of Et(cp:EGFP) larvae at 3 dpf
with GFP expression (green) in the dCP (arrow) and mCP (arrowhead). (F) Dorsal
confocal imaged of Et(cp:EGFP) larvae at 3 dpf with ubiquitous Glut1 expression (red)
throughout the head and eyes. (G) Merged image of GFP and Glut1 expression with
dCP (arrow) and mCP (arrowhead). (H) Transverse section through the mCP shows
Glut1 expression (red) on the surface and brain vasculature (arrow) and GFP expression
(green) in the mCP (arrowhead). Scale bars in (A) and (E) are 50 µm and in (D) and (H)
25 µm.
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studies have demonstrated transporter function in zebrafish CP. To determine whether
transporters contribute to the BCSFB at the zebrafish CP, we intravenously injected
rhodamine 123 into the Et(cp:EGFP)sj2 line at 4 dpf and observed its accumulation
within the CPe (Figure 2-10A-C). After injecting rhodamine 123 into the brain
ventricle/CSF, we also observe accumulation in CPe (Figure 2-11A-D) indicating that
independent of what interface the rhodamine 123 resides (whether blood or CSF), the dye
is transported by the CP.
Another transporter that is highly expressed in the CP is OAT3 (Keep and Smith,
2011) and fluorescein is taken up by the transporter on the apical side of CPe in a
Na+-dependent manner (Sykes et al., 2004). Because fluorescein is a
low-molecular-weight green fluorescent dye, we soaked Casper zebrafish in 50 µM
fluorescein to observe accumulation in the CP. The dye was ingested in the gut, but also
entered the circulation and concentrated in the dCP and mCP (Figure 2-10D and 2-10E).
Fluorescein injected into the brain ventricle had a similar pattern of accumulation in the
mCP and dCP (Figure 2-11E-H). Additionally, we looked at transporters such as Glut1.
Glut1 is a well-known marker of the BBB (Cullen et al., 2011; Daneman and Rescigno,
2009; Dermietzel et al., 1992; Klepper and Voit, 2002; Zlokovic, 2008). However we did
not observe its expression within the zebrafish CP (Figure 2-9E-H).
Zebrafish CP Possesses Size-Selective Barrier Properties
To date, there have been no studies on paracellular barrier properties of the
zebrafish CP (Abdelilah-Seyfried, 2010). To examine the function of the zebrafish CP in
regulating passage from the bloodstream into the CSF, we intravenously injected
fluorescently labeled dextrans of various molecular weights into Casper at 2, 3, and 4 dpf.
Time-lapse imaging at 2 dpf, before the CP has fully developed, showed that 3-kDa
fluorescein and 10-kDa rhodamine dextrans leaked from the bloodstream into the brain
ventricle, whereas little to no 40-kDa fluorescein dextran escaped from the bloodstream
into the ventricle (Figure 2-12A). By 3 dpf, there was still a significant difference with a
P value of < 0.0001 between the 3-kDa and 10-kDa dextrans and the 40-kDa dextran;
however, the overall permeability was lower at 3 dpf compared to 2 dpf (Figure 2-12B).
By 4 dpf, when the CP was fully formed, there were no significant differences between
the individual tracers (Figure 2-12B). Intravenous injection of the 10-kDa dextran into
Et(cp:EGFP)sj2 larvae at 2 dpf showed leakage into the brain ventricle as the CP
continued to develop. Once the CP formed by 4 dpf, the dextran did not accumulate
within the brain ventricle (Figure 2-13A). In addition, the 3-kDa and 10-kDa dextrans
were significantly more permeable at 2 dpf (P < 0.0001) compared to 3 dpf and 4 dpf, but
there was no significant difference in permeability for the 40-kDa dextran (Figure
2-13B).
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Figure 2-10. The Zebrafish CP Possesses Transporter Properties.
(A) Live imaging of Et(cp:EGFP)sj2 larvae at 4 dpf showed GFP expression in the CP.
(B,C) Accumulation of rhodamine 123 in the dCP (arrowhead) and mCP (arrow). (D)
Side view of live Casper zebrafish treated at 4 dpf with 50 µM fluorescein for 4 h showed
accumulation of fluorescein (represented in green) in the dCP (filled arrowhead) and
mCP (arrow) along with the gut (asterisk), and lateral line (open arrowhead). (E) Similar
image as in (D) except for dorsal view showing accumulation in the dCP (filled
arrowhead), mCP (arrow), and overlying vasculature (open arrowhead). Abbreviations:
dCP, diencephalic CP; mCP, myelencephalic CP; E, eye; OV; Otic vesicle. Scale bar is
50 µm.
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Figure 2-11. Rhodamine 123 and Fluorescein Ventricle Injection Demonstrates
Transporter Activity in the CP.
Dorsal fluorescent (A) and merged (B) confocal image of 4dpf Casper larvae with
Rhodamine 123 (red) injection into the brain ventricle. The rhodamine 123 concentrates
within the mCP (arrowhead). Rhodamine 123 also can fluoresce green and co-localizes
with red emission (not shown). Lateral fluorescent (C) and merged (D) confocal image
of 4dpf Casper larvae with Rhodamine 123 (red) injection into the brain ventricle. The
rhodamine 123 concentrates within the mCP (arrowhead) and dCP (arrow). Dorsal
fluorescent (E) and merged (F) confocal image of 4dpf Casper larvae with fluorescein
(green) injected into the brain ventricle. Fluorescein concentrates within the mCP
(arrowhead) and dCP (arrow). Lateral fluorescent (G) and merged (H) confocal image of
4dpf Casper larvae with fluorescein (green) injected into the brain ventricle. Fluorescein
concentrates within the mCP (arrowhead) and dCP (arrow). Abbreviations: mCP,
myelencephalic choroid plexus; dCP, diencephalic choroid plexus. Scale bar is 50 µm.
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Figure 2-12. The Zebrafish CP Is Functional and Possesses Size-Selective
Properties.
Casper zebrafish were intravenously injected with fluorescent tracers at 2, 3, and 4 dpf to
identify tracer leakage from blood into the CSF. (A) The top panel shows severe leakage
of the 3-kDa fluorescein dextran into the brain ventricle (inset) at 2 dpf, minor leakage at
3 dpf, and little, if any, dextran penetration at 4 dpf. The bottom panel shows
permeability of the 10-kDa rhodamine dextran at 2 dpf (inset), which decreases by 4 dpf.
The 40-kDa fluorescein dextran was the least permeable at each developmental time
point. Images were taken at 1h post-injection. (B) A one-way ANOVA shows that the
3-kDa fluorescein dextran and the 10-kDa rhodamine dextran are significantly more
permeable (i.e., greater mean fluorescence intensity) than the 40-kDa fluorescein dextran
at 2 dpf and 3 dpf. By 4 dpf, there was no significant difference in fluorescence intensity.
Measurements are expressed as mean ± SE (standard error) for n=7; ****p < 0.0001.
Abbreviations: Rhod, rhodamine dextran; Flour, fluorescein dextran. Scale bar is 50 µm.
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Figure 2-13. The Zebrafish CP Becomes Size-Selective as It Develops.
(A) Et(cp:EGFP)sj2 larvae were intravenously injected with a 10 kDa rhodamine-dextran
and the CP was imaged dorsally by confocal microscopy. At 2dpf, the CP is not fully
developed as observed by GFP expression and the 10 kDa rhodamine-dextran inundates
the brain ventricle. By 4dpf, the CP is fully formed and the 10 kDa rhodamine-dextran is
retained within the vasculature and does not enter the brain ventricle. (B) A One-Way
ANOVA analysis revealed that the 3 kDa fluorescein dextran and 10 kDa rhodamine
dextran have a significantly higher fluorescent intensity in the brain ventricle (i.e. more
permeable) at 2dpf compared to 3 and 4dpf. There is no significant difference between
developmental time points for the 40 kDa fluorescein dextran. Measurements are means
±SE for n=7; ****p<0.0001. Scale bar is 50 µm.
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Discussion
The goal of our study was to establish zebrafish as a functionally relevant model
to study CP development. Although the CP has been studied in various in vivo and in
vitro models (Dohrmann, 1970; Strazielle et al., 2003), the developmental and genetic
aspects of this structure remain poorly understood largely due to the lack of innovative
strategies and functionally relevant systems (Saunders et al., 2008). Also, other
vertebrate models do not easily allow for CP development to be visualized in real time.
To overcome this limitation, we created an enhancer trap zebrafish line, Et(cp:EGFP)sj2
expressing EGFP within the dCP and mCP. Using this line, CP development was easily
observed in a live vertebrate by monitoring EGFP expression.
Previous studies have also generated enhancer trap lines in zebrafish expressing
GFP in the CP (Bill et al., 2008; Garcia-Lecea et al., 2008). However, there are
variations within these lines, including the subsets of cells expressing GFP. For example,
in the EtMn16 line (Bill et al., 2008), only a subset of cells of the mCP express GFP. The
SqET33-E20 (Gateways) line (Garcia-Lecea et al., 2008) has additional GFP expression
in the rhombomeres. In our study, there was specific GFP expression in the dCP, mCP,
and swimbladder. In regards to GFP expression in the swimbladder, studies have shown
that Shh is expressed in the epithelial cells lining the swimbladder (Winata et al., 2009).
Interestingly, the CP of other vertebrates has also been compared to the mammalian lung
in a study by Nielsen and Dymecki (2010) demonstrating that Shh is required for the
synchronized outgrowth of the CP and fenestrated vasculature, similar to the need for Shh
in the coordinated outgrowth of the lung (Nielsen and Dymecki, 2010). Since the
zebrafish swimbladder has been compared to the mammalian lung (Winata et al., 2009),
this suggests that there are common underlying developmental pathways, such as Shh,
required in both the CP and swimbladder and the GFP expression in this enhancer trap
line may be regulated by one of these developmental cues.
By performing confocal time lapse imaging on the Et(cp:EGFP)sj2 line, we
observed a few GFP positive spots in the head and eyes. We attributed these green spots
to the high gain we used to acquire the time-lapse. Because we start the imaging before
the CP has formed, we increased the gain normally used to acquire snapshot images at 3
dpf in order to insure that we had sufficient exposure to capture GFP positive cells as
they develop into the CP. The variations in other enhancer trap lines may be due to
transgenic DNA constructs integrating into different regions of the genome. As seen with
the other zebrafish CP enhancer trap lines, we could not identify the enhancer element
regulating GFP expression, likely because of the enhancer’s ability to act at remote
distances upstream or downstream of the target gene.
We have demonstrated BCSFB properties in zebrafish by identifying tight
junction proteins and transporter activity. We have shown Cldn5 and ZO-1 expression
within the CP. Identifying these tight junctions confirms what is known in the literature
where ZO-1 interacts with Claudins to anchor them within the cell membrane (Brown
and Davis, 2002; Stamatovic et al., 2008). Using our Et(cp:EGFP)sj2 line, we
demonstrated that the zebrafish CP possess a chemical barrier that transports and
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concentrates rhodamine 123 and fluorescein in the CPe. Rhodamine 123 directly
interacts with MRP1 and MDR1 in an ATP-dependent manner (Daoud et al., 2000;
Shapiro and Ling, 1998). Because previous studies have shown the specificity of
rhodamine 123 to MDRs, similar drug transporters are likely expressed in the zebrafish
CP. Studies in mice have identified known transporters of rhodamine 123 such as MRP1
to be localized at the basolateral side of CP epithelia and keep drugs out of the CSF
(Keep and Smith, 2011; Wijnholds et al., 2000). Our findings also confirm that
transporters are present in the zebrafish CP by showing that: when coming from the
bloodstream, rhodamine 123 accumulates within the CP and is prevented from entering
the CSF. Likewise, when injected directly into the CSF, the CP functions in removing
rhodamine 123 from the fluid as is also shown by dye accumulation within CP epithelia.
OAT3, also known as solute carrier family 22 group 8 (Slc22a8) is expressed in
the kidney, intestine, retinal pigment, brain, and CP (Sweet et al., 2003). Its function has
been commonly studied by treating isolated mouse CPe cells with fluorescein and
incubating them in artificial CSF. A loss of OAT3 results in reduced fluorescein
accumulation (Sweet et al., 2003). A model system using intact CP from the dogfish
shark demonstrated Na+-dependent accumulation of fluorescein in the epithelia via OATs
(Villalobos et al., 2002). Our real-time studies also showed in vivo fluorescein
accumulation within the CPe, which was indicative of transport activity. Although the
current zebrafish genome database contains two annotated Oat proteins zfOat
(NP_996960) and zfOatX (NP_004781) (Aslamkhan et al., 2006), there are no expression
data for these genes. Future studies will investigate whether specific Oats are expressed
in the zebrafish CP and contribute to fluorescein transport. Additionally, while we did
not observe Glut1 expression within the zebrafish CP, a recent review by Keep and Smith
mention that the BBB, not the BCSFB is the major source of glucose transport into the
brain due to its close proximity to the brain itself and that the CP has only a minor role in
this process (Keep and Smith, 2011).
We demonstrated barrier function in the zebrafish CP by intravenously injecting
fluorescent tracers of different molecular weights and observing permeability across the
CPe into the CSF. Once the CP fully formed by 4 dpf, the smallest tracer tested, a 3-kDa
fluorescein dextran, was no longer permeable across the BCSFB as it was in earlier
developmental stages. This result indicated a tightening of the barrier as it develops.
There appears to be a correlation between CP formation and decreased permeability,
suggesting that a physical barrier is preventing molecule entry rather than being cleared
by a CSF drainage pathway. For example, this is demonstrated when we injected the
40-kDa tracer into the bloodstream on day 4 and never observed tracer accumulation
within the ventricle throughout the course of the time-lapse. Rather than suggesting that
the tracer is being cleared from the ventricle by CSF flow, we observed that the tracer
never entered the ventricle in the first place. This indicated to us that a physical barrier is
preventing the dextran from crossing the barrier. Had we observed accumulation of the
dextran within the CSF/brain-ventricle after injection, and then observed a decrease in the
amount of tracer in the ventricle over time, then we would suggest that CSF flow is the
contributing factor. In immature brain barriers, it has been reported that the accumulation
of molecules within the CSF is not due to increased permeability of the barrier but
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reduced CSF flow (Saunders et al., 2008). In contrast, more mature brain barriers have
increased CSF flow that limits the accumulation of molecules within the ventricular space
(Saunders et al., 2008). Our study showed that after CP formation, there was no tracer
penetration into the ventricle indicating that a decrease in tracer accumulation in the brain
ventricle was not attributable to an increase in CSF clearance, but barrier properties of the
CP. The decrease in barrier permeability as the CP develops establishes the zebrafish CP
as a functioning organ with size-selective barrier properties.
Conclusion
In summary, the goal for this investigation was to establish zebrafish as vertebrate
model to study the CP. By characterizing the CP in zebrafish, we have demonstrated that
it not only possesses barrier properties similar to mammals, such as have tight junctions
and transporter activity, but also functions in regulating entry into the CSF from the
bloodstream and transporting molecules out of the CSF. These findings will pave the
way for future investigations using zebrafish as a model for CP development and function
while providing tools for investigating barrier properties in mutants with CP
abnormalities.
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CHAPTER 3.

FORWARD GENETIC SCREEN IDENTIFIES CHOROID
PLEXUS MUTANTS
Introduction

Although the CP of the lateral brain ventricles was documented several centuries
ago by Herophilus, (Dohrmann, 1970; Dziegielewska et al., 2001), there has been little
research aimed towards genetically dissecting the pathways essential for CP formation
and function. To identify zebrafish with gene mutations specific to CP development, we
performed a small-scale ENU-mutagenesis screen using Et(cp:EGFP)sj2 and identified
10 recessive mutant lines. These mutants were classified into five categories on the basis
of EGFP expression and mCP morphology. We hypothesize that this unbiased approach
will uncover novel genes and pathways essential for CP development. The cloning and
characterization of these mutants will provide important insights into the genetic
mechanisms regulating CP formation and function in health and disease.
Forward genetic screens have been performed in various multicellular organisms
such as plants (Meinke and Sussex, 1979), flies (Nusslein-Volhard and Wieschaus,
1980), worms (Sin et al., 2014), zebrafish (Driever et al., 1996), and mice (Hrabe de
Angelis et al., 2000; Nolan et al., 2000) and have been very successful in discovering
genes involved in embryonic patterning, organ development, and behavior (Horvitz,
1999; Muto et al., 2005; Stemple and Driever, 1996). The genetic plant model
Arabidopsis thaliana, is a useful model system due to its small genome and minor
amount of repetitive sequences (Page and Grossniklaus, 2002). Mutants in A. thaliana
have been screened for phenotypes such as leaf or flower morphology, and in doing so; a
number of genes have been identified such as those involved in biosynthetic pathways
(Yang et al., 2011). Thomas Hunt Morgan was the first to use the fruit fly Drosophila
melanogaster; a genetic model system having only four chromosomes and easily
identifiable phenotypes such as eye color or wing vein patterning (St Johnston, 2002).
Utilizing this model for forward genetic screening identified genes such as Hedgehog,
which was found to play a role in segment polarity (Nusslein-Volhard and Wieschaus,
1980). These findings later resulted in Christiane Nüsslein-Volhard and Eric Wieschaus
being awarded a Nobel Prize for their work (St Johnston, 2002).
Another classical genetic invertebrate model is the nematode Caenorhabditis
elegans. This simple organism is excellent for studying nervous system development
having only 302 neurons that are easily tracked using fluorescent reporter lines
(Jorgensen and Mango, 2002). In addition to a nervous system, they also have muscles,
epidermis, reproductive structures, and a gastrointestinal tract (Jorgensen and Mango,
2002). Sydney Brenner was the first to suggest using C. elegans as a genetic model
system and he along with John Sulston and Robert Horvitz went on to receive a Nobel
Prize for their work (Moller, 2002) identifying genes involved in the cell death pathway
such as ced-3 (Ellis and Horvitz, 1986), correspond to Caspase-1 in mammals
(Thornberry, 1997). Forward genetic screens, including large-scale ENU mutagenesis
screens can also be performed in vertebrate models such as mice (Kile and Hilton, 2005).
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Genome-wide analyses have identified important genes such as Min (multiple intestinal
neoplasia), also known as Adenomatous Polyposis Coli (APC), where young mice who
inherit a dominant mutation in this gene are predisposed to developing adenomas in the
intestine (Moser et al., 1990; Su et al., 1992). Mouse embryos can be difficult to screen
in utero, however embryonic lethal mutations have been identified (Garcia-Garcia et al.,
2005). While mice provide an advantage by greatly mimicking human development,
large numbers of offspring for screening and the ability to visualize internal organs in real
time is limited in this system.
Zebrafish have long been known for their usefulness in forward genetic screening
as described in Zebrafish Genetic Screening Strategies on pg. 17. While many of these
early studies focused on embryonic patterning or organ development, genetic screens in
zebrafish can also be used to identify behavioral patterns. In 2005, a genetic screen was
published that identified mutants with visual behavior defects using screening tools such
as optokinetic response to monitor eye movement patterns and identify vision
abnormalities (Muto et al., 2005). In regards to CNS development, genetic screens have
also been used in isolating zebrafish with defects in brain ventricle development (Lowery
et al., 2009). By injecting fluorescent dyes into the brain ventricles, they were able to
categorize four classes of brain ventricle mutants based simply on morphological
development. Interestingly, related genes identified in these mutants also grouped
together in these four classes indicating that screening based on morphology is a good
indicator for identifying classes of genes later on in genetic mapping (Lowery et al.,
2009). While a few genes and signaling pathways have been identified to be essential in
CP formation as mentioned in Signaling Pathways and the Choroid Plexus on pg. 7,
the CP would greatly benefit from an unbiased approach to discover genes essential for
its development and function. Because the CP is visible and accessible in live transgenic
zebrafish models, mutants can be easily identified by screening for GFP expression and
patterning. As we demonstrate in the following study, zebrafish can be used to discover
phenotypes in a particular cell type or tissue by screening for fluorescence intensity and
patterning throughout development.
Materials and Methods
ENU Mutagenesis and Forward Genetic Screening
Twenty Et(cp:EGFP)sj2 males were treated three times with 3 mM ENU (Sigma)
for 1 h each at weekly intervals as described previously (de Bruijn et al., 2009; Pelegri,
2002). After one month, ENU-treated males were mated to Et(cp:EGFP)sj2 females to
produce the F1 generation. F1 pairwise crosses were performed to produce F2 families.
F2 families that did not contain at least four male/female pairs were sacrificed. Pairwise
crosses for each F2 family were done at least six times if possible to identify F3 offspring
with homozygous recessive mutations. F2 pairs deemed heterozygous for a recessive
mutation were maintained in miniboxes for use in genetic mapping experiments. To
screen for CP mutants, F3 larvae were anesthetized at 4 dpf and visualized using a Nikon
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SMZ1500 epifluorescence stereomicroscope to identify abnormal EGFP expression or
patterning in the CP. A mutant line was confirmed if approximately 25% of the total
offspring displayed a CP phenotype.
Live Confocal Imaging and Time-Lapse Movies
Scans of DIC and GFP images were acquired on a Nikon C1Si confocal
microscope using a 10x and 20x objectives at 4 µm intervals to create a z-stack maximum
intensity projection image. To compare CP development, wild-type and mutant larvae
were imaged on a Nikon C1Si confocal microscope beginning at 54 hpf with images
acquired every 30 min over a 48 h period. Supplemental movies run for the 48 h period
except for SupplementalMovie6, which runs for 42 h (SupplementalMovies1-7). All
images were analyzed using NIS-Elements AR 4.0 software.
Results
Forward Genetic Screen Identifies CP Mutants
We initiated a small-scale forward genetic screen to identify mutants with CP
abnormalities. This screen focused primarily on mCP defects. Table 3-1 shows the
numbers of fish generated from this screen. Briefly, twenty F0 Et(cp:EGFP)sj2 males
were mutagenized with ENU. One month after treatment, ENU efficiency was tested by
mating the males to Casper and screening for nacre or roy phenotypes (lacking
melanocytes and iridiphores, respectively). Approximately 1 in 250 (0.4%) larvae
showed the nacre or roy phenotype. The mutagenized males were mated with
Et(cp:EGFP)sj2 females to generate 409 F1 fish. Adult F1 pairs were mated together or
with non-mutagenized Et(cp:EGFP)sj2 fish to produce 224 F2 families. Of the F2 families,
73 contained sufficient numbers to screen 4-6 pairs for mutants in the F3 generation. We
set up 1330 F2 × F2 crosses (including re-crosses), with 421 crosses producing F3
embryos. Larvae were screened at 4 dpf to identify CP defects based on GFP expression
patterns. In total, we generated 16,339 F3 embryos and screened 12,196.
We identified 24 mutant lines with 10 recessive mutant lines having CP
deformities. In addition to CP phenotypes, each of the10 recessive lines had other defects
such as heart edema, small eyes, and small head. While several of the mutants exhibited
brain necrosis, many did not develop necrosis until after the CP already started to form.
A description of the onset of brain necrosis for each line is listed in Table 3-2. We found
spontaneous mutants that had normal morphology overall, but severely abnormal or no
CP (Figure 3-1). Spontaneous mutants can occur due to random errors in DNA
processing such as DNA replication that result in arbitrary mutations being introduced
into the genome (Moore et al., 2006). In addition, we found many mutants (some
recessive and some spontaneous) with severe brain necrosis, but normal CP development.
These mutants are shown in Figure 3-2. The 10 CP mutants we describe in the following
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Table 3-1.

Number of Zebrafish Generated from the Forward Genetic Screen.
Generation
G0 males mutagenized
G0 males survived
F1
F2 families started
F2 families screened
F2 × F2 crosses
F2 families that spawned
F3 embryos screened
Mutant lines identified
Mutant lines maintained
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Fish (n)
20
9
409
224
73
1330
421
12,196
24
10

Table 3-2.

Characterization of Et(cp:EGFP)sj2 Mutants Generated from the Forward Genetic Screen.

Class
I: reduced GFP
expression,
dispersed epithelia,
and irregularly
shaped CP

II: normal GFP
expression, smaller
epithelia aggregates,
and irregularly
shaped CP

Alleles

Map
dpf
Position

Other Phenotypes (at 4 dpf)

Fluorescein
Transport

Onset of
Brain
Necrosis
3 dpf

Initial
Circulation
Loss
3 dpf

cp26.3a

ND

cp140.2

ND

2

Small head; small eyes; no
swimbladder; heart edema; brain
necrosis; faint heartbeat and
circulation; slightly larger forebrain
and wider midbrain ventricle

Increased
uptake;
accumulates
within brain
ventricle

4 dpf

4 dpf

cp9.6

LG 4

2

Small head; small eyes; no
swimbladder; heart edema;
occasional hydrocephalus; brain
necrosis; no circulation; no distinct
forebrain or midbrain and severely
reduced hindbrain

Increased
uptake;
accumulates
within brain
ventricle

2 dpf

4 dpf

cp79.6

ND

2

Small head; small eyes; no
swimbladder; heart edema; many
still in chorion; brain necrosis;
hemorrhaging around heart; slow
heartbeat; little to no circulation;
wider midbrain ventricle

Dispersed
punctate
staining on
the dorsal
ventricle
surface

4 dpf

3 dpf

2–3 No swimbladder; brain and tail
necrosis; brain ventricle
hemorrhaging; faint heartbeat; no
circulation; no midbrain–hindbrain
ventricle boundaries
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Accumulates
within third
ventricle

Table 3-2.

(Continued).

Class

Alleles

Map
Position

dpf

III: normal
GFP
expression,
smaller
epithelia
aggregates, and
expanded CP

cp79.8

ND

2

Small head; and eyes; no
swimbladder; brain necrosis;
hemorrhaging around heart;
decreased heartbeat and circulation;
wider midbrain ventricle

Increased
uptake;
accumulates
within brain
ventricle

cp151.2

ND

2-3

Small head; small eyes; no
swimbladder; brain necrosis; minor
swelling around head; occasional
hemorrhaging around heart; smaller
forebrain and no defined midbrain

cp27.5

LG 21

2

IV: variable
GFP
expression,
smaller
epithelia
aggregates, and
expanded CP

cp44.10

ND

2

Other Phenotypes (at 4 dpf)

Onset of
Brain
Necrosis
4 dpf

Initial
Circulation
Loss
3 dpf

Increased
uptake;
accumulates
within brain
ventricle

4 dpf

4 dpf

Small head; small eyes; no
swimbladder; brain necrosis; heart
edema; small arched body; curved
tail; hydrocephalus; occasional
hemorrhaging in brain ventricle;
heartbeat, but little to no circulation;
no defined ventricle boundaries

Increased
uptake;
accumulates
within brain
ventricle

2 dpf
(localized

3 dpf

Small head; small eyes; no
swimbladder; brain necrosis; heart
edema; small arched body; curved
tail; hydrocephalus; occasional

Increased
uptake;
accumulates
within brain
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Fluorescein
Transport

to
forebrain)

2 dpf
(localized
to
forebrain)

4 dpf

Table 3-2.

(Continued).

Class

Alleles

Map
Position

dpf

Other Phenotypes (at 4 dpf)
hemorrhaging around heart;
heartbeat, but little to no circulation;
no forebrain or midbrain and
irregularly shaped hindbrain

V: normal GFP
expression,
compact
epithelia, and
enlarged CP

Fluorescein
Transport

Onset of
Brain
Necrosis

Initial
Circulation
Loss

ventricles

cp26.6b

ND

4

Rounded head, protruding lower jaw; N/A
no swimbladder; edema around
heart, eyes, and gut; faint heartbeat
and circulation; normal brain
ventricle

N/A

4 dpf

cp105.2b

ND

4-5

Rounded head, protruding lower jaw; N/A
no swimbladder; severe edema
around heart, eyes, and gut; faint
heartbeat and circulation; slightly
smaller hindbrain ventricle

N/A

6 dpf

a

observations recorded at 3dpf; b observations recorded at 5dpf. ND, not determined; N/A, not applicable. Onset of Brain Necrosis
and Initial Circulation Loss are observed up to 4 dpf.
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Figure 3-1. Spontaneous Mutants with Normal Body Morphology but
Absent/Abnormal CP.
(A) Wild-type (top) and mutant (bottom) 4 dpf larvae from cp147.1. (B) Lateral view of
wild-type cp147.1 larvae. Arrowhead refers to the mCP. (C) Lateral view of mutant
cp147.1 larvae. Arrowhead refers to presumptive mCP although it is absent at 4 dpf. (D)
Dorsal brightfield view of cp50.1 mutant at 4 dpf. (E) Magnified brightfield image of
cp50.1 mutant. Slight hemorrhage is present near the third ventricle (arrowhead). (F)
Dorsal fluorescent image of cp50.1 mutant. Arrowhead refers to presumptive mCP,
although it is absent at 4 dpf. (G) Dorsal fluorescent image of a spontaneous larva at 5
dpf with a larger dCP (arrowhead) and mCP (arrow) but normal overall body
morphology. Scale bars are 50 µm.
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Figure 3-2.

Spontaneous and Recessive Mutants with Normal CP Morphology.

Mutants have severe heart, eye and gut edema with little or no heartbeat and circulation
and brain necrosis; however dCP and mCP appear normal in GFP intensity and CP
morphology. Figure shows dorsal view in brightfield (A) and in fluorescence (B) of a
spontaneous Et(cp:EGFP) sj2 larvae from cp49.3 at 4dpf. In (A), eye edema is
represented by an open arrowhead. In (B), the dCP is represented by a filled arrowhead
and an arrow is pointing at the mCP. Lateral view in brightfield (C) and fluorescence (D)
of cp49.3larvae at 4dpf. In (C) heart edema is shown by an open arrowhead and an
asterisk represents edema in the gut. In (D), the arrow represents the mCP. (E-H) shows
larvae from cp50.3. We identified around 15% mutant. (E) Dorsal brightfield image of
cp50.3 mutant larvae at 4 dpf. (F) Dorsal fluorescent image of cp50.3 mutant larvae at 4
dpf. dCP (arrowhead) and mCP (arrow) shown for each mutant. (G) Lateral brightfield
image of cp50.3 mutants at 4 dpf. (H) Lateral fluorescent image of cp50.3 mutant larvae
at 4 dpf. dCP, diencephalic choroid plexus; mCP, myelencephalic choroid plexus. Scale
bar is 50 µm.
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paragraphs were named based on the original F2 family and pair number within that
family. No mutants were adult viable and most did not survive past 4 dpf, except for
cp26.6 and cp105.2, which lived until 5 dpf and 6 dpf, respectively. cp27.5 and cp44.10
mutants displayed similar phenotypes; however, complementation analysis showed that
they were not in the same complementation group. On the basis of GFP intensity,
epithelial localization, and overall CP morphology, we identified five classes: (1) mutants
with reduced GFP expression, dispersed epithelial cells, and irregularly shaped CP; (2)
mutants with normal GFP expression, small epithelial aggregates, and irregularly shaped
CP; (3) mutants with normal GFP expression, small epithelial aggregates, and expanded
CP; (4) mutants with variable GFP expression, small epithelial aggregates, and expanded
CP; and (5) mutants with normal GFP expression, compact epithelial cells, and enlarged
CP.
To further classify these mutants, we analyzed brain ventricle morphology and
transporter activity in the CP. To examine brain ventricle morphology, we injected a
40-kDa fluorescein dextran into the ventricle of Et(cp:EGFP)sj2 mutants that were GFP
negative by outcrossing the mutant lines to the wild-type TL strain, and selected based
upon other phenotypic traits. Fluorescein transport was used as a secondary assay to
measure transporter activity in the CP and overall permeability as described previously in
Fluorescein Treatment on pg. 29.
Class I Mutants Have Reduced GFP Expression, Dispersed Epithelial Cells,
and Irregularly Shaped CP. Class I comprised 2 mutant lines cp26.3 and cp140.2,
which had reduced GFP and dispersed epithelial cells, resulting in an irregularly shaped
mCP (Figure 3-3). The cp26.3 mutants were observed starting at late 2 dpf to early 3
dpf. By 3 dpf, the mutants had a very faint heartbeat, no circulation, and developed heart
edema. Although these mutants had relatively normal body morphology except for the
absence of a swimbladder, they developed severe necrosis and did not survive beyond 3
dpf. The necrosis was localized primarily within the head region. Although the majority
of the cp26.3 mutants exhibited hemorrhaging within the brain ventricle, there was no
ventricle expansion. The mutants had normal hindbrain ventricle morphology, but
ventricles were slightly smaller than those of wild-type larvae. They also had little to no
midbrain and forebrain ventricles (Figure 3-3E-F`).
Based upon additional phenotypes such as small head and eyes, cp140.2 mutants
were identifiable at 2 dpf. CP development was monitored by time-lapse confocal
imaging over a period of 48 h, starting at 54 hpf for wild-type larvae (see Appendix A.
SupplementalMovie2) and cp140.2 mutants (see Appendix A. SupplementalMovie3).
GFP intensity was reduced and there were defects in cell coalescence, resulting in a CP
with discrete boundaries. The overall body morphology of cp140.2 mutants was similar
to that of wild-type larvae but smaller in size and lacked the swimbladder. The mutants
developed heart edema but maintained a heartbeat and circulation until 4 dpf. They also
exhibited brain necrosis by 4 dpf, but there was no hemorrhaging within the brain
ventricle or ventricle expansion. cp140.2 mutants had normal hindbrain and broader
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Figure 3-3. Class I Mutants Have Reduced GFP Expression, Dispersed Epithelial
Cells, and Irregularly Shaped CP.
(A) Dorsal image of 3 dpf wild-type cp26.3 larvae at 20× magnification. (A’) Lateral
image of 3 dpf wild-type cp26.3 larvae at 10× magnification. (B) Dorsal image of 3 dpf
mutant cp26.3 larvae at 20× magnification. (B’) Lateral image of 4 dpf mutant cp26.3
larvae at 10× magnification. (C) Dorsal image of 4 dpf wild-type cp140.2 larvae at 20×
magnification. (C’) Lateral image of 4 dpf wild-type cp140.2 larvae at 10× magnification.
(D) Dorsal image of 4 dpf mutant cp140.2 larvae at 20× magnification. (D’) Lateral
image of 4 dpf mutant cp140.2 larvae at 10× magnification. (E) Bright-field image of 3
dpf wild-type cp26.3 larvae after ventricle injection of the 40-kDa fluorescein dextran.
(E’) Fluorescent image of 3 dpf wild-type cp26.3 larvae after ventricle injection of the
40-kDa fluorescein dextran. (F) Bright-field image of 3 dpf mutant cp26.3 larvae after
ventricle injection of the 40-kDa fluorescein dextran. (F’) Fluorescent image of 3 dpf
mutant cp26.3 larvae after ventricle injection of the 40-kDa fluorescein dextran. (G)
Bright-field image of 4 dpf wild-type cp140.2 larvae after ventricle injection of the
40-kDa fluorescein dextran. (G’) Fluorescent image of 4 dpf wild-type cp140.2 larvae
after ventricle injection of the 40-kDa fluorescein dextran. (H) Bright-field image of
4dpf mutant cp140.2 larvae after ventricle injection of the 40-kDa fluorescein dextran.
(H’) Fluorescent image of 4 dpf mutant cp140.2 larvae after ventricle injection of the
40-kDa fluorescein dextran. Images in (A)–(D’) were acquired by confocal microscopy,
and those in (E)–(H’) were acquired by fluorescent stereoscopy. Scale bar is 50µm.
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midbrain ventricles, but less defined and slightly larger forebrain ventricles than that of
wild-type larvae (Figure 3-3G-H`).
Class II Mutants Have Normal GFP Expression, Small Epithelial
Aggregates, and Irregularly Shaped CP. Class II comprised lines cp9.6 and cp79.6
(Figure 3-4). The cp9.6 mutants were isolated at 2 dpf, based on the brain necrosis.
Time-lapse imaging showed cell migration toward the dorsal midline to form the mCP;
however, the cells formed smaller aggregates, resulting in a misshapen CP (see
Appendix A SupplementalMovie4). These mutants also had a small head and eyes, no
swimbladder, heart edema, and brain necrosis. By 4 dpf, they continued to have a
heartbeat but slow circulation. Also, brain ventricle expansion or hydrocephaly occurred
in some mutants by late 3 dpf to 4 dpf. Ventricular morphology revealed no forebrain or
midbrain ventricle (Figure 3-4E-F`). The hindbrain ventricle appeared smaller in size
than that of wild-type larvae.
cp79.6 mutants were identified at approximately 2 dpf and had a small head and
eyes, no swimbladder, heart edema, and many mutants never hatched out of the chorion.
By 4 dpf, the mutants had a very slow heartbeat, little to no circulation, brain necrosis,
and hemorrhaging around the heart. Time-lapse imaging revealed that the epithelial cells
were initially dispersed and similar to those of the cp140.2 mutants (see Appendix A
SupplementalMovie5). Although the cells became more compact over time, the final
CP had internal regions with no GFP expression, suggesting that the cells formed smaller
aggregates rather than a compact structure. Although these mutants had a defect in CP
development, overall brain ventricle morphology was normal, except for a larger
midbrain ventricle as seen in cp140.2 (Figure 3-4G-H`)
Class III Mutants Have Normal GFP Expression, Small Epithelial
Aggregates, and Expanded CP. Class III comprised 2 mutant lines cp79.8 and cp151.2,
which had normal GFP expression but dispersed cell aggregates, resulting in an expanded
CP (Figure 3-5). Both mutants had a small head and eyes, heart edema, no swimbladder,
and brain necrosis. The cp79.8 mutants were isolated by 2 dpf. By 4 dpf, mutants
showed hemorrhaging in the heart and most had a decreased heartbeat and circulation.
Brain ventricle morphology was relatively normal and resembled that of cp79.6 mutants
(Figure 3-5E-F`).
The cp151.2 mutants were identified at approximately late 2 dpf to 3 dpf.
Although their overall body morphology was fairly normal but smaller in size, by 4 dpf,
these mutants developed minor swelling around the head and occasionally exhibited
hemorrhaging around the heart, but continued to have a heartbeat and circulation. CP
development over time showed normal GFP intensity, but the initial localization of CPe
was more expanded than that of wild-type larvae (see Appendix A.
SupplementalMovie6). Although the cells did coalesce, they tended to form smaller
aggregates rather than migrating together to form a compact CP. Also, toward the end of
the 48 h time course, cell death occurred within the epithelium. Although the CP was

58

Figure 3-4. Class II Mutants Have Normal GFP Expression, Small Epithelial
Aggregates, and Irregularly Shaped CP.
(A) Dorsal image of 4 dpf wild-type cp9.6 larvae at 20× magnification. (A’) Lateral
image of 4 dpf wild-type cp9.6 larvae at 10× magnification. (B) Dorsal image of 4 dpf
mutant cp9.6 larvae at 20× magnification. (B’) Lateral image of 4 dpf mutant cp9.6
larvae at 10× magnification. (C) Dorsal image of 4 dpf wild-type cp79.6 larvae at 20×
magnification. (C’) Lateral image of 4 dpf wild-type cp79.6 larvae at 10× magnification.
(D) Dorsal image of 4 dpf mutant cp79.6 larvae at 20× magnification. (D’) Lateral image
of 4 dpf mutant cp79.6 larvae at 10× magnification. (E) Bright-field image of 4dpf
wild-type cp9.6 larvae after ventricle injection of the 40-kDa fluorescein dextran. (E’)
Fluorescent image of 4 dpf wild-type cp9.6 larvae after ventricle injection of the 40-kDa
fluorescein dextran. (F) Bright-field image of 4 dpf mutant cp9.6 larvae after ventricle
injection of the 40-kDa fluorescein dextran. (F’) Fluorescent image of 4 dpf mutant cp9.6
larvae after ventricle injection of the 40-kDa fluorescein dextran. (G) Bright-field image
of 4 dpf wild-type cp79.6 larvae after ventricle injection of the 40-kDa fluorescein
dextran. (G’) Fluorescent image of 4 dpf wild-type cp79.6 larvae after ventricle injection
of the 40-kDa fluorescein dextran. (H) Bright-field image of 4 dpf mutant cp79.6 larvae
after ventricle injection of the 40-kDa fluorescein dextran. (H`) Fluorescent image of the
4 dpf mutant cp79.6 larvae after ventricle injection of the 40-kDa fluorescein dextran.
Images in (A)–(D’) were acquired by confocal microscopy, and those in (E)–(H’) were
acquired by fluorescent stereoscopy.
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Figure 3-5. Class III Mutants Have Normal GFP Expression, Small Epithelial
Aggregates, and Expanded CP.
(A) Dorsal image of 4 dpf wild-type cp79.8 larvae at 20× magnification. (A’) Lateral
image of 4 dpf wild-type cp79.8 larvae at 10× magnification. (B) Dorsal image of 4 dpf
mutant cp79.8 larvae at 20× magnification. (B’) Lateral image of 4 dpf mutant cp79.8
larvae at 10× magnification. (C) Dorsal image of 4 dpf wild-type cp151.2 larvae at 20×
magnification. (C’) Lateral image of 4 dpf wild-type cp151.2 larvae at 10× magnification.
(D) Dorsal image of 4 dpf mutant cp151.2 larvae at 20× magnification. (D`) Lateral
image of 4 dpf mutant cp151.2 larvae at 10× magnification. (E) Bright-field image of 4
dpf wild-type cp79.8 larvae after ventricle injection of the 40-kDa fluorescein dextran.
(E`) Fluorescent image of 4 dpf wild-type cp79.8 larvae after ventricle injection of the
40-kDa fluorescein dextran. (F) Bright-field image of 4 dpf mutant cp79.8 larvae after
ventricle injection of the 40-kDa fluorescein dextran. (F’) Fluorescent image of 4 dpf
mutant cp79.8 larvae after ventricle injection of the 40-kDa fluorescein dextran. (G)
Bright-field image of 4 dpf wild-type cp151.2 larvae after ventricle injection of the
40-kDa fluorescein dextran. (G’) Fluorescent image of 4 dpf wild-type cp151.2 larvae
after ventricle injection of the 40-kDa fluorescein dextran. (H) Bright-field image of 4
dpf mutant cp151.2 larvae after ventricle injection of the 40-kDa fluorescein dextran.
(H’) Fluorescent image of 4 dpf mutant cp151.2 larvae after ventricle injection of the
40-kDa fluorescein dextran. Images in (A)–(D’) were acquired by confocal microscopy,
and those in (E)–(H’) were acquired by fluorescent stereoscopy.
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expanded, there appeared to be one large ventricle near the hindbrain rather than distinct
midbrain–hindbrain boundaries. There was also very low accumulation of 40-kDa
fluorescein within the forebrain ventricle (Figure 3-5G-H`).
Class IV Mutants Have Variable GFP Expression, Small Epithelial
Aggregates, and Expanded CP. Class IV comprised 2 mutant lines cp27.5 and cp44.10
(Figure 3-6). The GFP expression in these mutants varied between cells having normal
GFP intensity and those with lower expression. Similar to Class III mutants, cp27.5 and
cp44.10 also formed clusters of cells rather than a single compact structure, which
resulted in an expanded CP (Figure 3-6). For cp27.5, CP formation over time showed a
pattern of development similar to that of cp151.2; however, GFP intensity varied
throughout the CP (see Appendix A. SupplementalMovie7). Both cp27.5 and cp44.10
were identified at 2 dpf and displayed small heads, small eyes, and no swimbladder.
Other unique features were a significantly smaller and arched body, expanded ventricles
or hydrocephaly by 3 dpf, and tails that curved to the side by 4 dpf. Additional
phenotypes at 4 dpf included brain necrosis and heart edema. The mutants had a
heartbeat at 4 dpf, but little to no circulation. Also, there was occasional hemorrhaging in
the brain ventricle for cp27.5 and near the heart for cp44.10. These mutants exhibited the
most severe defects in terms of brain ventricle morphology among all the classes. cp27.5
had one large ventricle with no clearly defined forebrain, midbrain, and hindbrain
boundaries (Figure 3-6E-F`). cp44.10 had a smaller, irregularly shaped hindbrain, but
the 40-kDa fluorescein could not penetrate into the midbrain or forebrain ventricles
(Figure 3-6G-H`).
Class V Mutants Have Normal GFP Expression, Compact Epithelial Cells,
and Enlarged CP. Class V comprising 2 mutant lines cp26.6 and cp105.2, exhibited the
least severe CP phenotype, and survived longer than other mutant classes. The CP
appeared relatively normal compared with that of wild-type larvae, although it was larger
in size (Figure 3-7). Also, both mutants had a rounder head and a protruding lower jaw.
The cp26.6 mutant was isolated by 4 dpf. Mutants had no swimbladder and had edema in
the heart, eyes, and near the presumptive swimbladder. They also had a faint heartbeat
and circulation by 4 dpf. For cp26.6 mutants at 4 dpf, the brain ventricle morphology
was normal, but more closely resembled wild-type larvae at 3 dpf (Figure 3-7E-F`).
Also, cp105.2 mutants had a slightly smaller hindbrain ventricle compared to wild-type
(Figure 3-7G-H`). The cp105.2 mutants were isolated by late 4 dpf to 5 dpf, based on
the absence of a swimbladder. The CP initially appeared normal, but became larger as
the mutants developed severe heart and eye edema. Though the swimbladder was absent,
severe edema was localized to this region. The heartbeat and circulation began to
diminish by late 5 dpf to early 6 dpf.
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Figure 3-6. Class IV Mutants Have Variable GFP Expression, Small Epithelial
Aggregates, and Expanded CP.
(A) Dorsal image of 4 dpf wild-type cp27.5 larvae at 20× magnification. (A’) Lateral
image of 4 dpf wild-type cp27.5 larvae at 10× magnification. (B) Dorsal image of 4 dpf
mutant cp27.5 larvae at 20× magnification. (B’) Lateral image of 4 dpf mutant cp27.5
larvae at 10× magnification. (C) Dorsal image of 4 dpf wild-type cp44.10 larvae at 20×
magnification. (C’) Lateral image of 4 dpf wild-type cp44.10 larvae at 10× magnification.
(D) Dorsal image of 4 dpf mutant cp44.10 larvae at 20× magnification. (D’) Lateral
image of 4 dpf mutant cp44.10 larvae at 10× magnification. (E) Bright-field image of 4
dpf wild-type cp27.5 larvae after ventricle injection of the 40-kDa fluorescein dextran.
(E’) Fluorescent image of 4 dpf wild-type cp27.5 larvae after ventricle injection of the
40-kDa fluorescein dextran. (F) Bright-field image of 4 dpf mutant cp27.5 larvae after
ventricle injection of the 40-kDa fluorescein dextran. (F’) Fluorescent image of 4 dpf
mutant cp27.5 larvae after ventricle injection of the 40-kDa fluorescein dextran. (G)
Bright-field image of 4 dpf wild-type cp44.10 larvae after ventricle injection of the
40-kDa fluorescein dextran. (G`) Fluorescent image of 4 dpf wild-type cp44.10 larvae
after ventricle injection of the 40-kDa fluorescein dextran. (H) Bright-field image of 4
dpf mutant cp44.10 larvae after ventricle injection of the 40-kDa fluorescein dextran.
(H’) Fluorescent image of 4 dpf mutant cp44.10 larvae after ventricle injection of the
40-kDa fluorescein dextran. Images in (A)–(D’) were acquired by confocal microscopy,
and those in (E)–(H’) were acquired by fluorescent stereoscopy.
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Figure 3-7. Class V Mutants Have Normal GFP Expression, Compact Epithelial
Cells, and Enlarged CP.
(A) Dorsal image of 4 dpf wild-type cp26.6 larvae at 20× magnification. (A’) Lateral
image of 4 dpf wild-type cp26.6 larvae at 10× magnification. (B) Dorsal image of 4 dpf
mutant cp26.6 larvae at 20× magnification. (B’) Lateral image of 4 dpf mutant cp26.6
larvae at 10× magnification. (C) Dorsal image of 4 dpf wild-type cp105.2 larvae at 20×
magnification. (C’) Lateral image of 4 dpf wild-type cp105.2 larvae at 10× magnification.
(D) Dorsal image of 4 dpf mutant cp105.2 larvae at 20× magnification. (D’) Lateral
image of 4dpf mutant cp105.2 larvae at 10× magnification. (E) Bright-field image of 4
dpf wild-type cp26.6 larvae after ventricle injection of the 40-kDa fluorescein dextran.
(E’) Fluorescent image of 4 dpf wild-type cp26.6 larvae after ventricle injection of the
40-kDa fluorescein dextran. (F) Bright-field image of 4 dpf mutant cp26.6 larvae after
ventricle injection of the 40-kDa fluorescein dextran. (F’) Fluorescent image of 4 dpf
mutant cp26.6 larvae after ventricle injection of the 40-kDa fluorescein dextran. (G)
Bright-field image of 4 dpf wild-type cp105.2 larvae after ventricle injection of the
40-kDa fluorescein dextran. (G’) Fluorescent image of 4 dpf wild-type cp105.2 larvae
after ventricle injection of the 40-kDa fluorescein dextran. (H) Bright-field image of 4
dpf mutant cp105.2 larvae after ventricle injection of the 40-kDa fluorescein dextran.
(H’) Fluorescent image of 4 dpf mutant cp105.2 larvae after ventricle injection of the
40-kDa fluorescein dextran. Images in (A)–(D’) were acquired by confocal microscopy,
whereas those in (E)–(H’) were acquired by fluorescent stereoscopy.
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Fluorescein Assay to Determine CP Transport
To determine if the CP could transport fluorescein in the mutants, GFP negative
larvae were treated at 3 dpf with 50 µM fluorescein as described in the characterization
study. For cp26.3, fluorescein tended to accumulate toward the anterior part of the brain
and no fluorescein accumulated within the CP (Figure 3-8E). Fluorescein did not
accumulate in the CPe in the cp140.2 mutant, but was localized throughout the brain
ventricle. These mutants also had a higher overall fluorescein uptake than wild-type.
(Figure 3-8M). cp9.6 mutants also exhibited a higher overall uptake of fluorescein than
wild-type and concentrated within the brain ventricle, gut, and heart. There was no
distinct accumulation within the CP (Figure 3-8F). For cp79.6, the overall uptake of
fluorescein was comparable to wild-type. We observed very faint punctate accumulate of
fluorescein within the general area of the CP indicating possible transport (Figure 3-8N).
Class III mutants (cp79.8 and cp151.2) had increased uptake of fluorescein
compared to wild-type and both had accumulation within the brain ventricle, gut, and
heart. No fluorescein accumulated within the CPe (Figure 3-8G and 3-8O). A similar
phenotype was observed in Class IV mutants (cp27.5 and cp44.10) in that they also had
increased uptake of fluorescein concentrated within the brain ventricle, gut, and heart, but
no localization within CPe (Figure 3-8H and 3-8P). We were not able conclude whether
Class V mutants (cp26.6 and cp105.2) demonstrated transport activity using this assay
because of the inability to confidently identify GFP negative mutants at 3 dpf and 4 dpf.
Once we identified mutants by late 4 dpf- 5 dpf, fluorescein was rapidly cleared by the
gut and was not distributed throughout the embryo (data not shown).
Discussion
To characterize mutants in our study, we examined not only GFP expression in
the CP but also ventricle morphology and transporter activity. Previous studies have
grouped zebrafish brain ventricle mutants into four categories: midline separation defects,
reduced ventricle size, midbrain and hindbrain abnormalities, and absence of lumen
inflation (Lowery et al., 2009). Because none of our CP mutants exhibited a phenotype at
24 hpf, we did not expect to see defects in midline separation as described in Lowery et
al. (2009) (Lowery et al., 2009). CP mutants such as cp79.6 and cp140.2 have a brain
ventricle that closely resembles a normal larva at 2 dpf (Lowery et al., 2007), indicating
that these mutants may have a developmental delay and not necessarily a brain ventricle
defect. Also, cp140.2 mutants at 3 dpf are similar to wild-type larvae at 2 dpf in that
fluorescein accumulated within the brain ventricle rather than concentrating within CPe
as it does normally on day 3. Many mutants exhibited an increased overall uptake of
fluorescein, which may indicate defects in the skin epithelial barriers as well resulting in
greater permeability to absorb small molecules from their surroundings.
While mutants exhibit little to no heart beat and circulation when screened on day
4, as described in Table 3- 2, the majority of mutants do have a strong heart beat and
rapid circulation indistinguishable from wild-type prior to this time point. The initial
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Figure 3-8.

Fluorescein Assay Determines CP Transport Activity in Mutants.

(A-D) and (I-L) Wild-type larvae treated at 3 dpf with 50 µM fluorescein. (E) cp26.3
mutant at 3 dpf. (F) cp9.6 mutant at 3 dpf. Inset image is acquired at the same exposure
to the corresponding wild-type in (B). (G) cp79.8 mutant at 3 dpf. Inset image is
acquired at the same exposure to the corresponding wild-type in (C). (H) cp27.5 mutant
at 3 dpf. Inset image is acquired at the same exposure to the corresponding wild-type in
(D). (M) cp140.2 mutant at 3 dpf. (N) cp79.6 mutant at 3 dpf. Punctate accumulation of
fluorescein in the brain ventricle is shown with an arrowhead. (O) cp151.2 mutant at 3
dpf. Inset image is acquired at the same exposure to the corresponding wild-type in (K).
(P) cp44.10 mutant at 3 dpf. Inset image is acquired at the same exposure to the
corresponding wild-type in (L). The larger images for F, G, H, O, and P were taken at a
lower exposure compared to the corresponding wild-type in order to visualize where the
fluorescein was concentrating throughout the larvae. Scale bar is 50 µm.
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onset of circulation loss describes when we first observed mutants with decreased or no
circulation. Not all of the mutants had circulation loss at the same time, but the onset
describes when we observed the first mutant from a spawn having no circulation.
Because most of the mutants began to have decreased heartbeat and circulation at 4 dpf,
after the CP has already developed, we conclude that other factors are regulating CP
formation. However, we cannot rule out that circulation is required for CP maintenance.
We also do not attribute the lack of blood flow to abnormal CP development because we
identified spontaneous mutants with a normal CP but no circulation as shown in Figure
3-2. Because many mutants continued to have a heartbeat and circulation at 3 dpf, which
are factors essential for brain ventricle expansion (Lowery and Sive, 2005), we did not
expect ventricle expansion defects in these mutants. While ventricle morphology varied
between lines, all had expanded ventricles.
The mutants identified in our screen will provide the tools necessary to investigate
several genes associated with CP development and barrier function. After isolating
defective genes in these mutants, we can begin to define the correlation between the
mutated gene and the phenotypic abnormalities we observed. Although we identified
mutants with brain necrosis, we do not contribute necrosis alone is a factor responsible
for abnormal CP development and believe that these processes can be unrelated. This is
supported as shown in Figure 3-2, where larvae with brain necrosis developed a normal
CP. Furthermore, for the mutants we characterized further, we did not observe the onset
of necrosis until after the CP had already started to develop for many of the lines, or if
necrosis was present, it was not near the mCP itself. We also found larvae that had
normal morphology overall, but a severely abnormal or absent CP as shown in Figure
3-1 indicating again that necrosis is not the sole mechanism responsible for abnormal CP
development and that specific pathways exist in regulation its formation and function.
We expect some of the genes we identify will be specifically related to a CP defect rather
than pleiotropy that results in an overall severely abnormal animal. Pleiotropy is where a
mutation in one gene can cause multiple phenotypes (Lobo, 2008)
Recent discoveries have shed light on the importance of the CP and its
contribution to disease. For example, transcriptome analysis during early development
revealed that the CP expresses numerous genes essential for CP function, including those
for tight junctions, transporters, and metabolic function (Liddelow et al., 2012),
protecting the brain from potentially harmful insults (Kratzer et al., 2013). The mutants
identified in our study will be used to identify genes essential for maintaining epithelial
barrier integrity as well as genes essential for initial barrier formation. Reverse genetics
studies have shown that transcription factors such as Otx2 aid in CP development and
maintenance (Johansson et al., 2013). Also, augurin, a protein encoded by the esophageal
cancer related gene-4 (Ecrg4) and thought to act as a tumor suppressor, has a higher
expression in the CP than other tissues. Interestingly, morpholino knockdown of Ecrg4
in zebrafish results in increased CNS cell proliferation and hydrocephaly (Gonzalez et al.,
2011). Additional studies in zebrafish showed that the clusterin gene, which encodes a
secreted glycoprotein that aids in aggregation and contributes to Alzheimer’s disease by
co-localizing with plaques (Thambisetty et al., 2010), is similar to its human counterpart
and is expressed in the dCP and mCP (Jiao et al., 2011). Demonstrating similarities in
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gene expression in zebrafish and human CP is important when considering the use of
zebrafish as a disease model for CP-related conditions. Ultimately, the genes discovered
from these mutants will provide a better understanding of the genetic and molecular
mechanisms involved in CP formation and function and provide new insights into how
these normal processes become altered in disease.
Conclusion
Forward genetic screening is a powerful tool to uncover genetic processes
essential for development and/or maintenance of specific cell types, tissues, or overall
morphology of an organism. We have performed the first forward genetic screen to
identify mutants with CP defects using GFP as a readout to observe its development over
time. Using this unbiased approach, we discovered 10 recessive mutant lines with CP
phenotypes. While these mutants also exhibit other abnormalities, we have provided
evidence that specific pathways essential for CP development do exist by discovering
mutants with normal morphology and no CP or mutants with severe abnormalities, but
normal CP development. Future studies will investigate whether the genes responsible
for the recessive mutant phenotypes are specific to the CP and play a role in its
development, function, and maintenance.
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CHAPTER 4. POSITIONAL CLONING AND WHOLE-EXOME SEQUENCING
(WES) IDENTIFIES SART1 AS DEFECTIVE GENE IN CHOROID PLEXUS
MUTANT
Introduction
The spliceosome consists of a complex network of proteins and small nuclear
ribonucleoproteins called snRNPs that remove introns from precursor messenger RNA
(pre-mRNA) to form mature mRNA. Although the process of splicing was discovered
more than thirty years ago (Matera and Wang, 2014), the mechanisms of spliceosome
assembly and splicing regulation are not well understood. Over 100 proteins have been
identified in regulating spliceosome assembly or function (Jurica and Moore, 2003).
Understanding the role these proteins play in splicing is important because a number of
disorders, such as retinitis pigmentosa (RP) (Tanackovic et al., 2011), amyotrophic lateral
sclerosis, spinal muscular atropy (Tsuiji et al., 2013) , and chronic lymphocytic leukemia
(Rozovski et al., 2013) can occur as a result of mutations in splicing factors.
Here we present a mutation in one of these proteins, squamous cell carcinoma
antigen recognized by T-cells (sart1), which was discovered from the forward genetic
screen in zebrafish identifying mutants in CP development. This mutant line previously
referred to as cp27.5, not only has defects in CP development but also ventricle
expansion, eye formation, and CNS and epithelial barrier permeability. Mutants are
embryonic lethal dying around late day 4. We genetically mapped the mutation from
cp27.5 using bulked-segregant analysis and identified a critical interval along
Chromosome 21. We identified the gene as sart1 using WES, which has recently been
utilized as an effective and time-efficient strategy to identify mutations in lines
discovered from zebrafish forward genetic screens (Kettleborough et al., 2013; Ryan et
al., 2013). Using this approach, we discovered that sart1 has a point mutation containing
a G to A transition at the donor site of exon 12. We also confirmed by mRNA rescue that
sart1 is the gene responsible for the phenotypes we described previously in cp27.5
mutants.
Materials and Methods
Genomic DNA Isolation
Adult zebrafish were anesthetized in 0.02% tricaine (Sigma-Aldrich) and tail
clipped. As the fish recovered in system water, the tail clip was immediately immersed
into 50 µL digest buffer (0.2 M NaCl, 10 mM Tris 8.0, 5 mM EDTA, 0.1% SDS, 0.1
mg/ml Proteinase K). Samples were incubated overnight at 50⁰. After brief
centrifugation, 450 µL of 100% ethanol (EtOH) was added. Samples were centrifuged at
21,130 g or 15,000 rpm for 10 min, the supernatant was removed, and 500 µL of 70%
EtOH added to wash the pellet. Samples were centrifuged at 21,130 g or 15,000 rpm for
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5 min. After removing the supernatant, the samples were stored at room temperature for
about 30 min to evaporate excess EtOH. The DNA pellets were resuspended with 50 µL
of TE buffer (10 mM Tris and 1 mM EDTA, pH 8.0).
For zebrafish larvae, wild-type and mutants were anesthetized, separated into 1.5
mL eppendorf tubes, and immersed in 1 mL 100% methanol (MeOH) (Sigma-Aldrich).
Samples were stored at -20° overnight. The following day, individual wild-type and
mutant larvae were transferred into 0.5 mL tubes and the excess MeOH removed. Once
all the MeOH evaporated, 10 µL of digest buffer (same as above) was added to each tube.
Samples were incubated overnight at 50°. DNA was isolated as described above for
adults except the volume of 100% EtOH and 70% EtOH was 180 µL and the volume of
TE buffer was 25 µL.
Positional Cloning
After identifying a mutant line, the Et(cp:EGFP)sj2 F2 heterozygous parents were
each outcrossed to the polymorphic TL strain. From this outcross, heterozygous hybrid
adults were isolated based their offspring with the recessive mutant phenotype. The
wild-type and mutant offspring from these heterozygous hybrids were collected and their
DNA was extracted (see above). A genome scan using 192 polymorphic Z-markers was
performed with DNA pooled from 30 wild-type and 30 mutant larvae as previously
described (Muto et al., 2005). Wild-type and mutant DNA was amplified using the
Accuprime Taq DNA Polymerase System (Invitrogen). The resulting PCR products were
analyzed for genetic linkage by agarose gel electrophoresis. For fine genetic mapping,
individual wild-type and mutant DNA was amplified using Platinum PCR Supermix
(Invitrogen). Z-markers used for genetic mapping were acquired from the zebrafish
genome database at http://www.ensembl.org/index.html (Flicek et al., 2014). Additional
markers were designed by examining the Ensembl genome browser for polymorphic
regions in the genome (Flicek et al., 2014).
Whole-Exome Sequencing and Analysis
cp27.5 wild-type and mutant larvae (20 each) were collected in MeOH at 3 dpf.
The 20 larvae were generated from 3 different heterozygous parents. DNA was extracted
and using the MagAttract HMW DNA kit (Qiagen) following the manufacturer’s
instructions. Values for DNA concentration and purity were obtained by a ND-1000
NanoDrop Spectrophotometer and Qubit assay. Concentration was adjusted to the
required 3 µg/120 µL for sequence capture. Sequence capture and sequencing was done
by the Genome Sequencing Facility Hartwell Center for Bioinformatics and
Biotechnology at St. Jude Children’s Research Hospital. Paired end 100 cycle
sequencing was run on a HiSeq 2500 using TruSeq SBS v3 chemistry according to the
manufacturer’s instructions (Illumina, San Diego, CA.). From the sequencing results, we
had coverage of all exons with at least 20x coverage for 80% of the regions and average
coverage of the target regions was even higher.
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From the raw sequencing data, the quality control, read mapping and variant
calling were performed using CLC Genomic Workbench v6.5 (CLC Bio, Denmark). In
brief, the reads were trimmed against the sequencing adapters and only reads with a
sequencing quality greater than 20 and a read length greater than 50 bp were retained.
The filtered reads were then aligned to the zebrafish reference genome sequence (Zv9
assembly, 2010), and the lists of single-nucleotide variants (SNV) and indels were
generated. To identify the causative mutation responsible for the phenotype, we
compared the variants of mutant with those of wild type, and a region enriched with
mutant-specific homozygosities was observed at a peak of homozygosity scores defined
by the percentage of mutant-specific homozygous variants within a 1-Mb window across
the genome. A candidate mutation was further pinpointed by screening the region for
nonsense and essential splice mutations. A diagram of the WES workflow and analysis is
represented in Figure 4-1.
sart1 RNA Rescue
cDNA from 3 dpf wild-type larvae was amplified using the AccuPrime Taq DNA
Polymerase System to produce a ~2.5 kb fragment of sart1 open reading frame (ORF).
After analyzing the PCR product on a 1% gel, the product was cut out of the gel and
purified using the QIAquick Gel Extraction kit (Qiagen). Molecular cloning was done to
insert the sart1 fragment into the PCRII TOPO vector using the PCRII TOPO TA cloning
kit dual promoter (Life Technologies) and transformed into TOP 10F’ chemically
competent E. coli (Invitrogen). Plasmid DNA was purified using the DNA Miniprep kit
(Qiagen). The plasmid was then cut using EcoRV and Spe1 restriction enzymes (New
England BioLabs) to release the sart1 fragment. The pCS2+ vector was cut using SnaB1
and Xba1 and a ligation reaction was performed to insert sart1 into the pCS2+ vector.
After molecular cloning of pCS2+:sart1, DNA was purified using the DNA Miniprep Kit
(Qiagen). Purified DNA was linearized using Not1 (New England BioLabs) and
incubated at 37° for 2 h. RNase A was added to the reaction and incubated at 37° for 5
min.
Following the protocols as outlined in the mMessage machine kit (Ambion),
transcription-quality plasmid DNA was prepared and RNA was synthesized from the
linearized DNA plasmid. The RNA quality was analyzed on a 1% agarose gel and the
quantity was measured using a ND-1000 NanoDrop Spectrophotometer. For the rescue,
approximately 150 pg of sart1 mRNA was injected into single-cell embryos produced
from sart1 heterozygous parents. Embryos were observed daily to look for rescue of the
mutant phenotype. A scoring system based on the phenotype at 4 dpf was used to
determine the rescue efficiency. Larvae were scored as wild-type, mutant, or abnormal.
Embryos were considered abnormal if there was an observable defect that did not
resemble a wild-type or mutant phenotype. After scoring the larvae based on phenotype,
samples were also collected and genotyped using PCR and Sanger DNA sequencing to
determine how many mutant larvae were rescued. The percentage rescued was based on
the number of mutants (based on genotype) that had wild-type phenotypes. Abnormal

70

Figure 4-1.

Schematic of WES Sequencing Workflow and Analysis.
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phenotypes for mutants were considered a partial rescue since most “abnormalities” were
minor compared to phenotypes of uninjected mutants, such as reduced head size or slight
heart edema.
Results
Positional Cloning and Whole-Exome Sequencing of cp27.5 Identifies Mutation in
sart1
To identify the mutated gene for cp27.5, we performed genetic mapping using
192 polymorphic markers distributed evenly across the genome. For cp27.5, we
identified markers z2363 and z15891 by bulked segregant analysis to map the mutation to
chromosome 21. Within this critical interval, we identified the marker z9233 and found
no recombinants out of 48 meioses. We then tested additional polymorphic markers and
counted the number of recombinants on either side of z9233 to refine the critical interval.
By testing polymorphic markers, BX530031.5 and BX530023.5, selected from the
zebrafish genome as published in Ensembl Zv9 (Flicek et al., 2014), we narrowed the
region to ~0.4 Mb. In total, we analyzed 450 meioses. A map of the defined critical
interval is represented in Figure 4-2. Genes within this region include: sart1
(NM_001002673.1), rin1a (XP_697152.1), slc29a2 (NM_001012501.2), and dpp3
(NM_001002683.1).
After defining the critical interval using positional cloning, we utilized WES
technology to identify the gene and type of mutation. We performed WES on cp27.5
mutants and their wild-type siblings. Using this technique, we isolated a point mutation in
sart1 containing a G to A transition at the donor site of exon 12. Upon sequencing
wild-type and mutant cDNA, we discovered the retention of intron 12 that contained a
TAA premature stop codon (Figure 4-3).
sart1 mRNA Rescues Mutant Phenotype
To verify sart1 as the causal gene resulting in the phenotypes seen in cp27.5
mutants, a rescue experiment was done by injecting sart1 mRNA into single-celled
embryos and observing them at 4 dpf to look for rescue. We screened 462 uninjected and
375 sart1 mRNA injected larvae. While overexpression of sart1 mRNA in wild-type
embryos did not cause any overt phenotype, sart1 mRNA was able to rescue defects seen
in mutants such as abnormal CP development, heart edema, curved body, and survived
past 4 dpf. Some larvae survived as late as 8 dpf. From this rescue, we quantified the
results and found that, based strictly on phenotype, the number of mutants for uninjected
controls was 23.3%, while mutant larvae from a spawn injected with sart1 mRNA was
1.5% (Table 4-1).
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Figure 4-2.

Positional Cloning Defines Critical Interval on Chromosome 21.

A critical interval was defined on Chromosome 21 using positional cloning. For bulked
segregant analysis, the polymorphic marker z9233 demonstrated linkage having zero
recombinants identified out of 450 meiotic events. Additional markers were analyzed
both proximal and distal to z9233 to define a critical interval of approximately 0.4 Mb.
The numbers of recombinants on the proximal side are shown in regular type and those
distal to z9233 are shown in bold italic font. sart1 lies within the contig sequence
BX530031.5.
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Figure 4-3.

WES Identifies a Point Mutation in sart1.

In (A), the blue peak is representative of the highest homozygosity score where mutants
are homozygous within this defined loci along Chromosome 21. This finding is further
demonstrated in the panel below where the reference genome contains a guanine (G) (in
orange) at this position and all mutants have an adenine (A) (in green). An adenine is
present in a portion of the wild-type sequence due to the fact that wild-type siblings may
be heterozygous for the mutation. (B) and (C) confirm that the gene containing the
mutation is sart1 as shown by a point mutation at the end of exon 12 (red asterisk) in (B).
(C) DNA Sanger Sequencing of cp27.5 wild-type and mutant cDNA confirms the GA
transition and reveals the retention of intron 12 and introduction of a premature stop
codon (TAA).
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Table 4-1.

sart1 mRNA Rescues Mutant Phenotypes.

Samples

Total Number Screened

Morphologically Mutant
(%)

462
375

23.3%
1.5%

No Injection Control
sart1 mRNA

To confirm that cp27.5 mutants were among those rescued, we collected
uninjected cp27.5 wild-type and mutant larvae and sart1 mRNA injected larvae and
sequenced individual DNA. We sequenced a total of 90 larvae with 20% of those having
a mutant genotype. Not surprisingly, we identified mutants with wild-type phenotypes as
represented in Figure 4-4. Some mutants appear to have complete rescue as shown in the
lower right-hand panel, while others had slight heart edema, smaller head size and
somewhat larger CP compared to wild-type (presented in two upper panels under Rescue
in Figure 4-4). Sequencing results are quantified in Figure 4-5. Based on the
sequencing data, we identified 10% of mutants we scored as having a wild-type
phenotype. The other 10% were scored as abnormal or having only a partial rescue.
However, even partially rescued mutants are far more phenotypically normal compared to
uninjected mutants shown in the middle panel of Figure 4-4.
Discussion
A recent study has cited that more than 9,000 mutants have been discovered as a
result of forward genetic screens in zebrafish, but many of the mutants have not been
further studied and 62% of them are uncloned (Obholzer et al., 2012). This is because of
the limitations involved in positional cloning including time, money, and effort it takes to
identify the gene (Obholzer et al., 2012). Hundreds of PCRs and sequencing of multiple
candidate genes is sometimes necessary to identify the mutation. Other times, the gene is
never identified simply because of its location along the chromosome, such as near the
telomere where multiple recombination events can occur. New technology with next
generation sequencing is redefining the way genes and their mutations are discovered.
WES has been used for many studies in humans and animal model systems. In human
samples, sequences can be compared between parents and their children to isolate de
novo mutations, between unrelated persons to identify new variations of the same gene,
or a sequenced region within the genome can be compared between multiple persons
within the same family to look for variations of a particular gene (Bamshad et al., 2011).
These studies have identified genes related to a number of human conditions including
hearing loss, cardiovascular disease, and cancer. An extensive list of the mutations
related to these conditions is presented by Rabbani et al. (Rabbani et al., 2014).
In a recent study, WES was used in zebrafish to identify the gene mutation for
four mutants all of which were characterized by having kidney cysts. Using this
approach, they were able to identify the genes and types of mutations, including
nonsense, splice site, and missense mutations for all four mutants (Ryan et al., 2013). A

75

Figure 4-4.

sart1 Rescues Mutant Phenotypes.

Dorsal bright field and fluorescent images are shown for three uninjected wild-type, three
uninjected mutant, and three sart1 injected mutant larvae in the left, middle, and right
panels, respectively. Injection of sart1 mRNA resulted in mutants with phenotypes
similar to wild-type larvae. The three rescued mutants represent a range of phenotypes
we observed after sart1mRNA injection. Scale bars are 100µm for bright field images at
3× magnifications and 50µm for fluorescent images acquired at 9 × magnifications.
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Figure 4-5.

Quantification of sart1 Rescue.

Sequencing a total of 90 cp27.5 wild-type and mutant larvae identified 20% with a
mutant genotype. Of the total number of mutants 10% were scored as wild-type and 10%
were scored as abnormal based on phenotype. The 10% abnormal were considered to be
partially rescued. Error bars are based on the mean of 3 rounds of injections using
standard error.
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unique study by Kettleborough et al. identified protein coding genes in zebrafish by
performing WES on the F1 generation and isolating nonsense and splice site mutations
(Kettleborough et al., 2013).
WES offers an advantage over WGS in that it can provide better coverage of the
genome. Coverage is described as the number of times the genome is sequenced and can
be calculated as follows in Equation 4-1:
C=LN/G

(Eq. 4-1)

Where C is coverage, G is the haploid genome length, L is the read length, and N is the
number of reads. This equation is also known as the Lander/Waterman equation (Lander
and Waterman, 1988). Although WGS usually has 4x coverage or less, we had 20x
coverage or greater for our samples using WES. While WES is improving, there are still
setbacks that can occur with this strategy. For example, a gene may be undetected if it is
novel and unrecognized by the exome capture, there may be poor coverage of that region,
or incorrect variants might be recognized if the reads become incorrectly mapped or
unaligned (Bamshad et al., 2011).
In our current study, we found that WES provided a significant advantage in
regards to the reduced time required to identify the gene and the type of mutation. By
first defining the critical interval using positional cloning, we were able to validate WES
as a suitable method for identifying genes in zebrafish since both strategies isolated the
same genomic region. However, had we not performed WES, traditional mapping
strategies would have required additional time and effort sequencing multiple genes
within the critical interval. Studies in mice have also shown that by using course genetic
mapping to identify the chromosome location followed by WES significantly reduces the
“validation burden” and helps to eliminate more false positives from the data (Fairfield et
al., 2011).
For our study, we decided to sequence both mutant and wild-type siblings and
align the sequences to the Ensembl ZV9 reference genome (Flicek et al., 2014) rather
than compare mutants to the reference genome alone. While this approach is more costly
by having two samples, we were able to more efficiently circumvent any nucleotide
changes that may simply be polymorphic to the strain. In addition, the DNA used for
sequencing was from larvae whose parents had been outcrossed into a polymorphic
strain. This step creates greater diversity throughout the genome except at the locus
containing the mutation, since the phenotype caused by the gene was specifically selected
for after outcrossing. In scoring for homozygous regions, some wild-type samples also
contained an adenine as seen in the mutants. This is because the wild-type sibling DNA
also contained heterozygous carriers for the mutation. Comparing homozygous wild-type
and homozygous mutant siblings may provide a more obvious map position of the
mutation.
Additional validation of sart1 as the target gene was done by performing mRNA
rescue experiments. Injections of mRNA into single-cell embryos prevented forebrain
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necrosis at 2 dpf which is the earliest detectable phenotype in cp27.5 mutants. Although
mRNA rescue is transient and is not sustained far past 4 dpf in zebrafish, we were able to
rescue phenotypes that begin at 3–4 dpf such as heart edema, small head and eyes,
reduced heartbeat and circulation. Mutants also had a longer lifespan than their
uninjected siblings. Important to this study, we were also able to restore normal CP
development. From this analysis, a number of wild-type larvae were scored as abnormal.
Abnormal phenotypes for wild-type larvae may be due to off target effects of the
injection. Also, when sequencing wild-type and mutant DNA from sart1 mRNA
injections, we identified only 20% as mutant rather than the 25% predicted by Mendelian
genetics. We attributed the decreased percentage due to damaged embryos from
microinjection that may not have survived past early development. For uninjected
samples, we observed between 23-25% mutant. Since this gene was identified from a
genetic screen for the CP, future studies will determine whether sart1 is directly affecting
CP formation and investigate potential pathways sart1 may be activating or suppressing
that contribute to CP development and function. Because sart1 is involved in formation
of the spliceosome that converts precursor mRNA into mature mRNA, defects in the
splicing process may produce altered transcripts that result in defective translation and
formation of proteins necessary for CP formation. The lack of coalescence in CPe may
be due to alternative splicing in transcripts encoding for tight junction or adherens
proteins or signals involved in cell survival and migration.
Conclusion
Supplemental to previous publications, our current study endorses the use of WES
in zebrafish by identifying the gene sart1precisely within the critical interval we defined
previously by positional cloning. We confirmed WES data using Sanger DNA
sequencing to sequence wild-type and mutant cDNA. In doing so, we identified a
retained intron and the introduction of a premature stop codon in mutant samples. Using
mRNA rescue, we identified 10% of mutants having wild-type properties with another
10% partially rescued. These experiments further validated that sart1 is the gene
responsible for the mutant phenotype. Future studies will characterize sart1 mutants to
define its role in CNS development and WES will be used to map the gene for additional
mutants from the genetic screen described in Chapter 3.
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CHAPTER 5. CHARACTERIZATION OF SART1 MUTANT REVEALS
UP-REGULATION OF GENES INVOLVED IN APOPTOSIS AND
DOWN-REGULATION OF VISION-RELATED GENES
Introduction
Sart1 also known as U4/U6.U5 tri-small nuclear ribonucleoprotein-associated
protein 1, HAF in mouse, and Snu66 in yeast, is a complex protein involved in U4/U6.U5
tri-snRNP recruitment to the spliceosome (Makarova et al., 2001). Sart1 has two protein
forms. One is an 800 amino acid sequence located in the nucleus of proliferating cells and
contains a leucine zipper motif suggesting it may bind to DNA (Shichijo et al., 1998).
Another 259 amino acid protein is synthesized by a -1 frame shift in an internal
ribosomal entry site that has been shown to be expressed in the cytosol in squamous cell
carcinomas (Shichijo et al., 1998).
In addition to splicing, Sart1 has been implicated in a number of different
processes such as cell cycle arrest and apoptosis. It has been suggested as a target for
gene therapy due to its activation of apoptosis and its role as an antigen recognized by
cytotoxic T lymphocytes (CTLs) in certain types of cancer (Hosokawa et al., 2005).
More recently, Sart1 has been shown to contribute to drug resistance in cancer cells.
Silencing of this gene resulted in increased apoptosis in colorectal cancer cells in
response to 5-Fluorouracil and SN38 drug treatment (Allen et al., 2012). Similarly, Sart1
has been shown to aid in Mcl1 activity, a pro-survival factor and contributor to drug
resistance in cancer (Laetsch et al., 2014). Knockdown of Sart1 caused Mcl1-dependent
neuroblastoma cells to become more responsive to treatment (Laetsch et al., 2014).
While splicing genes are thought to be ubiquitously expressed, recent evidence
suggests that certain components of the spliceosome may be temporally or spatially
regulated. Studies have identified spliceosome components such as U2 that have high
RNA levels specifically in the cerebellum and mutations in this gene result in
neurodegeneration (Jia et al., 2012). In zebrafish, we observed that sart1 is expressed
specifically in the brain and is actually up-regulated in sart1 mutants providing further
evidence that splicing components may be regulated or expressed in specific tissues and
may result in tissue-specific phenotypes.
Using RNA-Seq analysis, we identified that sart1 itself is up-regulated due to the
mutation described previously in Chapter 4. It also results in up-regulation of genes
essential to the apoptotic pathway such as tp53 and mdm2. Conversely, this mutation
causes genes regulating eye development and function to be down-regulated. This
analysis confirmed our observations of increased cell death observed in the brain and
eyes and lack of retinal lamination in these mutants. We also observed an up-regulation
of other components of the spliceosome such as U6 SnRNA-Associated Sm-Like Protein
(lsm7) and pre-mRNA processing factor 31 (prpf31), which may indicate a compensation
mechanism due to defects in sart1 function.
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While previous studies have identified the major role of Sart1 as recruiting the
U4/U5/U6 tri-snRNP to the spliceosome, understanding how Sart1 regulates the
expression of other genes will reveal how spliceosome components not only play a role in
splicing, but also other cellular processes such as apoptosis and the cell cycle and
conditions such as degeneration and cancer.
Materials and Methods
Reverse Transcriptase-PCR (RT-PCR)
Larvae were collected on ice in 50 µL Trizol (Life Technologies) and stored
at -80° until use. Samples were homogenized with a dounce for 30 s. Additional Trizol
was added to bring the final volume to 100 µL. Samples were mixed and incubated at
RT for 5 min. Chloroform was added (0.2 mL for every 1 mL of Trizol) and samples
were mixed and incubated at RT for 5 min. Samples were centrifuged at 4° at 12,000 x g
for 15 min. The top aqueous layer was transferred to a new tube. Isopropanol (0.5 mL
for every 1 mL of original volume of Trizol) and 2 µL of glycogen were added to the
clear aqueous solution followed by mixing and incubating a RT for 5 min. Samples were
centrifuged at 4° at 12,000 x g for 10 min. Isopropanol and chloroform were removed
leaving a RNA pellet. The pellet was washed in 100 µL 75% ethanol. Wash volumes
were the same as the original Trizol volume. Samples were centrifuged at 4 at 7,500 x g
for 5 min. Ethanol was removed and the pellet was air-dried for 20 min or until excess
ethanol evaporated. RNA was resuspended in 20 µL nuclease-free water.
cDNA synthesis was performed using SuperScript® III Reverse Transcriptase
(Life Technologies). A mixture of 50 µM oligo dT, 10mM dNTP, and 8 µL of RNA
product was incubated at 65° for 5 min and placed on ice for > 1 min. A mixture of 10 x
RT buffer, 25 mM MgCl2, 0.1 M DTT, RNAse Out, and Superscript III was added to the
mix containing the RNA. The reaction was incubated at 50° for at least 50 min. The
reaction was terminated by incubating at 85° for 5 min. Samples were chilled on ice and
1 µL of RNAse H was added to each reaction. Samples were incubated at 37° for 20 min
and then stored at -20°. cDNA was diluted 1:5 in water for PCR. RT-PCR was done
using the AccuPrime Taq DNA Polymerase System (Invitrogen). Primer sequences
included sart1F1:5’-CGTTTTTAAGCCAAAGTCTGTGCTG-3’ and sart1R1:
5’-CACCTCCTTCTTTCTCGTCATCCTT-3’. Samples were analyzed on a 1% agarose
gel.
Whole Mount In Situ Hybridization
The RNA probe was synthesized from the PCRII TOPO vector containing the 2.5
kb sart1 fragment as mentioned above using the DIG RNA Labeling Kit (SP6/T7)
(Roche). A probe for deltaC was also synthesized to use as a control. The probes were
purified using illustra Probe Quant G-50 micro columns (GE Healthcare) and
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resuspended in 80 µL hybridization buffer. Hybridization buffer was prepared as
described in Thisse and Thisse (Thisse and Thisse, 2008). Probes were analyzed on a 1%
agarose gel to determine the quality of the RNA.
cp27.5 wild-type and mutant larvae were collected at 3dpf were anesthetized in
0.02% tricaine and fixed in 4% paraformaldehyde (PFA) (Electron Microscopy Sciences)
made in 1x Dulbecco’s PBS (Sigma, cat. no. D-5652) and Diethyl pyrocarbonate (DEPC)
(Sigma Aldrich) -treated water. Larvae were stored at 4° for 16 h. Samples were then
washed in 100% methanol (Sigma Aldrich) at room temperature for 15 min and stored in
fresh methanol at -20° until use. The following procedure was carried out in 1.5 mL
Eppendorf tubes: Samples were rehydrated to 1x PBT (phosphate buffered saline/ 0.1%
tween 20 (Sigma) as described previously by Thisse and Thisse (Thisse and Thisse,
2008). Larvae were digested with 10 µg/mL Proteinase K (New England Biolabs) at
room temperature for 30 min followed by treatment with 4% PFA for 20 min at room
temperature. After washing 4 times for 5 min in 1x PBT, larvae were prehybridized for 2
h at 67° in 700 µL hybridization buffer. Larvae were then incubated in 200 µL of
hybridization buffer containing probe at 67° for approximately 48 h. Probes were used at
a 1:100 dilution. After incubation, larvae were washed following the series described in
Thisse and Thisse (Thisse and Thisse, 2008) except for the hybridization buffer/ 2x SSC
series was done for 15 min each and the 0.2x SSC/ PBT series was done for 5 min each.
Larvae were blocked in 2% lamb serum (Gibco) made in PBT at room temperature for 1
h. After blocking, larvae were incubated in anti-DIG antibody (Roche) at 1:5000 made in
blocking buffer at 4° overnight. Washes were carried out the next day as described in
Thisse and Thisse (Thisse and Thisse, 2008).
To develop, 500 µL alkaline phosphatase buffer containing
5-Bromo-4-chloro-3-indolyl phosphate/nitro-blue tetrazolium (BCIP/NBT)
(Sigma-Aldrich) was added to the larvae in 12 well plates. Larvae were incubated in the
dark and observed periodically until a purple precipitate appeared. The reaction was
terminated by removing staining solution and adding 1x PBS/1 mM EDTA followed by
washes in 1x PBS. Samples were stored in >99% glycerol (Sigma-Aldrich) and imaged
on a Nikon SMZ1500 epifluorescence stereomicroscope with Nikon NIS-Elements 3.1
software. All reagents were prepared following the protocol as described in Thisse and
Thisse (Thisse and Thisse, 2008).
Immunohistochemistry (IHC)
IHC was performed as described in on pg. 30. Primary antibodies included rabbit
anti-activated Caspase 3 (1:200; Cell Signaling), rabbit anti-Glut1 (1:200; Novus), mouse
anti-SV2 (1:300; Developmental Studies Hybridoma Bank), mouse anti-Zpr1 (1:100;
ZIRC), mouse anti-HuC/HuD neuronal protein (1:500; Life Technologies), and rabbit
anti-S100β (1:1000; Dako). Secondary antibodies included Alexa Fluor goat anti-rabbit
488 (1:200; Invitrogen) and Alexa Fluor goat anti-mouse 555 (1:200; Invitrogen).
Antibody dilutions were prepared in blocking buffer. Sections were counterstained with
1 µg/mL DAPI (Roche) for 1 min, rinsed briefly in PBS, and mounted with Fluoromount
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(Electron Microscopy Sciences). Images were taken on a Nikon C1Si laser scanning
confocal microscope and analyzed using NIS-Elements AR 3.0 software.
Whole Mount IHC
Whole mount IHC was performed as described on pg. 30. Antibodies used
included rabbit anti-GFP (1:100; Invitrogen), rabbit anti-activated Caspase-3 (1:100; Cell
Signaling), mouse anti-Zpr1 (1:50; ZIRC), and mouse anti-Cldn5 (1:100; Invitrogen),
Alexa Fluor goat anti-rabbit 488 (1:200; Invitrogen) and Alexa Fluor goat anti-mouse 555
(1:200; Invitrogen). Samples were imaged on Nikon C1Si laser scanning confocal
microscope. Z-stacks were compiled to create maximum intensity projection images
using Nikon NIS-Elements 3.0 imaging software.
Western Blot
An equal number of wild-type and mutant larvae were each collected in a 1.5mL
Eppendorf tube, the embryo media removed, and stored at -80°C. Homogenization
buffer (2x) (Mini Complete tablet, Roche) containing 0.002% DNase (Ambion) was
added and larvae were homogenized on ice. Samples were removed from ice and
SDS/gel loading buffer containing DTT was added to the homogenate. Samples were
then placed in boiling water for 5 min, cooled afterwards at RT, and centrifuged briefly
before gel loading. Samples and the Precision Plus Kaleidoscope Protein Standard ladder
(BioRad) were run on a 4-15% polyacrylamide gel (BioRad) at 200V for 30’ at RT.
Proteins were transferred to a nitrocellulose membrane using the Trans-Blot Turbo
Transfer System (BioRad). Following protein transfer, the nitrocellulose membrane was
blocked in 5% milk for 1 hr. Membranes were incubated in 5mL of primary antibody at
4°C overnight. The membrane was then washed in 1x Tris-buffered saline/0.1% Tween
(TBST) at RT and incubated in 20mL of secondary antibody for 1hr at RT. After
incubation, the membranes were washed in 1x TBST and imaged using LI-COR Odyssey
1393 and Odyssey Infrared Imaging System Version 3.0. Primary antibodies included
rabbit anti-p53 (1:500; GeneTex) and mouse anti-actin (1:1000; Sigma Aldrich).
Secondary antibodies included goat anti-rabbit IRDye ® 680 (1:20,000; LI-COR) and
goat anti-mouse IRDye ® 800 CW (1:15,000; LI-COR).
Doxycycline Treatment
cp27.5 wild-type and mutant larvae were treated at 24 hpf with 50 µg/mL
doxycycline (ClonTech). Larvae were observed at 3dpf to look for GFP expression in the
CNS and imaged using a Nikon SMZ1500 epifluorescence stereoscope and Nikon
NIS-Elements 3.1 software.
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Fluorescent Tracer Injections
Wild-type and mutant cp27.5 larvae were anesthetized in 0.02% tricaine and
co-injected intravenously into the common cardinal vein with approximately 1.8 nL of 10
mg/mL 3-kDa Cascade blue dextran, 10-kDa rhodamine dextran, and a 40-kDa anionic
fluorescein dextran (Invitrogen). Injections were performed using a micromanipulator
and a pneumatic picopump (World Precision Instruments). Immediately after injection,
larvae were embedded in 1.2% low-melting-point agarose (Invitrogen) made in egg
water. Larvae were imaged within 30 min post-injection on a Nikon C1Si confocal
microscope and analyzed using Nikon EZC1 3.91 software.
RNA-Seq
RNA was extracted as described before (see RT-PCR pg. 81) from wild-type and
mutant cp27.5 larvae at 72 hpf. Samples were submitted to the Genome Sequencing
Facility Hartwell Center for Bioinformatics and Biotechnology at St. Jude Children’s
Research Hospital for QC and quantification analysis and sequencing. Approximately
500 ng total RNA was used to generate libraries with the TruSeq RNA v2 kit according
to the manufacturer’s instructions (Illumina, San Diego, CA.). PolyA-selected RNAs
from wild-type and mutant zebrafish were sequenced using Illumina HiSeq 2500. The
raw 100-bp pair end reads were mapped to zebrafish genome (Zv9) using STAR (Dobin
et al., 2013). Duplicated reads were marked using Picard (http://picard.sourceforge.net/).
The detailed mapping statistics are listed in Table 5-1. Considering genome duplication,
FPKM (fragments per kilobase of exon per million fragments mapped) for each RefSeq
gene was calculated as following: first fragments mapped to each exon region of a gene,
regardless of their genomic location, were marked and summed up as the gene counts.
The final FPKM value for the gene was calculated as shown in Equation 5-1:
FPKM = Fgene*1000*1000,000/(Fallexon*Lgene)

(Eq. 5-1)

Where Fgene is the total fragments mapped to a gene, Fallexon is total fragments mapped to
exonic region in Zv9, and Lgene is size of unique exonic bases for the gene. Differential
expression analysis was done using purely fold change between the mutant and wild type
cells. GO analysis was done using DAVID (Huang, 2009a, b) with differentially
expressed genes that have moderate expression level (FPKM>0.1).
Quantitative Real Time PCR (qRT-PCR)
RNA was extracted from nine cp27.5 wild-type and nine cp27.5 mutant larvae
and cDNA was synthesized using the same method as described in RT-PCR on pg. 81.
RNA concentrations were normalized between wild-type and mutant prior to DNAse I
treatment. Samples were treated with DNAse I (Ambion) and 10x Reaction buffer made
in DEPC water at 37˚ for 15 min followed by treatment with 25 mM EDTA (Ambion) at
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Table 5-1.
Sample
cp27.5
Wild-type
cp27.5
Mutant

Mapping Statistics of RNA-Seq Data.
Reads
61515460

Mapped
58536062

NonDupMapped
45999884

Mpd%
95.16

Dup%
21.42

99288072

94481824

74744636

95.16

20.89

Mdp (mapped); Dup (duplicate).
65˚ for 15 min to inactivate DNAse I. Samples were then placed on ice for 1 min. After
cDNA was synthesized, 20 ng of cDNA was used per reaction for quantitative real-time
PCR (qRT-PCR). Primers were designed using NCBI Primer-BLAST and prepared at
500 nmol.. qRT-PCR was performed using SYBR ® Green PCR Master Mix (Life
Technologies) on a 7500 Fast Real Time PCR machine (Applied Biosystems) and
analyzed using 7500 Software v2.0.6. Relative gene expression was calculated using the
Delta Delta CT (ddCt) method relative to the reference gene β-actin. A bar graph
showing the normalized fold change in mutant compared to wild-type was made in
GraphPad Prism. Error bars are based on the mean of 3 rounds of injections using
standard error. The primer templates used for each gene are found in Table B-1.
Results
sart1 mRNA Is Maternally Derived and Expressed in the Zebrafish Brain
To determine when sart1 is expressed, we performed RT-PCR using cDNA from
day 0 to day 5 wild-type samples. We observed sart1 expression for each time point and
also established that sart1 is maternally derived based on its expression at day 0 (Figure
5-1A). Because we observed phenotypes primarily within the head and eye region in
cp27.5 mutants, we were curious to determine whether sart1 is spatially or temporally
regulated within these regions or ubiquitously expressed. We looked at three
developmental time points to determine sart1 expression: 48 hpf when we begin to
observe mutant phenotypes, 72 hpf, and 96 hpf when mutants begin to deteriorate. Using
whole-mount in situ hybridization, we observed sart1 localized in the head at 48 hpf
(Figure 5-1B). This expression was consistent throughout development although it
appeared to become less prominent in this region by 96 hpf (Figure 5-1B). We also
wanted to see whether there were differences in expression between cp27.5 wild-type and
mutant. While sart1 was seen in the head at 72 hpf for both wild-type and mutant, sart1
was more highly expressed in mutant compared to wild-type (Figure 5-1C). We do not
contribute increased expression to increased permeability of the probe in mutant due to
the fact that the positive control, deltaC, was not intensified in mutants (Figure 5-2).
Interestingly, deltaC expression which is normally localized in the brain and eyes was
disordered and reduced in cp27.5 mutants.
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Figure 5-1.
Expression.

RT-PCR and Whole Mount In Situ Hybridization Identifies sart1

(A) RT-PCR shows sart1 expression from day 0 to day 5 in zebrafish larvae including a
water negative control (-). (B) Whole mount in situ hybridization shows sart1 expression
localized to the brain at 48 hpf, 72 hpf, and 96 hpf. (C) Whole mount in situ
hybridization shows localization and relative expression levels of sart1 incp27.5
wild-type and mutant larvae at 72 hpf. Images are ordered as lateral view at low
magnification, lateral view at high magnification, and dorsal view at high magnification
for both antisense (left column) and sense (right column). Scale bars are 50 µm.
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Figure 5-2.

deltaC Expression Is Disordered in cp27.5 Mutants.

Whole mount in situ hybridization using deltaC as a control probe identified disordered
expression in cp27.5 mutants (bottom panel) compared to wild-type (top panel). In
wild-type, deltaC is localized to the retina proliferative zone and brain ventricular zone.
deltaC intensity is decreased in cp27.5 mutant. While the probe does label the ventricular
zone and eyes, the patterning is altered in mutant. Scale bars are 50 µm.
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sart1 Mutants Have Altered Protein Expression of Brain and Eye Markers Along
with Increased Activated Caspase 3
Because sart1 expression was localized to the brain we wanted to determine if
there were other proteins in this region whose expression may be affected by sart1
up-regulation. Using IHC, we looked at Zpr1, a marker that labels the pineal gland in the
brain and photoreceptors in the eye. cp27.5 mutants had little to no Zpr1 expression in
the eye (Figure 5-3A and 5-3B). Counterstaining with DAPI revealed that retinal
lamination was also absent. However, Zpr1 expression was present in the pineal gland in
mutants indicating that not all Zpr1 expression was affected by sart1 (Figure 5-4).
Another protein, SV2, that labels synaptic vesicles in the brain and eye, was also affected.
Not surprisingly, mutants had no SV2 expression in the eye (Figure 5-3C and 5-3D).
However, SV2 was present in the brain and appeared to be slightly increased compared to
wild-type.
Because we did not detect expression of Zpr1 and SV2 in the eye and because
mutations in splicing factors have previously been shown to contribute to retinal
degeneration, (Chen et al., 2014; Yin et al., 2011) we hypothesized that cells in the eye
may be undergoing apoptosis. To test this hypothesis, we used an activated Caspase-3
antibody. While no activated Caspase-3 was detected in cp27.5 wild-type larvae (Figure
5-3E), it was significantly expressed throughout the eye of cp27.5 mutants (Figure
5-3F). Caspase-3 was also detected in the dorsal region of the brain near the ventricle
(Figure 5-3F inset and Figure 5-5). To determine if vasculature was affected, we used
Glut1, to visualize blood vessels in the brain and eye. While mutants do have blood
vessel formation, they are not as numerous and extensive as those seen in wild-type
(Figure 5-3G and 5-3H). We also examined neuronal markers such as HuC labeling
neurons and S100β detecting astrocytes. HuC could be detected in mutant brain, but little
if any was present in the eye (Figure 5-3I and 5-3J). Because the original line from
cp27.5 was generated using the Tet-On system containing a HuC promoter driving GFP
expression, we confirmed these results by treating wild-type and mutant larvae with
doxycycline to induce neuron-specific GFP expression. As seen with the HuC antibody,
the brain and spinal cord contain HuC expression in wild-type and mutant, but there is
little to no expression in the eye for mutants (Figure 5-6). For S100β, we detected
expression in the brain and eye of wild-type larvae (Figure 5-3K), but detected little if
any expression in mutant (Figure 5-3). Overall, these findings suggested that sart1 is
affecting expression of genes specifically expressed in the eye and occasionally in the
brain, ultimately resulting in cell death.
sart1 Mutants Have Increased Permeability in the Brain Ventricle
Although there appeared to be a reduced number of blood vessels in the brain, we
wanted to examine whether reduced vasculature led to increased permeability throughout
the larva. We injected fluorescent tracers of different molecular weights intravenously
into wild-type and mutant at 2 dpf and looked for leakage. Because the increased
permeability may be size-selective, we co-injected a 3-kDa cascade blue, a 10-kDa
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Figure 5-3.

IHC Characterizes cp27.5 Mutants.

IHC identifies additional abnormalities in protein expression in cp27.5 mutants at 3 dpf.
All sections are counterstained with DAPI (blue). Zpr1 (red) labels photoreceptors in the
eye which are present in wildtype (A) but not in mutant (B). SV2 labels synaptic vesicles
within the brain and as seen within the inner plexiform layer of the eye in wild-type (C).
SV2 is present in the brain, but absent in the eye in mutant (D). Caspase 3 is not
expressed in wild-type (E), but is prominent in the eyes in mutant (F). Mutant brain also
contains punctate Caspase 3 expression (inset). Glut1 is noticeably expressed in brain
and eye vasculature in wild-type (G), but mutants have faint Glut1 expression in brain
vasculature (arrows) and eye (H). HuC is expressed in neurons throughout the brain and
eye in wild-type (I). HuC is expressed in the brain in mutant; however it is not as
organized as wild-type and only remnants of HuC are detected in mutant eye. (J) S100β
labels astrocytes in the brain and eyes in wild-type (K), but is greatly reduced and
sporadic in the brain and eyes of mutant (L). Scale bars are 50 µm.
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Figure 5-4.

Zpr1 Is Expressed in the Pineal Gland in cp27.5 Mutants.

(A) Wild-type cp27.5 larvae at 4 dpf with GFP (green) in the dCP (open arrowhead) and
mCP (arrow) and Zpr1 expression (red) in the pineal gland (filled arrowhead) and eyes.
(B) Mutant cp27.5 larvae at 4 dpf with GFP (green) in the dCP (open arrowhead) and
mCP (arrow) and Zpr1 expression (red) in the pineal gland (filled arrowhead). Mutants
have no Zpr1 expression in the eye. dCP, diencephalic choroid plexus; mCP,
myelencephalic choroid plexus. Scale bar is 50 µm.
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Figure 5-5.

Activated Caspase-3 Is Expressed in cp27.5 Mutant Brain.

Whole mount IHC with activated Caspase-3 antibody reveals expression in the dorsal
midline and eye in cp27.5 mutants (right column). Activated Caspase-3 was not detected
in cp27.5 wild-type (left column). Scale bars are 50 µm.
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Figure 5-6.

Doxycycline Induces GFP in the CNS of cp27.5 Larvae.

cp27.5 larvae treated with doxycycline induces the TetON system using the HuC
promoter resulting in GFP expression throughout the CNS. Wild-type larvae (shown on
left and upper sides) express GFP in the brain, spinal cord, and eyes. Mutant larvae
(shown right and bottom sides) express GFP in the brain and spinal cord but little to no
expression in the eyes. Scale bars are 50 µm.
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rhodamine, and a 40-kDa fluorescein dextran. While the 3-kDa and 10-kDa tracers
leaked into the brain ventricle in wild-type, it did not penetrate into the brain itself or
surrounding areas. In mutants, these tracers entered the brain ventricle, but they were not
confined to the ventricle and leaked into nearby tissues (Figure 5-7A-D). In wild-type,
the 40-kDa tracer was retained within the vasculature (Figure 5-7E-F). Because this
tracer remained within the blood vessels, we were able to observe reduced vasculature
throughout the brain and abnormal vascular patterning around the eye in cp27.5 mutants.
However, this phenotype was restricted only to these regions. Vascular patterning and
permeability along the tail was normal (Figure 5-7G-H).
RNA-Seq Analysis Identifies Up-Regulated Apoptotic Genes
To determine what genes are affected by this specific mutation in sart1, we
performed an RNA-Seq analysis and looked for up or down-regulation of genes
throughout the zebrafish genome by comparing cp27.5 wild-type and mutant RNA
expression levels. The complete analysis is found in Appendix B. SupplementalFile1.
Because Sart1 is involved in spliceosome assembly, a process that occurs ubiquitously in
all cell types, we expected to identify dysregulation of genes involved in a number of
processes. Because the entire RNA-Seq data is too extensive to be described here, we
have reported in the following paragraphs only the genes we confirmed to be up or
down-regulated by qRT-PCR (Table 5-2). The fold change normalized to β-actin for
each gene is found in Figure 5-8. For a more widespread look at the genes analyzed by
RNA-Seq and their relative expression, please refer to Table B-2.
From the RNA-Seq analysis, we identified up-regulation of sart1 in mutants, thus
confirming the whole mount in situ hybridization data showing elevated sart1 expression
in the brain compared to wild-type. As mentioned previously, sart1 has been
demonstrated to be involved in apoptosis where it appears to play a duel role by inducing
cell cycle arrest(Hosokawa et al., 2005), but also aiding in drug resistance in cancer cells
(Laetsch et al., 2014). One of the more highly up-regulated genes was tp53. While the
tp53 transcript was up-regulated, we were also interested to see whether p53 protein was
increased. By performing Western blot analysis, we observed that both wild-type and
mutant had a faint band at the predicted protein size of 42 kDa. However in cp27.5
mutants, a larger and highly expressed band was detected closer to 50 kDa, and another
band, while not as prominent, was detected to be greater than 50 kDa. These bands are
faintly present in wild-type samples perhaps due to heterozygous siblings in the wild-type
pool (Figure 5-9). We also observed an increase in mdm2 expression, which acts as an
inhibitor of tp53 by ubiquitinating p53 and targeting it for degradation. Alternatively, a
feedback loop can occur where p53 can in turn activate Mdm2 (Zhao et al., 2014).
During cellular stress, the cell death pathway is initiated causing p53 levels to increase
and Mdm2 levels to decrease. As a result of decreased Mdm2, p53 initiates mdm2
transcription. As Mdm2 levels then increase, Mdm2 in turn acts to inhibit p53 (Zhao et
al., 2014). In addition, we detected increased expression of another interesting gene
clusterin (clu). Studies in zebrafish have observed clusterin expression specifically
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Figure 5-7.
Mutants.

Fluorescent Tracer Injections Reveal Increased Permeability in

cp27.5 wild-type and mutant larvae were intravenously injected with a mixture of a
3-kDa Cascade blue dextran, 10-kDa Rhodamine dextran, and 40-kDa Fluorescein
dextran at 2 dpf. (A) Wild-type injected with 3-kDa Cascade blue dextran has tracer
permeable to the brain ventricle (arrow), but is restricted from the brain and eye
(asterisks). (B) Mutant injected with 3-kDa Cascade blue dextran has tracer retained in
the brain ventricle (arrow), but also leaks into the surrounding tissue (asterisks). (C)
Wild-type injected with 10-kDa Rhodamine dextran has tracer permeable to the brain
ventricle (arrow), but is also restricted from the brain and eye (asterisks). However, the
10-kDa Rhodamine dextran is more restricted to the brain vasculature compared to the
3-kDa Cascade blue (arrowhead). (D) Mutant injected with 10-kDa Rhodamine dextran
has tracer permeable to the brain ventricle (arrow), but also leaks into the surrounding
tissue (asterisks) and is not restricted to the brain vasculature as seen in wild-type
(arrowhead). (E) Wild-type injected with 40-kDa Fluorescein dextran has little to no
tracer leakage into the brain ventricle (arrow) and is restricted from entering the brain and
eye (asterisk). The tracer is also retained within the brain vasculature (arrowhead). (F)
Mutant injected with 40-kDa Fluorescein dextran has tracer slightly permeable to the
brain ventricle (arrow), but not as severe compared to the 3-kDa Cascade blue and
10-kDa Rhodamine dextrans. The tracer does not appear to leak into the brain, eye, or
surrounding tissue as severely as the smaller tracers; however, there is still absence of the
tracer retained within the brain vasculature (arrowhead). (G) Merged image of wild-type
larvae co-injected with all three tracers. (H) Merged image of mutant larvae co-injected
with all three tracers. Tracers are retained within the peripheral tail vasculature in
mutants comparable to wild-type (arrowheads). Scale bars are 50 µm.
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Table 5-2.
Gene
sart1
tp53
mdm2
clu
cldn5a
mmp9
prpf31
lsm7
pde6h
opn1sw1
crx
actb1

Up-Regulated and Down-Regulated Genes Confirmed by qRT-PCR.
Accession Number

log2(MUT-WT)
from RNA-Seq

NM_001002673
NM_131327
NM_131364
NM_200802
NM_213274
NM_213123
NM_200504
NM_001048006
NM_200785
NM_131319
NM_152940
NM131031

3.35
4.22
4.07
3.76
3.42
8.38
3.71
3.71
-16.92
-7.29
-1.71
0.71
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Fold Increase
from
qRT-PCR
1.64
3.14
2.99
3.61
1.20
61.99
2.75
3.22
0.00
0.00
0.05
1.00

Normalized
for
qRT-PCR
0.64
2.14
1.99
2.62
0.20
61.01
1.76
2.23
-1.00
-1.00
-0.95
0.00

Figure 5-8. qRT-PCR Confirms Up-Regulated or Down-Regulated Genes from
RNA-Seq Analysis.
RNA-Seq analysis was confirmed using qRT-PCR. Fold changes were normalized to
β-actin which was set to zero. The majority of genes are up-regulated including sart1,
apoptotic genes (tp53, mdm2, clu), tight junctions (cldn5a), extracellular matrix enzymes
(mmp9), and spliceosome factors (lsm7, prpf31), while vision-related genes are
down-regulated (pde6h, opn1sw1, crx). Measurements are expressed as mean ± SE
(standard error) for n=3 from mutant samples.

98

Figure 5-9. Western Blot Analysis Reveals a Larger, More Highly Expressed p53
in cp27.5 Mutant.
Both cp27.5 wild-type and mutant express p53 with a protein size of 42 kDa (red).
However, cp27.5 mutants also highly express a p53 protein that is absent in wild-type
(arrow). Protein levels were normalized to β-actin (green).
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within the choroid plexus (Jiao et al., 2011). It acts as a chaperone and is a pro-survival
gene in its secreted form by binding to Bax and preventing Bax from traveling to the
mitochondria (Trougakos et al., 2009). In its nuclear form, which originates from
alternative splicing, it acts as a pro-death gene by promoting cell death in a Caspase-3
independent manner (Leskov et al., 2003; Trougakos et al., 2009).
RNA-Seq Analysis Identifies Up-Regulated Spliceosome Components
Previous studies have identified increased expression of spliceosome transcripts
when another component of the spliceosome itself, or a protein involved in spliceosome
assembly is defective (Chen et al., 2014; Jia et al., 2012). Because Sart1 is involved in
the recruitment of U4/U6.U5 tri-snRNP to the spliceosome, we wanted to observe
whether additional factors involved in spliceosome assembly were also defective or
up-regulated in order to compensate for possible defects in Sart1 function. The first gene
we confirmed by qRT-PCR was prpf31. This gene is a member of the precursor RNA
processing (PRP) genes and similar to sart1, it also plays a role in recruiting U4/U6.U5
tri-snRNP to the spliceosome (Vithana et al., 2001). Interestingly, mutations of prpf31
are found in patients with RP, a degenerative disease of photoreceptors in the eye
(Vithana et al., 2001). We determined that prpf31 was up-regulated in cp27.5 mutants.
We also observed up-regulation of a gene from another class of spliceosome components,
lsm7. Lsm7, which binds to U6 in the spliceosome is a member of a family of proteins
called Sm proteins that are also involved in assembling major spliceosome factors (He
and Parker, 2000).
RNA-Seq Analysis Identifies Up-Regulated Claudin 5a and Matrix
Metalloproteinase Protein (MMP9)
In characterizing cp27.5 mutants, we also observed defects in Cldn5 protein
expression. Whole mount IHC showed Cldn5 expression on the surface of the brain
ventricle in mutants, however, we did not observe co-localization with CPe as seen in
wild-type larvae (Figure 5-10). The results also suggested increased Cldn5 protein in
mutants. Based on RNA-Seq and qRT-PCR data, we observed increased expression of
cldn5a transcript in mutant, indicating that protein expression in the brain ventricle may
also be up-regulated. In a recent study, mmp9 was suggested to lead to Cldn5
degradation at the BCSFB allowing for leukocytes entry into the CSF (Chiu and Lai,
2013). mmp9 is also said to be up-regulated in the CP in the presence of inflammation
(Kratzer et al., 2013). We observed a significant increase in mmp9 expression in cp27.5
mutants; however, whether up-regulation is specific to the BCSFB requires further
investigation.
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Figure 5-10. Claudin 5 Is Expressed in cp27.5 Mutants, but Does Not Co-Localize
with Choroid Plexus Epithelia.
Whole mount IHC was performed on cp27.5 wild-type and mutant larvae at 3 dpf In
wild-type, the dCP (arrowhead) and mCP (arrow) express GFP (green). Claudin 5 (red)
is localized to the surface vasculature and co-localizes with the CP epithelia (yellow). In
mutant, the dCP is absent and the mCP consists of individual sporadic GFP positive cells
(arrow). Claudin 5 is expressed throughout the brain ventricle and surrounds CP
epithelia, but does not co-localize with the cells as seen in wild-type. Scale bar is 50 µm.
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RNA-Seq Analysis Identifies Down-Regulation of Vision-Related Genes
The final class of genes we confirmed by qRT-PCR were those specific to the
eye. Because retinal degeneration has been shown as a result of splicing defects or
mutations in spliceosome components (Chen et al., 2014; Tanackovic et al., 2011), we
were interested to see if mutations in sart1 led to decreased expression of vision-related
genes. Cone-rod homeobox (crx) is a transcription factor found in photoreceptor cells
and mutations in this gene have been associated with cone-rod dystrophy (Freund et al.,
1997). We observed a dramatic decrease in crx expression, which is not surprising due to
our IHC data showing a loss of photoreceptors in cp27.5 mutants. We also looked at
phosphodiesterase 6H (pde6h), a gene that encodes for the γ (gamma) subunit of a cyclic
guanosine monophosphate phosphodiesterase specific to cone photoreceptors. Mutations
in this gene have been associated with achromatopsia, which is an inherited retinal
dystrophy (Kohl et al., 2012). pde6h was also down-regulated in cp27.5 mutants. The
final gene we analyzed was opsin-1, short-wave-sensitive 1 (opn1sw1), a gene specific to
zebrafish expressed in ultraviolet cone photoreceptors (Aluru et al., 2014). Opsins found
in cone photoreceptors belong to G-protein-coupled receptors (GPCRs). These receptors
are important in light absorption so that the signal can be relayed to activate downstream
components such as G-proteins, transducin, and phosphodiesterases (Aluru et al., 2014).
Again, not surprisingly, due to its specific expression in the retina, opn1sw1 was
down-regulated in cp27.5 mutants. While here we provide a brief overview of specific
genes identified from the RNA-Seq analysis and their response to the sart1 mutation,
future studies will examine in more depth the role of sart1 in regulating the expression
levels and patterning of these genes. Suggested roles for sart1 are described in the
Discussion below.
Discussion
The current study describes a zebrafish mutant from cp27.5 with a point mutation
in the splicing component sart1. In addition to splicing, sart1 has been implicated in a
number of different processes such as cell cycle arrest and apoptosis and has been
suggested as a target for gene therapy due to its activation of apoptosis and its role as an
antigen recognized by CTLs in certain types of cancer (Hosokawa et al., 2005). More
recently, sart1 has been shown to contribute to drug resistance in cancer cells (Allen et
al., 2012; Laetsch et al., 2014). The goal of this study was to characterize mutant sart1
and determine what other genes are affected due to this mutation. In doing so, we plan to
discover the role of sart1 in overall cellular processes such as cell death; in addition to
better understanding its traditional role at the transcriptional level in splicing.
One of the earliest phenotypes detected in these mutants was forebrain necrosis at
approximately late 2 dpf. Prior to this time point, mutants were undistinguishable from
wild-type siblings. The maternally derived transcript identified by RT-PCR was present
on day zero and may explain why we were unable to isolate mutant embryos prior to 2
dpf due to the contribution of wild-type sart1 from the mother. Interestingly, by whole
mount in situ hybridization and RNA-Seq analysis we determined that the point mutation
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in sart1 results in an obvious up-regulation of the transcript. Up-regulation of mutated
splicing genes have been demonstrated in other studies such as prpf4, a gene encoding a
protein that interacts with the U4/U6 di-snRNP and stabilizes the complex (Chen et al.,
2014). A mutation from a proline to leucine in prpf4 led to its increased expression and
also up-regulation of other splicing factors including sart1. Similar to our study, they
also detected a loss of photoreceptors in the zebrafish eye and a down-regulation of
vision related genes such as opn1lw1, another opsin gene (Chen et al., 2014).
The loss of protein expression in genes found in the eye, such as Zpr1, SV2, HuC,
and S100β, is not surprising due to previous studies showing that mutations in splicing
factors can result in photoreceptor degeneration in diseases such as RP (Chen et al., 2014)
where the most noticeable phenotype is a loss of photoreceptor cells (Mordes et al.,
2006). A recent study cited that six genes related to splicing have been found to have
mutations in patients with RP including PRPF31, PRPF8, PRPF3, PAP-1, SNRNP200,
and PRPF6 and that these mutations are responsible for autosomal dominant RP in more
than 12% of cases (Benaglio et al., 2014). Of these genes, PRPF8, PRPF31, and PRPF3
are involved in forming and recruiting the U4/U6.U5 tri-snRNP to the spliceosome
(Mordes et al., 2006). The exact cause of how mutations in splicing genes result in RP is
still unknown; however, several models or hypotheses have been suggested. Because
photoreceptor cells require a high level of mRNA and protein synthesis due to a high
turnover rate in cell types such as the rod outer segment, a haploinsufficiency model
explains how losing a functional copy of the gene results in decreased mRNA processing
and therefore decreased protein resulting in degeneration (Mordes et al., 2006). Another
hypothesis is that these mutations are specific only to photoreceptor cells and that the
spliceosome is never activated in these cells due to mutations in genes essential for
forming and recruiting the complex to pre-mRNA (Mordes et al., 2006). How this
splicing defect is specific to photoreceptors is proposed in a third model where it is
believed that cofactors specific to photoreceptors act alongside the spliceosome to
regulate splicing; however specific factors found only in photoreceptors have yet to be
identified (Mordes et al., 2006). A final hypothesis is that these mutations have a toxic
effect on the cells due to a gain-of-function where the mutated splicing genes interfere
with normal splicing in wild-type copies resulting in increased defective splicing and cell
death even if the wild-type gene is present (Mordes et al., 2006).
A similar hypothesis was suggested by Jia et al. where mis-splicing due to
mutations in U2, a major spliceosome component, results in a buildup of mis-spliced
mRNA that translates into dysfunctional proteins. Another hypothesis by Jia et al.
proposes that introns retained within the mRNA sequence cause the spliceosome to
remain at the intron rather than be released, resulting in alternative splicing and a toxic
feedback loop where mRNA continues to be mis-spliced and cell death occurs (Jia et al.,
2012). In addition to splicing factors, mutations in other genes such as crx encoding a
transcription factor, and pde genes involved in phototransduction, both of which we
identified as down-regulated in cp27.5, also contribute to RP (Mordes et al., 2006).
In cp27.5 mutants, we detected increased cell death within the eye as observed by
activated Caspase 3 antibody staining. However, from the RNA-Seq data, we also
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detected up-regulation of tp53 and mdm2. While up-regulation of tp53 explains the
increased cell death found in the eye and brain, increased expression of mdm2 may
indicate that it is trying to compensate for increased tp53 expression. Alternatively,
because of p53 up-regulation, Mdm2 may also be overexpressed due to the ability of p53
to activate its expression. Future studies will investigate whether Mdm2 is functional in
inhibiting p53 protein and whether p53 is functional and activating Mdm2 and forming a
negative feedback loop. By Western blot, we were able to detect an alternative p53
protein synthesized in cp27.5 mutants. Based on these findings, we suggest that
alternative splicing due to mutated sart1, causes additional p53 proteins to be synthesized
in cp27.5 mutants that cannot be inhibited by Mdm2 thereby resulting in increased cell
death (Figure 5-11). As to why cell death is localized to the eye and brain has yet to be
determined.
While we observed defects primarily related to the eye, sart1 was majorly
expressed in the brain as demonstrated by whole mount in situ hybridization. Because
mRNA splicing occurs in every cell type, spliceosome genes are presumed to be
ubiquitously expressed. However, recent studies have suggested that these genes may be
temporally or spatially regulated. A previous study in mice with a U2 mutation resulted
in the retention of introns in genes such as the cell adhesion molecule L1CAM, and
caused specific phenotypes, such as neurodegeneration within the cerebellum (Jia et al.,
2012). Similar to our findings in the zebrafish eye, mice also had activated Caspase-3
protein expression in granule cells of the cerebellum. This study identified that the
mutant gene was most highly expressed in the cerebellum compared to other tissues (Jia
et al., 2012). This phenomenon may also occur in cp27.5 mutants as we detected a
dramatic increase in sart1 mRNA within the mutant brain compared to wild-type. We
have supported this claim by demonstrating that this increase in expression is due to
up-regulation of the transcript rather than increased permeability of the probe since
deltaC expression was decreased in mutant.
cp27.5 was originally identified from a genetic screen isolating mutants with CP
developmental defects. Interestingly, one of the genes we identified from the RNA-Seq
data was clusterin. This gene has been demonstrated in recent studies to be expressed
specifically within the zebrafish CP in early development (Jiao et al., 2011). A more
detailed description of this study was presented on pg. 16. This finding is relevant to our
analysis in that the nuclear form of clusterin has also been described to play a role in cell
death (Leskov et al., 2003; Trougakos et al., 2009). Future studies will investigate
whether the nuclear form of clusterin is localized to the CP and contributes to cell death
in cp27.5 mutants since the CP has dispersed GFP positive cells and never fully develops.
Up-regulation of clusterin from the RNA-Seq analysis may prove this hypothesis to be
true since alternative splicing of clusterin may cause inhibitors to no longer prevent its
expression. A lack of clusterin inhibition would then result in its overexpression and
increased cell death. Alternatively, as mentioned before, the secreted form of Clusterin
can act as a pro-survival protein (Trougakos et al., 2009). If the secreted protein is
up-regulated in mutants, Clusterin may be acting in competition with pro-apoptotic genes
such as p53 and compensating for cell death in the CP. However, even though clusterin
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Figure 5-11. Schematic Diagram for the Hypothetical Role of sart1 in Apoptosis.
In wild-type, Sart1 acts to recruit the U4/U6.U5 tri-snRNP to the spliceosome complex
where U1 and U2 are already bound to pre-mRNA at the 5’ splice site and branch point
site, respectively. Once the spliceosome is assembled, it processes pre mRNA by
removing introns and producing mature mRNA transcripts for genes such as tp53 and
mdm2. Mdm2 inhibits p53 allowing for cell survival of photoreceptors. In mutant, while
the sart1 transcript is up-regulated, altered Sart1 protein may result in defective
recruitment of U4/U6.U5 to the spliceosome thereby causing alternative splicing of p53
and mdm2. Alternative splicing may result in altered proteins such as Mdm2 which can
no longer function to inhibit p53 activity. In addition, alternatively spliced p53
transcripts may result in proteins that can no longer be inhibited by Mdm2. This
phenomenon may lead to up-regulation of p53 and increased cell death in photoreceptors.
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was found to be up-regulated at the transcript level, future studies will need to determine
whether the functional protein is also increased.
Another protein we demonstrated to be expressed in the CP was Cldn5. From the
RNA-Seq data, we determined that cldn5a is also slightly up-regulated in cp27.5 mutants.
While we were able to detect Cldn5 expression in mutants by whole mount IHC, future
experiments will need to determine if this protein is actually functional. Cldn5 appeared
to be mis-localized in mutants due to an absence of its expression overlapping with GFP
in CPe. Another hypothesis is that a disruption of anchoring proteins that tether tight
junctions to the plasma membrane, such as ZO-1, may also be disrupted resulting is
mislocalization of Cldn5 to the cell membrane. Additional evidence for defects in Cldn5
was demonstrated by injecting fluorescent dextrans intravenously into cp27.5 larvae.
Due to the developmental time point for analysis at 2 dpf, both wild-type and mutants had
leakage into the brain ventricle since the CP had not yet developed. However, mutants
demonstrated increased permeability outside the ventricle where smaller tracers leaked
into surrounding tissues suggesting defects in tight junctions. Tracer studies also
revealed abnormal vasculature in the CNS indicating that the sart1 mutation may strictly
be CNS specific and not affecting tight junctions or vasculature of the periphery. mmp9
was also very highly up-regulated as confirmed by qRT-PCR. As mentioned previously,
mmp9 can result in the degradation of Claudin 5 at the BCSFB resulting in increased
barrier permeability (Chiu and Lai, 2013). The same phenomena may result as a
downstream effect of mutated sart1 where overexpression of mmp9 causes
mis-localization of Claudin 5 and increased barrier permeability and leakiness.
Interestingly the previous study mentions that up-regulation of mmp9 was
dependent on the NF-κB pathway (Chiu and Lai, 2013). We identified from the
RNA-Seq data that nfkbiaa (nuclear factor of kappa light polypeptide gene enhancer in
B-cells inhibitor, alpha a), a component of the NF-κB pathway, is one of the top
up-regulated genes in mutant (see Table B-2). This gene is also known as IkappaBalpha
and acts as an inhibitor of the NF-κB signaling pathway (Correa et al., 2004). Again, this
may indicate compensatory mechanisms as a result of the sart1 mutation where inhibitors
of the NF-κB pathway attempt to reduce MMP9 activity and restore Cldn5 to its normal
expression.
While the genetic pathways downstream of sart1 in cp27.5 mutants have yet to be
determined, the current study has revealed dysregulation of genes involved in apoptosis,
splicing, vision, tight junctions, and matrix metalloproteinases. RNA-Seq analysis has
provided substantial insights into genes and potential pathways regulated by sart1. This
study and others have demonstrated that mutations in splicing machinery or proteins
associated with the spliceosome have widespread affects in a number of signaling
processes in addition to splicing defects. Also, differences between phenotypes observed
in the CNS versus periphery may suggest that sart1 regulates the expression of certain
genes in a tissue-specific manner.
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Conclusion
In conclusion, sart1 is a fascinating gene whose complex expression and function
will provide interesting insights into cellular pathways for years to come. We have
discovered a zebrafish model with a mutation in sart1 that will aid in these future
investigations. By performing RNA-Seq, we have already identified numerous genes
affected by this mutation. Using IHC and Western blot, we have also identified defects
in protein expression in a number of genes including those specific to brain and eye.
Future studies will aim to answer the outstanding question of how genes expressed in
multiple cell types, such as splicing-related genes, result in defects or abnormalities in a
spatially or temporally tissue or cell-specific manner.
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CHAPTER 6.

SUMMARY AND CONCLUSIONS

The current study had three primary goals: 1) to establish zebrafish as functional
model to study CP development, 2) to perform a forward genetic screen identifying CP
mutants, and 3) to discover the gene responsible for the phenotypes identified in cp27.5.
For the first aim, we have supplemented previous studies describing CP
development in zebrafish by generating an enhancer trap line expressing EGFP within
CPe. This line we termed Et(cp:EGFP)sj2 allowed us to monitor CP formation over time
and investigate its functional properties. While we have demonstrated that zebrafish
provide a suitable model for observing this process in a living system due to its rapid
development and transparent nature in early stages, we have also shown that the zebrafish
CP possess barrier properties and functions comparable to other vertebrates. The CNS
has long been known for its barrier components including tight junctions and transporters
localized to the cell membrane. These proteins create both a physical and chemical
barrier, respectively, allowing for CNS homeostasis and protection from insult. Here, we
have shown that the zebrafish CP expresses the tight junction protein, Claudin 5 and its
anchoring protein ZO-1. While additional tight junctions have been shown to be highly
expressed in the CP, antibodies against these proteins in zebrafish are difficult to acquire
or do not exist. With gaining popularity of the zebrafish model in recent years, access to
commercially available antibodies for zebrafish may continue to increase allowing for
additional tight junction proteins in the CP to be identified.
In addition to tight junctions, we provided evidence for transporter activity at the
BCSFB. While we were not able to identify antibodies that labelled transporter proteins
in the CP, we did observe accumulation of fluorescent dyes including Rhodamine 123
and Fluorescein. These dyes are known substrates of transporters expressed in the CP
such as Mrp1 and Oat3. By injecting these tracers intravenously, we observed that the
dyes can be transported from the fenestrated blood vasculature into the CPe signifying
transporter localization at the basolateral surface of the epithelia. Alternatively, by
injecting tracers directly into the CSF in the brain ventricle, we observed accumulation in
the CP suggesting that transporters are also localized to the apical membrane of CPe.
Future studies will identify specific transporter expression at the CP and determine their
localization within the cell membrane.
We also determined when the BCSFB forms in zebrafish. By injecting
fluorescent tracers conjugated to different molecular weight dextrans, we observed that
the BCSFB acquires size-selective properties as it develops and forms by 4 dpf. Using
fluorescent tracers attached to various sized dextrans allowed for physical barrier
properties to be determined since these molecules are transported between cells, not
through them. This characterization study using the Et(cp:EGFP)sj2 line has paved the
way for future endeavors investigating the genes and signaling pathways essential for CP
development, function, and maintenance by providing an in vivo model system with a
BCSFB similar to other vertebrates and the ability to monitor barrier development over
time.
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Zebrafish are also exceptional models for forward genetic screening. After
characterizing the CP in zebrafish, we performed a genetic analysis by mutagenizing the
Et(cp:EGFP)sj2 line and screened for mutants based on abnormalities in EGFP
expression or patterning in the mCP. We identified a number of spontaneous mutants
with abnormalities outside of the CP such as heart and eye edema or smaller head size.
However, for some of these mutants the CP developed normally. Alternatively, we
identified spontaneous mutants having normal overall development, but no CP formation.
Isolating these classes of spontaneous mutants suggests that specific genetic pathways are
governing CP development, function, and maintenance. We also identified five classes
of recessive mutants following Mendelian genetics with approximately 25% of the
offspring containing CP abnormalities. While these mutants were screened initially for
defects in CP development, we observed additional phenotypes such as small head and
eyes, heart and eye edema, or no swimbladder.
We were interested to determine whether the mutated genes from these lines were
specific to the CP or whether they were ubiquitously expressed genes promoting global
defects. We performed genetic mapping experiments for the line cp27.5 due to its severe
brain ventricle expansion in addition to CP defects. We hypothesized that the gene may
be specific to CSF production or regulation due to the expanded ventricle phenotype.
Using traditional genetic mapping strategies such as positional cloning, we identified the
mutation on Chromosome 21. Since the sequencing of the zebrafish genome, positional
cloning has become easier to define a critical interval due to polymorphic markers
designed throughout the genome. However, this strategy is often time consuming by
sequencing multiple candidate genes and can be difficult to identify a map position based
on recombination frequency. For this study, we also employed an innovative approach
using WES that identified the gene mutation based on isolating homozygous regions in
the mutant genome. Using this strategy, we identified a point mutation in sart1, a gene
involved in spliceosome assembly. We confirmed that sart1 was the gene responsible for
the abnormalities observed in sart1 mutants by performing rescue experiments that
restored the most of the mutants to normal or near normal phenotypes.
In characterizing cp27.5 mutants by in situ hybridization and RNA-Seq analysis,
we identified that a G to A point mutation at the donor site of exon 12 results in
up-regulation of sart1 specifically in the brain. Increased expression of sart1 resulted in
dysregulation of genes involved in a number of pathways and processes such as apoptotic
and vision-related genes, and genes important for cell-cell interactions and splicing.
Future studies will investigate the mechanisms of sart1 in regulating the expression levels
and patterning of these genes and determine whether it plays specific role in CP
development.
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APPENDIX A. CHAPTER 2 AND CHAPTER 3 SUPPLEMENTAL MOVIES
All supplemental files are available via links on the ET/D access page.
SupplementalMovie1
Confocal time lapse imaging of Et(cp:EGFP)sj2 larvae to observe CP
development. Time lapse was initiated at approximately 30 hpf and images were
acquired every 30 min for 65 h. The image is a dorsal view at 20× magnification.
SupplementalMovie2
Confocal time lapse imaging of wild-type Et(cp:EGFP)sj2 larvae. Time lapse was
initiated at 54 hpf and images were acquired every 30 min for 48 h. The image is a dorsal
view at 20× magnification.
SupplementalMovie3
Confocal time lapse imaging of cp140.2 mutant larvae. Time lapse was initiated
at 54 hpf and images were acquired every 30 min for 48 h. The image is a dorsal view at
20× magnification.
SupplementalMovie4
Confocal time lapse imaging of cp9.6 mutant larvae. Time lapse was initiated at
54 hpf and images were acquired every 30 min for 48 h. The image is a dorsal view at
20× magnification.
SupplementalMovie5
Confocal time lapse imaging of cp79.6 mutant larvae. Time lapse was initiated at
54 hpf and images were acquired every 30 min for 48 h. The image is a dorsal view at
20× magnification.
SupplementalMovie6
Confocal time lapse imaging of cp151.2 mutant larvae. Time lapse was initiated
at 54 hpf and images were acquired every 30 min for 42 h. The image is a dorsal view at
20× magnification.
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SupplementalMovie7
Confocal time lapse imaging of cp27.5 mutant larvae. Time lapse was initiated at
54 hpf and images were acquired every 30 min for 48 h. The image is a dorsal view at
20× magnification.
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APPENDIX B. CHAPTER 5 EXTENDED METHODS AND RESULTS OF
RNA-SEQ ANALYSIS
All supplemental files are available via links on the ET/D access page.
RNA-Seq analysis is found in SupplementalFile1. This analysis identifies a
number of genes up-regulated and down-regulated due to a point mutation in sart1. The
file contains the list of genes with at least one read observed in either one of the samples
(wild-type or mutant), genes expressed where the (FPKM>0.1) in both samples, gene
ontology for biological processes and molecular function, the Kyoto Encyclopedia of
Genes and Genomes (KEGG), and a list of up-regulated spliceosome-related genes.
The primers used for methods described in qRT-PCR on pg. 84 are listed in Table
B-1, and the top ten up-regulated and down-regulated genes with a FPKM>0.1 as a result
of the sart1 mutation are listed in Table B-2.
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Table B-1.

Primer Sequences for qRT- PCR.

Gene

Primer

Primer Sequence (5`-3`)

Tm

sart1

Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse
Forward
Reverse

GTCGCAAACTCGCCAAAGAG
TATGCTTGCCGCTTCTCCTG
CTCTCCCACCAACATCCACT
ACGTCCACCACCATTTGAAC
AACCGAGGCAGACTACTGGA
TCTGGAAGCCAATCAGCTCG
ACACCTCAAGTCTGCTCGAC
CCTTTGGACATCACTGCCTG
ATGCTGTCTGGCTGACCAAA
CTTTCTGTTTTCGACGCGCT
AGACTTGGAGTCCTGGCGTT
ACGCTTCAGATACTCATCCGCTA
ACATGCGAGATCCTGATGACC
CAACAGACGTCCCTCGACAA
GTCAAGCAGGTCAAGCCTCT
GCTTGTCTGACTCTGCCACT
GACCACTCGCACCTTCAAGA
ACAGTGATGTCTGTGCCGAG
CGATTGCAGGTCTTGTGACG
GACCCTCGGGAATGTATCTGC
CCATTATGCTGTGAACGGGT
CTCGGAGTGGCTGGGTA

60.1
60.5
59.0
58.7
60.3
60.1
59.7
58.8
59.9
59.8
61.1
61.3
59.9
60.0
60.0
60.0
60.0
60.0
59.6
60.3
58.3
57.5
58.5
59.0

p53
mdm2
clu
cldn5a
mmp9
lsm7
prpf31
pde6h
opn1sw1
crx
actb1

TGAATCCCAAAGCCAACAGAG
TCACACCATCACCAGAGTCC
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GC
%
55
55
55
50
55
55
55
55
50
50
55
48
52
55
55
55
55
55
55
57
50
65
48
55

Product
Length
127
178
105
115
190
147
84
221
99
195
84
150

Table B-2.
Top Ten Up-Regulated and Down-Regulated Genes from RNA-Seq
with FPKM >0.1 in Both Samples.
Name

Gene

Chromosome

fibronectin 1b

fn1b

1

4.6840

TIMP metallopeptidase inhibitor 2b

timp2b

3

4.6815

jun B proto-oncogene b

junbb

3

4.5556

nuclear factor of kappa light
polypeptide gene enhancer in
B-cells inhibitor, alpha a

nfkbiaa

20

4.5268

insulin-like growth factor binding
protein 1a

igfbp1a

20

4.4076

CCAAT/enhancer binding protein
(C/EBP), delta

cebpd

24

4.2910

tumor protein p53

tp53

5

4.2233

hepcidin antimicrobial peptide

hamp

16

4.1544

MDM2 oncogene, E3 ubiquitin
protein ligase

mdm2

4

4.0737

clu

20

3.7648

fibroblast growth factor binding
protein 2b

fgfbp2b

1

-2.3904

parvalbumin 8

pvalb8

3

-2.5884

tcnl

5

-2.7405

guanine nucleotide binding protein
(G protein), gamma transducing
activity polypeptide 1

gngt1

19

-2.7876

actinodin4

and4

14

-3.0036

ckmt2a

10

-3.1316

zgc:73075

19

-3.3992

zgc:13622

7

-3.5883

zgc:73359

3

-3.8776

clusterin

transcobalamin like

creatine kinase, mitochondrial 2a
(sarcomeric)
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log2(MUT-WT)

Table B-2.

(Continued).

Name

Gene

Chromosome

matrilin 1

matn1

19

133

log2(MUT-WT)
-5.4303
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